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STUDIES ON THE IMPACT OF AMINE-CONTAINING COMPOUNDS ON 
LYSOSOMES 
 
Ryan Sol Funk 
The University of Kansas, 2011 
 
 Lysosomes accumulate weakly basic amine-containing drugs (i.e., 
lysosomotropic amines) through an ion trapping-type mechanism and are capable of 
disrupting lysosomal structure and function.  A common finding following treatment with 
hydrophobic amine-containing drugs is a cellular lipidosis marked by the lysosomal 
accumulation of lipids.  The impact of this drug-induced lipidosis on the lysosomal 
accumulation of weakly basic amine-containing drugs is unknown.  In this work, 
hydrophobic (logP > 2) amine-containing drugs (imipramine, haloperidol, risperidone, 
chlorpromazine, lidocaine, bupivacaine, amiodarone, verapamil, propranolol) were 
found to cause a significant increase in the cellular accumulation of the lysosomotropic 
amine, LysoTracker Red (LTR).   
Imipramine was further found to specifically increase the cellular accumulation of 
amine-containing substrates of lysosomal ion trapping (LysoTracker Green, 
daunorubicin, methylamine, propranolol) but not compounds that don’t accumulate by 
ion trapping in lysosomes, suggesting that the drug-induced lipidosis specifically 
increases the cellular accumulation of drugs that accumulate in lysosomes.  Imipramine-
induced accumulation of LTR occurred in a time- and temperature-dependent manner in 
agreement with an energy-dependent intracellular remodeling process that has been 
reported to coincide with induction of the cellular lipidosis.  Prevention of the 
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imipramine-induced lipidosis by treatment with 0.1% hydroxypropyl-ß-cyclodextrin or 
growth in lipoprotein-depleted media prevented the increased accumulation of LTR, 
suggesting the hyperaccumulation of LTR is secondary to the drug-induced lipidosis.  
Determination of lysosome specific accumulation of LTR in cells with or without an intact 
lysosomal pH gradient revealed that imipramine caused an approximately three-fold 
increase in the lysosome-specfic uptake of LTR.   
Previous reports have suggested that drugs accumulate following a cellular 
lipidosis through enhanced hydrophobic binding sites.  However, these results are 
consistent with an increased aqueous volume of lysosomes resulting in increased drug 
accumulation.  Theoretical calculations of lysosomal volume changes following 
imipramine treatment reveal an approximately 4-fold increase in apparent lysosomal 
volume.  Therefore, drug-induced lipidosis is found to increase the cellular accumulation 
of amine-containing drugs by causing a marked increase in the lysosomal volume of 
cells.  These findings have implications towards understanding how drugs can interact 
at the intracellular level.  The ability of one drug to affect the distribution properties of a 
second is further hypothesized to result in drug-drug interactions.
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1.1. Statement of the problem 
The ability of drugs that induce the lysosomal accumulation of lipids to influence 
the cellular accumulation of weakly basic amine-containing drugs and the mechanisms 
involved are the focus of this work.  Weakly basic amine-containing drugs accumulate in 
lysosomes through an ion trapping-type mechanism that is important in the cellular 
(Ishizaki, Yokogawa et al. 1996) and tissue (Daniel, Bickel et al. 1995) uptake of these 
drugs.  By accumulating in lysosomes these drugs are capable of altering the structural 
and functional properties of lysosomes resulting in effects such as:  alkalinization of 
lysosomes (Ohkuma and Poole 1978), accumulation of large cytoplasmic vacuoles 
(Ohkuma and Poole 1981) and lysosomal accumulation of lipids (Hein, Lullmann-Rauch 
et al. 1990).  These alterations may significantly influence the capacity of lysosomes to 
participate in the normal accumulation and distribution of amine-containing drugs.  
Specifically, alkalinization of lysosomes has been found to reduce the cellular and tissue 
accumulation of amine-containing drugs (Daniel and Wojcikowski 1999).  To date no 
studies have evaluated the effect of drug-induced lysosomal lipid accumulation on the 
cellular accumulation of amine-containing drugs.  Studies into the drug-induced lipidosis 
have suggested a time-dependent remodeling process resulting in the accumulation of 
lipid-laden lysosomes (Reasor, Ogle et al. 1988) independent of effects on lysosome pH 
(Lange, Ye et al. 1998).  Such changes are hypothesized to result in the increased 
cellular accumulation of amine-containing drugs into lysosomes, either by an increase in 
the volume of the lysosomal compartment or by an increase in intralysosomal binding 
sites (i.e., lipids) for many of these drugs.  The ability of one drug to alter the cellular 
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accumulation of a secondarily administered drug is further hypothesized to represent a 
novel pathway for distribution-based drug-drug interactions. 
 
1.2. Objectives of this work 
This work seeks to understand the effect of drug-induced lysosomal lipidosis on 
the cellular disposition of amine-containing drugs and the mechanism involved.  Initially, 
the impact of the drug-induced lipidosis on the cellular accumulation of amine-
containing substrates for lysosomal ion trapping will be assessed.  The drug-induced 
lipidosis will be evaluated for its specificity in increasing the cellular accumulation of 
substrates for ion trapping in lysosomes using a series of substrate and non-substrate 
molecules.  The mechanism of enhanced lysosomal accumulation of these amine-
containing drugs will be evaluated using a series of assays to differentiate possible 
mechanisms of increased retention.  Measurements of lysosomal pH, drug uptake and 
efflux, intralysosomal drug-binding and lysosomal volume will elucidate how the drug-
induced lipidosis affects the lysosome-specific retention of these drugs.  An 
understanding of the mechanism by which the drug-induced lipidosis increases the 
cellular retention of these drugs would allow for the prediction of drugs that would be 
substrates for this potential drug-drug interaction.  The drug-induced lipidosis is found to 
result in a lysosomal volume expansion that is further tested on its ability to non-
specifically inhibit lysosomal enzyme activity as a potential mechanism of drug-induced 
defects in lysosomal lipid metabolism.  Finally, amine-containing drugs are 
characterized based on their ability to differentially affect lysosomal properties that are 
important in the cellular accumulation of substrates for lysosomal ion trapping, such as 
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lysosomal volume and lysosomal pH.  Expansion of the lysosomal compartment in the 
form of a cytoplasmic vacuolization is assessed by light microscopy and the lysosomal 
lipidosis is measured using a fluorescent phospholipid analog.  Lysosomal alkalinization 
is determined using indirect measurements of lysosome pH.  The culmination of these 
effects is hypothesized to impact the lysosomal ion trapping capacity of cells.  
 
1.3. Introduction 
A common feature among the majority of currently marketed low-molecular 
weight drugs is the presence of a weakly basic amine functional group.  The presence 
of this functional group often results in the distribution to, and accumulation in, 
lysosomes (MacIntyre and Cutler 1988).  Lysosomes accumulate these drugs to a high 
degree because of the low luminal pH of the organelle relative to the rest of the cell (de 
Duve, de Barsy et al. 1974).  Because of the intense accumulation in the lysosome of 
these amine-containing drugs, these compounds are often referred to as 
‘lysosomotropic amines’.  Drug accumulation in lysosomes is known to impact the 
pharmacokinetic properties of the drug by providing a tissue site for drug accumulation 
(Siebert, Hung et al. 2004), often resulting in a large apparent volume of distribution 
(Yokogawa, Ishizaki et al. 2002).  In addition, the accumulation of these drugs in the 
lysosome has been observed to influence the normal physiological and morphological 
characteristics of the lysosome itself.  These off-target drug effects are gaining interest 
from drug discovery and development scientists as they may relate to the 
pharmacological and toxicological effects elicited by many of these drugs.  Also, the 
potential that these off-target effects can impact the ability of lysosomes to contribute to 
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the tissue uptake and accumulation of drugs reveals the possibility that one drug, by 
affecting lysosomes, can alter the pharmacokinetic properties of a second resulting in 
drug-drug interactions.      
In this chapter the major concepts and literature related to amine-containing drug 
accumulation in lysosomes and its importance in drug discovery and development will 
be reviewed with an emphasis on how drug accumulation in the lysosome impacts 
organelle structure and function.  First, an overview of the theoretical aspects of 
lysosomal ion trapping of drugs will be covered (Section 1.4).  Next, an overview of the 
literature on the influence of lysosomal accumulation of amine-containing drugs on drug 
activity and pharmacokinetics will be covered (Section 1.5).  Finally, is a discussion on 
published reports illustrating the ability of amine-containing drugs to alter the normal 
physiology and morphology of lysosomes resulting in a variety of off-target effects 
mediated by these drugs (Section 1.6).  Specifically, a focused review on the ability of 
lysosomotropic amines to cause alkalinization of the lysosome, the formation of large 
cytoplasmic vacuoles and the lysosomal accumulation of lipids will be discussed along 
with references to their potential pharmacological and toxicological implications.  In 
addition, commentary on the observed relationships between drug hydrophobicity and 
these different effects will be presented. 
 
1.4. Overview of lysosomal ion trapping 
1.4.1. Ion trapping mechanism 
The mechanism by which weakly basic amine-containing drugs accumulate in 
lysosomes is through an ion trapping-type mechanism (de Duve, de Barsy et al. 1974).  
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Like other drug disposition mechanisms the properties of the compartment and that of 
the drug are pivotal in imparting this selective accumulation.  The most important 
property of the drug is that it contains a weakly basic, ionizable amine functional group 
that renders the drug relatively membrane-permeable in its unionized form and 
membrane-impermeable in its ionized form (Figure 1.1A).  These properties are 
described by the acid dissociation constant for the drug (i.e., pKa) and the permeability 
parameter of the drug known as alpha (α).  The important property of the lysosome is its 
pH, which is maintained at a low level relative to the rest of the cell (Figure 1.1B).  
Lysosomes are characterized by their acidity which is critical to the endogenous 
metabolic function of the organelle (Coffey and De Duve 1968).  The low luminal pH is 
maintained through the activity of a membrane-bound protein complex that functions in 
the ATP-dependent inward pumping of protons (Nelson and Harvey 1999).  This protein 
complex is commonly referred to as the vacuolar-type H+-ATPase (V-ATPase).   
Upon exposure of cells to the amine-containing drug, the drug is able to diffuse 
across cellular membranes in its membrane-permeable, unionized form.  It is able to 
enter the various cellular compartments, diffusing down its concentration gradient.  
Upon entering the highly acidic lysosome the amine-containing drug experiences a 
dramatic shift in pH and the ionic equilibrium is re-established, highly favoring the 
membrane-impermeable ionized form of the drug.  Because the ionized form of the 
amine-containing drug is relatively membrane-impermeable and not able to diffuse out 
of the lysosome, or does so very slowly, it becomes effectively ‘trapped’ within the 
compartment (Figure 1.1B).  Therefore, this subcellular disposition mechanism would be 
best described as a passive transport of amine-containing drug into the lysosome that is  
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Figure 1.1.  Ion trapping mechanism of amine-containing drug accumulation in 
lysosomes.  (A) Physicochemical properties of substrates are described by the 
presence of a weakly basic ionizable amine (R-NH2), described by its pKa, and the 
membrane permeability parameter, alpha (α).  (B) Diagram of the mechanism of 
lysosomal ion trapping for weakly basic amine-containing drugs highlighting the pH 
gradient existing between acidic lysosomes and the extralysosomal compartments.  
The drug (D) enters the lysosome by passive diffusion and becomes ‘trapped’ in the 
lysosome because of the increased formation of membrane-impermeable, ionized 
drug (DH+).    
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facilitated by the activity of the V-ATPase.  The importance of the V-ATPase in 
lysosomal accumulation of these drugs is illustrated by the significant reduction in drug 
accumulation in lysosomes following treatment with the specific V-ATPase inhibitor, 
concanamycin A (Figure 1.2).   
 
1.4.2. Physicochemical properties of lysosomotropic amines 
Studies into physicochemical predictors of the lysosomotropism of a compound 
have yielded two key parameters, pKa and alpha (de Duve, de Barsy et al. 1974; 
Duvvuri, Gong et al. 2004; Duvvuri, Konkar et al. 2005).  The alpha value is a measure 
of the ratio of the octanol:water partition coefficients of the ionized versus unionized 
form of the drug and is therefore an indicator of the relative membrane permeability of 
the ionized versus unionized form of the drug.  The pKa of the amine-containing drug 
determines its ionic distribution as a function of pH.  This relationship can be best 
described by the Henderson-Hasselbalch equation where the difference between the 
pKa of the compound and the pH of the solution is directly related to the logarithm of the 
fractional ionic distribution.  Using an equation derived to approximate the steady state 
accumulation of amine-containing drugs in lysosomes by ion trapping (Figure 1.3A) an 
estimate of the lysosome:extracellular concentration ratio of the drug can be predicted 
based on lysosomal pH ([H+]L), extracellular pH ([H
+]E), pKa (Ka) and alpha (α) for the 
amine-containing drug (de Duve, de Barsy et al. 1974).   
 To first assess the impact of pKa on lysosome:extracellular concentration ratios 
alpha is set at zero (i.e., the drug is membrane-permeable when unionized and 
completely membrane-impermeable when ionized), a plot of predicted  
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Figure 1.2.  Lysosomal drug accumulation is dependent on V-ATPase mediated 
acidification of lysosomes.  The specific inhibitor of the lysosomal V-ATPase, 
concanamycin A, reduces the lysosomal uptake of LysoTracker Red.  LysoTracker 
Red is a fluorescent amine-containing compound that accumulates by ion trapping in 
lysosomes.  Figure reproduced with permission Future Sciences Ltd (Goldman, Funk 
et al. 2009). 
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Figure 1.3.  Theoretical predictions of the lysosomal accumulation of weakly basic 
amine-containing compounds by ion trapping.  (A) Equation predicting the lysosomal 
accumulation of weakly basic amine-containing drugs allows predictions of 
lysosome:extracellular drug concentration ratios ([lysosome]/[extracellular]) based on 
extracellular pH ([H+]E), lysosome pH ([H+]L), pKa of the drug (Ka) and alpha of the 
drug (α).  (B) A graphical representation of the effect of pKa on predicted lysosomal 
drug accumulation ([lysosome]/[extracellular]) using the equation in (A) and 
assuming: a lysosome pH of 4, extracellular pH of 7 and an alpha of 0. 
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lysosome:extracellular concentrations is shown with extracellular pH set at 7.0 and 
lysosomal pH set at 4.0 (Figure 1.3B).  As illustrated the ratio of drug concentrations in 
the lysosome as compared to the extracellular space is highly dependent on pKa with a 
maximum ratio of 1000 in this plot.  The maximum concentration ratio is directly 
proportional to the ratio of the hydrogen ion concentration in the lysosome relative to the 
extracellular space.  Therefore, a three pH-unit difference results in a predicted 
concentration ratio of 1000, revealing the potential extent of this trapping phenomenon 
and the possibility of extremely high local concentrations of drug within the lysosome.  
Although this hypothetical plot suggests that amines with pKa values greater than 8 will 
show significant lysosomotropism, it has been argued that as the pKa becomes 
significantly greater than 8, such a small portion of the drug will exist in the membrane-
permeable unionized form that attainment of steady state levels becomes kinetically 
infeasible with years required to reach steady state (de Duve, de Barsy et al. 1974).  
Experimental data measuring the effect of pKa on lysosome to cytosol concentration 
ratios (Duvvuri, Konkar et al. 2005) has confirmed the importance of pKa on lysosomal 
drug accumulation and shown that compounds up to pKa 9 are still significant 
substrates for accumulation in lysosomes (Figure 1.4).  Although no work has confirmed 
the hypothetical limited pKa range for optimal lysosomal ion trapping, a targeted pKa to 
impart lysosomotropic properties in the region of 6 to 10 has since been proposed 
(Trapp, Rosania et al. 2008).  
 To assess the impact of the alpha value on predicted lysosome:extracellular 
concentration ratios for an amine-containing drug a range of alpha values from zero to 
one were plugged into the equation shown in Figure 1.3A.  The resulting plots reveal the  
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Figure 1.4.  Experimental data supporting the relationship between pKa and 
lysosomal accumulation of amine-containing compounds.  Amine-containing 
compounds of similar structure but varying pKa values were assessed for their ability 
to accumulate in lysosomes ([lysosome]/[cytosol]) by measuring lysosome and 
cytosol drug concentrations from drug treated cells.  Lysosomal accumulation 
increases with pKa.  Reproduced with permission from the American Chemical 
Society copyright 2005 (Duvvuri, Konkar et al. 2005).     
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importance of the alpha value in the predicted lysosome:extracellular concentration 
ratios (Figure 1.5).  As seen, compared to the ideal scenario where alpha is zero the 
relationship between pKa and lysosome:extracellular concentration ratios significantly 
deviates.  This large deviation reflects the increased fraction of the drug in its ionized 
form with increasing pKa and its relative ability to permeate cellular membranes as the 
alpha approaches one.  An alpha value of one indicates no difference in membrane 
permeability between the ionized and unionized form of the drug and therefore should 
completely eliminate the lysosomal ion trapping mechanism.   
Experimental measurements of amine-containing drug accumulation in the 
lysosome relative to the cytosol for compounds of varying alpha (Duvvuri, Gong et al. 
2004) have illustrated that as alpha approaches one these drugs no longer accumulate 
in lysosomes (Figure 1.6).  In fact, as the alpha of the amine-containing compounds 
approached one, they began to accumulate in the mitochondria rather than lysosomes 
(Duvvuri, Gong et al. 2004).  Therefore, these results illustrate the importance of the 
alpha value with maximal lysosomotropism, in the form of lysosome:extracellular 
concentration ratios, predicted to occur as alpha approaches zero. 
 
1.5. Lysosomal ion trapping in drug development 
Although a variety of therapeutic drugs have been either directly (Ishizaki, 
Yokogawa et al. 2000) or indirectly (Lemieux, Percival et al. 2004; Nadanaciva, Lu et al. 
2011) identified as substrates for ion trapping-based accumulation in lysosomes, the 
subcellular disposition of drugs into lysosomes isn’t something routinely considered.  
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Figure 1.5.  The importance of alpha on predicted lysosomotropism of amine-
containing drugs.  The predicted membrane-permeability of ionized drug relative to 
unionized drug, represented by alpha, strongly influences the theoretical predictions 
of drug disposition by lysosomal ion trapping.  Predicted lysosomal drug 
accumulation ([lysosome]/[extracellular]) as a function of pKa was plotted with alpha 
values between 0 and 1 (lysosome pH of 4, extracellular pH of 7).  Increased alpha 
results in a predicted decrease in lysosomal ion trapping with no ‘trapping’ effect 
observed when alpha is 1.  
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Figure 1.6.  Experimental data illustrating the importance of alpha in the lysosomal 
accumulation of weakly basic amine-containing drugs.  Four compounds with pKa 
values near neutrality (pKa range 7.2 to 8.0), but differing alpha values ranging from 
0.004 to 1.440, were assessed for lysosomal accumulation 
(AmountLYSO/AmountCYTO).  Lower alpha values correlated with increased drug 
accumulation in the lysosome relative to the cytosol with lysosome specific 
accumulation lost when alpha ≥ 1.  Reproduced with permission from the American 
Society for Biochemistry and Molecular Biology (Duvvuri, Gong et al. 2004). 
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Therefore, the actual prevalence of this drug trapping phenomenon is largely unknown.  
The speculation for the pervasiveness of this phenomenon is strongly rooted in the 
understanding of the physicochemical parameters that impart lysosomotropism and the 
realization that a large portion of drugs fit these parameters.  These observations reveal 
the need for a more thorough understanding of the prevalence of this subcellular 
disposition phenomenon and its role in the observed pharmacology and toxicology of 
amine-containing drugs.  
Perhaps one of the most obvious implications for drug accumulation in the 
lysosomes is a high degree of uptake into tissues such as the liver, lungs and kidneys, 
that are enriched with lysosomes, with lower concentrations in tissues with reduced 
lysosomal content, such as the heart, skeletal muscle and adipose tissue (Bickel, 
Graber et al. 1983).  The high volume of distribution seen with these drugs is often 
attributed to lysosomal ion trapping in tissues and is also typically associated with a 
prolonged half-life which may, or may not, be a desirable pharmacokinetic property 
depending on the drug and disease being treated.  Along with this extensive 
accumulation in lysosomes many of these drugs have been associated with a 
toxicological phenomenon known as phosphoplipidosis (Lullmann-Rauch 1979) which is 
described by the accumulation of a variety of lipid species, most notably phospholipids, 
in perinuclear bodies of lysosomal origin (Lullmann, Lullmann-Rauch et al. 1973).  Drug-
induced phospholipidosis has been attributed to a variety of potential pathologies of the 
eye (Lullmann-Rauch 1981), kidneys (Lullmann, Lullmann-Rauch et al. 1981), lungs 
(Cantor, Osman et al. 1984), liver (Shikata, Oda et al. 1970) and immune system 
(Sauers, Wierda et al. 1988).  Despite these finding, phospholipidosis is typically 
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thought of as a compensatory cellular response to the cellular accumulation of drugs 
that fails to result in overt organ dysfunction or toxicity (Reasor and Kacew 2001). 
 Another interesting finding is that the accumulation of therapeutic agents in 
lysosomes results in a reduction in the pharmacological activity of drugs with 
extralysosomal targets (Duvvuri, Konkar et al. 2006).  Such an observation suggests 
that the subcellular distribution of drugs can impact their ability to interact with their 
pharmacological targets and therefore modulates their therapeutic activity.  The work in 
this area has been primarily conducted in anticancer therapeutics and refers to the 
accumulation of these drugs in lysosomes as an intracellular sequestration 
phenomenon.  It has been found that cancer cells that are able to sequester the weakly 
basic anticancer agent, daunorubicin, in lysosomes are far less sensitive to the drug 
than cancer cells that fail to significantly sequester the drug in lysosomes (Duvvuri, 
Konkar et al. 2005).  In fact, one of the mechanisms of drug resistance by cancer cells 
is thought to be the acquisition of the ability to sequester daunorubicin in lysosomes 
through a re-acidification of their lysosomes (Gong, Duvvuri et al. 2003; Duvvuri and 
Krise 2005).  In addition, the fact that many cancer cells have an elevated lysosome pH 
and non-cancerous, normal cells have acidified lysosomes has resulted in a novel drug 
design strategy whereby anticancer agents are designed to be substrates for lysosomal 
sequestration (Ndolo, Jacobs et al. 2010).  The hypothesis is that non-cancerous cells 
will be capable of sequestering the drug in non-target containing lysosomes, whereas, 
cancer cells without acidified lysosomes, will not.  This intracellular distribution-based 
selectivity platform is currently under investigation as a strategy to reduce the activity of 
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the drug in normal, non-cancerous cells, while maintaining its activity in cancer cells, 
thus improving the selectivity or therapeutic index of the drug. 
 
1.6. Effect of amine-containing drug accumulation on lysosomes 
1.6.1. Amine-containing drugs affect lysosomal structure and function 
In considering the importance of lysosomal ion trapping in drug development 
many have focused on how this subcellular disposition mechanism is important to drug 
distribution and drug activity.  Of great importance is the potential affect of these drugs 
on the normal physiology of the lysosome, thus playing a potential role in the 
therapeutic activity or toxicity of these drugs.  Realizing that these drugs are predicted 
to reach concentrations within the lysosome several hundreds to thousands of times 
that seen in the extracellular space, it would be expected that these drugs would have 
local effects within the lysosome.  A variety of studies utilizing lysosomotropic 
compounds have illustrated the ability of these drugs to influence lysosomal structure 
and function (Matsuzawa and Hostetler 1980; Ohkuma and Poole 1981; Poole and 
Ohkuma 1981; Ohkuma, Chudzik et al. 1986; Morissette, Lodge et al. 2008).  Despite 
the multitude of observations it appears that these effects are most likely secondary to 
one of three primary effects of amine-containing drugs on lysosomes, including: 
lysosomal alkalinization, cytoplasmic vacuolization and lysosomal lipid accumulation.  
All of these effects have been observed with various lysosomotropic compounds and 
have been directly attributed to the lysosomal accumulation of these drugs.  In addition, 
these effects are believed to result in changes in normal cellular processes that rely on 
functioning lysosomes.   
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The following sections will highlight the three main effects of amine-containing 
drugs on lysosomes and how they result in additional defects in normal lysosomal and 
cellular functioning.  In addition, the hypothesized mechanisms through which these 
drugs mediate these effects will be discussed along with the observed importance of 
drug hydrophobicity in differentiating the ability of these drugs to cause these various 
alterations in lysosome-related properties. 
 
1.6.2. Lysosomal alkalinization 
Perhaps the most intuitive as well as most mechanistically understood effect of 
amine-containing drugs on lysosomes is a significant alkalinization of the normally 
highly acidic lysosome (Poole and Ohkuma 1981).  The development of lysosomal 
probes with pH-sensitive fluorescence properties has made this a rather simple 
parameter to monitor in cell culture models using either ratiometric imaging (Maxfield 
1989) or whole cell spectrofluorometric measurements (Ohkuma and Poole 1978).  
Because of the simplicity of this measurement, amine-induced lysosomal alkalinization 
has been extensively studied and is a well-accepted phenomenon.  Measurements of 
lysosomal pH in cells following treatment with ammonia shows that this effect occurs 
rapidly following addition of drug, reverses rapidly upon removal of ammonia and is 
dependent on the dose (Figure 1.7).   
The ability of amine-containing drugs to cause a relative alkalinization of the 
lysosome is thought to be a direct result of lysosomal uptake of the amine-containing 
drug (Ohkuma and Poole 1978).  Once the amine-containing drug enters the lysosome 
it is hypothesized to cause a pronounced decrease in the free hydrogen ion  
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Figure 1.7.  Measurements of lysosomal pH using a fluorescence-based assay 
shows the effect of amine-containing compounds on lysosomal pH in living cells.  
Lysosome pH at the start of each experiment was below 5.0 and following the 
addition of (A) 100 µM (B) 1 mM or (C) 10 mM ammonium chloride the lysosomal pH 
increased rapidly (< 5 minutes) to a steady state level that significantly depended on 
dose.  At the end of 20 minutes the cells were washed (W) of ammonia and the 
lysosomal pH rapidly returned to levels at or below its initial value.  Open circles 
represent a non-ratiometric measurement of lysosome pH and closed circles 
represent a concentration corrected ratiometric measurement of lysosome pH.  
Reproduced with permission from the National Academy of Sciences (Ohkuma and 
Poole 1978).   
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concentration (i.e., increased pH) by either its ability to 1) act as a buffer within the 
lysosomal lumen or 2) short-circuit the lysosomal pH gradient by transporting hydrogen 
ions out of the lysosome by diffusing out of the lysosome in its ionized form (Poole and 
Ohkuma 1981), see illustration in Figure 1.8.  In addition, it has also been hypothesized 
that amine-containing drugs can potentially affect lysosomal pH by inhibiting V-ATPase 
activity, thereby reducing the transport of protons into the lysosome (Goldman, Funk et 
al. 2009).  Regardless of the mechanism, treatment with weakly basic amine-containing 
drugs results in a reduced hydrogen ion concentration within the lumen of the lysosome 
and therefore an increase in pH.   
Normally, the acidic lysosomal pH is maintained through the active inward 
pumping of protons by the V-ATPase, therefore to cause lysosomal alkalinization the 
rate of proton consumption or transport by the amine drug must exceed the active 
inward pumping of protons.  Intuitively, it might be expected that after prolonged activity 
of the proton pump, lysosomal pH would rebound resulting in re-acidification, but in vitro 
time-based studies have not shown that to be the case with no re-acidification of the 
lysosome occurring over several hours following introduction of drug into the media 
(Poole and Ohkuma 1981).  An ex vivo study assessing the time dependence of 
chloroquine-induced lysosomal pH perturbations in hepatocytes suggested that 
treatment with the amine-containing drug results in a transient alkalinization of the 
lysosome that is reversed within 3 hours of drug administration in rats (Tietz, Yamazaki 
et al. 1990).  The authors speculate that re-acidification of the lysosomes results from 
the compensatory activity of the V-ATPase, but one must question the role of drug 
clearance in this apparent reversal of lysosomal alkalinization.  Especially since in vitro 
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Figure 1.8.  Amine-induced lysosomal alkalinization.  Illustrated are the hypothesized 
mechanisms by which amine-containing compounds accumulating in the lysosome 
cause an alkalinization of lysosomes. Mechanism 1 is the local buffering effect 
mediated by the amine-drug entering in its unionized form (B) and consuming free 
hydrogen ions through its protonation (BH+).  Mechanism 2 is the diffusion of ionized 
drug (BH+) out of the lysosome transporting a hydrogen ion with it.  Reproduced with 
permission copyright Poole et al., 1981 (Poole and Ohkuma 1981). 
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studies have shown that amine-containing drug-induced lysosomal alkalinization occurs 
rapidly following drug exposure and reverses rapidly upon removal of drug (Ohkuma 
and Poole 1978).  Such a rapid effect is expected since the amine-containing drug 
enters and exits the lysosome through simple passive diffusion, but interestingly it was 
found that lysosomal pH doesn’t directly correlate to cellular uptake of the amine-
containing drug (Poole and Ohkuma 1981).  This effect was illustrated using the highly 
lysosomotropic amine, methylamine, where the initial uptake phase for methylamine 
appears to correspond to a rapid elevation in lysosomal pH but a subsequent secondary 
uptake phase ensues that doesn’t correspond to any further change in lysosomal pH 
(Figure 1.9).  This apparent lack of direct correlation between uptake of lysosomotropic  
amines and changes in lysosomal pH makes one question the information that can be 
obtained from recently developed assays that measure the lysosomotropic properties of  
drugs based on their ability to cause lysosomal alkalinization (Lemieux, Percival et al. 
2004; Nadanaciva, Lu et al. 2011).  These assays may provide a more qualitative than 
quantitative determinant of a drug’s lysosomotropic properties and may make direct 
comparisons of lysosomotropism between drugs quite difficult. 
Interestingly, different amine-containing compounds have a very large difference 
in their potency in causing lysosomal alkalinization (Poole and Ohkuma 1981).  
Investigations into the structural predictors of what causes one amine-containing drug to 
be more potent at causing lysosomal alkalinization than a second resulted in a 
relationship between drug hydrophobicity and potency in causing lysosomal 
alkalinization (Ishizaki, Yokogawa et al. 2000).  Lysosomal pH was measured in isolated 
lysosomes treated with several amine-containing drugs (Figure 1.10).  The potency of  
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Figure 1.9.  Lysosomal alkalinization by the amine containing compound, 
methylamine, doesn’t directly correlate to cellular uptake of the drug.  Time-based 
measurements of lysosome pH (triangles) and cellular uptake of methylamine 
(circles) after the addition of 10 mM methylamine to cells in culture shows a rapid 
alkalinization of lysosomes.  Initial pH values are below 5.0 and reach a steady state 
level (pH 6.5) in less than 5 minutes following addition of drug.  Cellular uptake of 
methylamine appears to be biphasic with an initial uptake phase that correlates to the 
observed pH change, and a secondary uptake phase that continues through the 
remainder of the experiment with no further change in lysosome pH.  Reproduced 
with permission copyright Poole et al., 1981 (Poole and Ohkuma 1981). 
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Figure 1.10.  Measurement of pH in isolated lysosomes following treatment with 
weakly basic amine-containing drugs of varying hydrophobicity.  Isolated lysosomes 
were treated with dose titrations of chlorpromazine (closed triangles), imipramine 
(open triangles), propranolol (open circles) and ammonium chloride (closed circles).  
Dose-relationships for alkalinization of lysosomes showed that the potency of these 
compounds (chlorpromazine > imipramine > propranolol > ammonium chloride) 
correlated to their relative hydrophobicity (chlorpromazine > imipramine > propranolol 
> ammonium chloride) as determined by logP values which were determined using 
the logP plug-in from the MARVIN software freely available at www.chemaxon.com.  
Reproduced with permission from (Ishizaki, Yokogawa et al. 2000).  
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these compounds in causing lysosomal alkalinization (chlorpromazine > imipramine > 
propranolol > ammonium chloride) appeared to correlate to their relative hydrophobicity 
(chlorpromazine > imipramine > propranolol > ammonium chloride).   
Subsequent studies that indirectly measured lysosomal alkalinization by 
measuring inhibition of imipramine uptake into isolated lysosomes found a similar 
relationship (Figure 1.11).  Concentrations of drug necessary to inhibit lysosomal uptake 
of imipramine by 50% (i.e., IC50) were plotted as a function of the hydrophobicity of the 
drug (i.e., logP).  Increased hydrophobicity correlated with a decreased IC50, indicating 
that hydrophobic drugs were more potent lysosomal alkalinizers than their relatively 
hydrophilic counterparts.  In addition, it was found that amine-containing drugs with  
increased hydrophobicity accumulate in lysosomes to a much higher degree as 
compared to the hydrophilic ones (Ishizaki, Yokogawa et al. 2000).  The enhanced 
capacity of lipophilic amines to accumulate in lysosomes and cause lysosomal 
alkalinization was proposed to result from intralysosomal binding and/or aggregation of 
the ionized lipophilic amines which facilitates the enhanced lysosomal accumulation of 
the amine-containing drugs. 
The acidic environment of lysosomes is an important physiological characteristic 
that facilitates many of the organelle’s biological functions.  Many of the lysosomal 
enzymes are known to be optimally active under acidic conditions and to require 
activation within the acidic environment of the lysosome in order to be processed from 
their inactive pro-forms into their active forms (Kornfeld 1986).  Therefore, amine-
induced alkalinization of lysosomes results in both a decrease in the hydrolytic activity 
of lysosomal enzymes (Ohkuma, Chudzik et al. 1986) and a defect in the normal  
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Figure 1.11.  Potency in causing alkalinization of lysosomes correlates with drug 
hydrophobicity.  A series of amine-containing drugs were experimentally evaluated 
for the concentration necessary to inhibit lysosomal uptake of imipramine by 50% 
(IC50).  Inhibition of imipramine uptake is assumed to be directly related to 
alkalinization of lysosomes.  Regression analysis of the plot of IC50 versus 
hydrophobicity (LogPoct) shows a strong correlation.  Drugs of increased 
hydrophobicity appear to be more potent at causing lysosome alkalinization.  
Reproduced with permission (Ishizaki, Yokogawa et al. 2000).  
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processing of lysosomal enzymes (Cardelli, Richardson et al. 1989).  Additionally, the 
pH of the lysosome has been shown to be an important regulator of lysosomal calcium 
concentrations with amine-induced lysosomal alkalinization resulting in decreased 
lysosomal calcium levels (Christensen, Myers et al. 2002).  Under the normal 
processing of ligands for receptor-mediated endocytosis, the acidic environment of 
endocytic compartments is instrumental in the dissociation of receptor-ligand 
complexes; therefore, amine-induced perturbations in endocytic acidification results in 
the accumulation of un-dissociated complexes that either accumulate in the endocytic 
compartment (Harford, Wolkoff et al. 1983) or recycle back to the cell surface 
(Ciechanover, Schwartz et al. 1983).   
Although few drugs are known to cause significant lysosomal alkalinization at 
therapeutically relevant concentrations, the toxicological and pharmacological 
implications of such effects have been hypothesized and tested in various systems.  
The anti-malarial chloroquine is perhaps the most studied drug that is known to cause a 
significant lysosomal alkalinization at drug concentrations reached in vivo and has had 
many of its pharmacological properties attributed to this unique effect.  Since 
chloroquine is a dibasic compound with two ionizable amines with near neutral pKa 
values (Hollemans, Elferink et al. 1981), its lysosomotropic properties far exceed those 
of mono-basic amines, and thus, results in an extremely high level of lysosomal 
accumulation and alkalinization that is observed at therapeutically relevant drug 
concentrations.  The anti-malarial activity of chloroquine relies heavily on its ability to 
accumulate in the acidic food vacuole of the malaria parasite, but is not mediated by its 
alkalinizing effect (Ginsburg, Nissani et al. 1989).  However, pharmacological activity of 
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chloroquine as an anti-viral and anti-inflammatory agent has been more closely linked to 
its ability to cause lysosomal alkalinization (Savarino, Boelaert et al. 2003).  Studies 
using other amine drugs have further suggested the potential therapeutic utility of 
lysosomal alkalinization in the treatment of viral infections, through inhibition of viral 
escape from endocytic compartments and/or the intracellular processing of viral proteins 
(Baxt 1987; Ashfaq, Javed et al. 2011).   
In addition to the pharmacological utility of lysosomal alkalinization, other studies 
have indicated potential toxicological ramifications.  For example, the lysosomal 
alkalinizing amine, ammonium chloride, was found to cause the intracellular 
accumulation of inclusion bodies similar to those seen in Parkinson’s disease with the 
selective loss of dopaminergic and noradrenergic neurons resulting in movement 
disorders in medaka fish (Matsui, Ito et al. 2010).  This work suggested that 
environmental toxins with lysosomotropic properties may be pathogenic mediators of 
Parkinson’s disease, but would also include many therapeutic agents because of their 
lysosomotropic properties.  Another interesting study that was born out of the 
association of methamphetamine use with advanced progression of AIDS revealed that 
the lysosomal alkalinizing effect of methamphetamine results in immunosuppressive 
effects in vitro (Talloczy, Martinez et al. 2008).  At pharmacologically relevant 
concentrations, methamphetamine exposure resulted in defective antigen processing 
and presentation, as well as, reduced phagocytic activity and increased intracellular 
proliferation of fungi that are common mediators of secondary disease in HIV+ patients.  
The hypothesis that methamphetamine mediates its immunosuppressive activity 
through lysosomal alkalinization was supported by illustrating the ability of chloroquine-
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induced lysosomal alkalinization to cause the same immunosuppressive phenotype in 
vitro. 
Because lysosomal pH is a large driving force for the cellular and tissue 
accumulation of various drugs it plays a significant role in the tissue-distribution and 
pharmacokinetic properties of these drugs, therefore factors that influence the 
accumulation of these drugs in lysosomes would be expected to result in altered 
pharmacokinetic properties.  One such example would be the co-administration of these 
drugs with other compounds that cause alkalinization of lysosomes, resulting in reduced 
drug uptake into lysosomes.  In fact, a series of studies has illustrated that drugs 
causing lysosomal alkalinization result in decreased lysosomal uptake of secondarily 
administered lysosomotropic amine drugs (Daniel 2003).  Reduced lysosomal uptake 
results in decreased drug uptake into tissues enriched with lysosomes (i.e., lysosome-
rich) and increased drug concentrations in tissues lacking in lysosomal content (i.e., 
lysosome-poor).  The significance of this interaction is seen with neuroleptic agents that 
accumulate in lysosomes.  These agents mediate anticholinergic toxicity through their 
interaction with the lysosome-poor cardiac tissue.  Therefore, co-administration of the 
neuroleptic agents with drugs known to cause lysosomal alkalinization would result in 
decreased drug uptake in lysosome-rich tissue and increased drug concentrations in the 
lysosome-poor cardiac tissue.  Increased concentrations in the cardiac tissue would be 
expected to facilitate an increased risk for anticholinergic cardiotoxicity (Daniel and 
Wojcikowski 1999) and would represent a significant pharmacokinetic drug-drug 
interaction. 
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1.6.3. Cytoplasmic vacuolization 
Even before lysosomal ion trapping was recognized as a subcellular disposition 
phenomenon, it was realized that a variety of drugs can induce an apparent expansion 
of the vacuolar compartment that was referred to as cytoplasmic vacuolization (Yang, 
Strasser et al. 1965).  Later studies sought to reveal the mechanism of this apparently 
non-toxic, gross morphological effect on cells.  It was shown that the amine-containing 
compound, methylamine, causes the development of large cytoplasmic vacuoles that 
decrease in size when methylamine accumulation in lysosomes is reduced by either 
decreasing the pH of the culture medium or reducing its concentration (Figure 1.12).  
Similarly, comparison of the cellular uptake of several amine-containing 
compounds and the resulting appearance of cytoplasmic vacuoles indicated that 
vacuolization was directly dependent on cellular uptake of the drug (Figure 1.13).  
Following exposure to drugs at various concentrations cytoplasmic vacuolization was 
assessed by microscopy and scored based on intensity, with three being major 
vacuolization and zero being no vacuolization.  These results suggested that 
cytoplasmic vacuolization was secondary to the intense lysosomal accumulation of 
weakly basic amine-containing drugs by an ion trapping-based mechanism (Ohkuma 
and Poole 1981).    
 Further studies using the weakly basic amine-containing drug, procainamide 
(Morissette, Moreau et al. 2004; Morissette, Lodge et al. 2008), have found that amine-
drug accumulation in lysosomes results in a time-dependent osmotic swelling of the 
lysosome that is reversible upon removal of drug and can be inhibited by either 
treatment with the V-ATPase inhibitor bafilomycin A1 or co-treatment with the  
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Figure 1.12.  Cytoplasmic vacuolization following methylamine treatment depends on 
pH of the media and methylamine concentration.  Addition of 10 mM methylamine to 
cells at (A) pH 7.6, (B) pH 7.0 or (C) pH 6.6 observed by phase microscopy shows an 
intense vacuolization that decreases with decreases in media pH.  (D) 1 mM 
methylamine at pH 7.6 shows a reduced level of vacuolization as compared to (A).  
These results support a lysosomal ion trapping dependent induction of cytoplasmic 
vacuolization by methylamine.  Reproduced with permission copyright Poole et al., 
1981 (Ohkuma and Poole 1981).  
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Figure 1.13.  Cellular uptake of weakly basic amine-containing compounds is 
associated with cytoplasmic vacuolization.  Measurement of cellular uptake of a 
variety amine-containing compounds in nmol/mg of protein is plotted as a function of 
the vacuolization score determined following drug treatment by phase microscopy.  A 
score of 0 indicates no vacuolization and 3 is the most intense vacuolization.  A high 
level of cellular uptake of the compound appears to be necessary to cause 
vacuolization.  Reproduced with permission copyright Poole et al., 1981 (Ohkuma 
and Poole 1981).   
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membrane-impermeable osmotically active sugar, mannitol (Figure 1.14).  The 
procainamide-induced cytoplasmic vacuoles were characterized by the presence of a 
variety of cellular organelle markers, including: lysosomes, late endosomes and the 
Golgi apparatus.  The presence of these various organelle markers led to the 
hypothesis that cytoplasmic vacuolization results from the fusion of various cellular 
compartments resulting in enlarged hybrid organelles.  Similarly, studies of amine-
induced vacuolization have shown that the lysosomal membrane protein, NPC1, is 
important in the regulation of the fusion of late endosomes and lysosomes in the 
formation of the amine-induced vacuoles (Kaufmann and Krise 2008), therefore despite 
the role of osmotic pressure in the formation of vacuoles the fusion of intracellular 
compartments is critical in the formation of the vacuoles.  In addition, it was found that 
the cytoplasmic vacuoles labeled with autophagic markers, indicating a role for the 
autophagic stress response in drug-induced vacuole formation (Morissette, Lodge et al. 
2008).  The proposed mechanism of drug-induced cytoplasmic vacuolization is 
illustrated in Figure 1.15.  Lysosomal accumulation of the amine-drug increases the 
tonicity of the lysosomal lumen resulting in the osmotic influx of water.  Through the 
fusion of lysosomes with other cellular organelles, grossly enlarged hybrid organelles 
are formed (i.e., cytoplasmic vacuoles) containing the drug and water.   
Studies investigating drug-induced vacuolization with amine-containing 
compounds have documented the ability of a variety of relatively hydrophilic amine-
containing compounds (logP < 2) to cause a pronounced cytoplasmic vacuolization 
marked by the accumulation of large translucent vacuoles, whereas, the ability of 
amine-containing drugs of relative hydrophobicity (logP > 2) rarely cause this effect  
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Figure 1.14.  Cytoplasmic vacuolization induced by the weakly basic amine, 
procainamide (PA), is a reversible process that is time dependent, osmotically driven 
and dependent on lysosomal uptake of drug.  (A) Cells treated with procainamide 
(structure shown) at a concentration of 2.5 mM for up to 4 hours show a time 
dependent development of cytoplasmic vacuoles as shown by phase microscopy.  
Addition of the V-ATPase inhibitor, bafilomycin A1 (4h+bafilo), prevents the formation 
of vacuoles.  Removal of procainamide with a 2-hour washout (4h+w/o at 2h) 
reversed the vacuolization.  (B) Addition of the membrane-impermeable osmotically 
active sugar, mannitol, prevented the procainamide-induced vacuolization as seen by 
phase microscopy with quantiative analysis of the images measuring vacuolization as 
pixels above threshold.  Reproduced with permission from Elsevier (Morissette, 
Lodge et al. 2008). 
 
 
 36
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15.  Amine-induced cytoplasmic vacuolization.  Illustrated is the 
hypothesized mechanism by which amine-drugs (DH+) accumulating in the lysosome 
cause the development of cytoplasmic vacuoles. Amine-drugs accumulating in 
lysosomes facilitate the osmotic influx of water resulting in grossly enlarged 
cytoplasmic vacuoles.  Vacuoles form through the recruitment of organelle 
membrane components from a variety of organelles including lysosomes, endosomes 
and the Golgi apparatus.   
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(Ohkuma and Poole 1981).  Although both hydrophilic and hydrophobic amine-
containing compounds accumulate in lysosomes, the reason why one group appears to 
cause vacuolization while the other does not remains unclear.  These observations led 
early investigators to speculate that amine-containing drugs that do not cause 
cytoplasmic vacuolization fall into one of four categories that may help explain this 
observation (Figure 1.16).  Group 2 and 3 compounds are proposed to be poor 
substrates for lysosomal ion trapping because of their low pKa or poor membrane 
permeability, respectively.  Without significant accumulation in lysosomes, cytoplasmic 
vacuolization can not occur.  Group 1 and 4 compounds on the other hand are 
proposed to be significantly lysosomotropic but because of their hydrophobicity or 
toxicity are not capable of causing vacuolization.   Group 1 compounds are thought to 
be hydrophobic, even in their ionized state and therefore able to readily diffuse out of 
lysosomes in their ionized form resulting in dissipation of lysosome pH but insufficient 
lysosomal concentrations of drug necessary to cause vacuolization.  Group 4 
compounds, including the well-known hydrophobic amine-drug chlorpromazine, are 
thought to be toxic to cells at concentrations below those necessary to result in 
cytoplasmic vacuolization.  The reason hydrophobic amine-drugs are not typically 
associated with cytoplasmic vacuolization requires further elucidation.  Since 
cytoplasmic vacuolization is proposed to be directly related to the lysosomal uptake of 
the drug, perhaps measurements of lyososmal drug levels would help answer this 
question.  
 Although lysosomal volume expansion through the induction of a cytoplasmic 
vacuolization is an interesting in vitro observation, it often requires exposure to  
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Figure 1.16.  Amine-containing compounds that fail to induce a significant 
cytoplasmic vacuolization: importance of hydrophobicity.  Compounds that fail to 
cause vacuolization are divided into 4 groups based on the proposed reasoning.  
Group 2 and 3 are proposed not to be ideal substrates for lysosomal ion trapping 
because of their pKa or poor membrane permeability, respectively.  Group 1 and 4 
compounds include a number of relatively hydrophobic amines and are hypothesized 
to be too hydrophobic or too cytotoxic to cause vacuolization, respectively.  These 
results suggest hydrophobicity of the amine-containing compound may be an 
important predictor of the ability of a drug to cause vacuolization with drugs of 
increased hydrophobicity unable to cause vacuolization.  Reproduced with 
permission copyright Poole et al., 1981 (Ohkuma and Poole 1981). 
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extremely high (i.e., millimolar) concentrations of amine-containing drug and is therefore 
of questionable therapeutic significance.  In addition, amine-induced vacuolization has 
not been observed in vivo and may be strictly an in vitro phenomenon.  Studies into the 
role of cytoplasmic vacuolization in the pharmacological activity of various drugs have 
been hypothesized for local anesthetics (Bawolak, Morissette et al. 2010) and topical 
anti-wrinkle cosmeceuticals (Morissette, Germain et al. 2007).  One issue is the ability 
to differentiate the effect of vacuolization versus lysosomal alkalinization since both are 
known to occur at these extreme drug concentrations.  Some evidence has suggested 
that cytoplasmic vacuolization inhibits the cellular secretory pathway and mediates 
cytotoxicity independent from the drug-induced effects on lysosomal pH (Morissette, 
Moreau et al. 2005).  This lack of supportive evidence necessitates further studies to 
illustrate the potential therapeutic relevance of amine-induced vacuolization before this 
off-target effect is seriously considered as a pharmacological mediator of drug activity or 
toxicity. 
 
1.6.4. Lysosomal lipid accumulation 
 Arguably the most therapeutically relevant of the drug-induced alterations in 
normal lysosomal physiology is the inhibition of normal lysosomal lipid metabolism.  In 
fact, this phenomenon is routinely screened for in pre-clinical drug development.  The 
discovery of this drug-induced syndrome came after a number of clinical cases of an 
idiopathic syndrome that was identified simply as a “foam cell syndrome” marked by the 
cellular accumulation of lipids.  These cases were found to coincide with the chronic 
administration of the drug, 4-4’-diethylaminoethoxyhexesterol (Yamamoto, Adachi et al. 
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1971).  The syndrome was described by a variety of findings, including 
hepatosplenomegaly, hyperlipidemia as well as the observation of intracellular inclusion 
bodies by electron microscopy.  The drug was found to cause a systemic drug-induced 
lipidosis that resulted in the tissue accumulation of cholesterol, cholesterol esters, 
triglycerides and phospholipids (Yamamoto, Adachi et al. 1971).  Further studies found 
this effect to be associated with a number of drugs from differing pharmacological 
classes (Lullmann, Lullmann-Rauch et al. 1973); since phospholipids appeared to be 
the primary lipid species involved, this effect became commonly referred to as a drug-
induced phospholipidosis.  Electron microscopic studies with the lipidosis-inducing drug, 
AY-9944, revealed the presence of discrete intracellular inclusion bodies that have a 
distinct multilamellar structure (Figure 1.17) similar to those seen in cells from patients 
suffering from genetic errors in lipid metabolism (Sakuragawa 1976).  These inclusion 
bodies are often referred to as multilamellar bodies (MLBs) and are thought to be of 
lysosomal origin as evidenced by positive staining for the lysosomal enzyme, acid 
phosphatase.  Observations of this drug-induced phenotype with significant similarity to 
the enigmatic hereditary lysosomal storage disease, Niemann-Pick disease, led to the 
suggestion that an understanding of the pharmacology of the drug may allow for an 
understanding of the pathogenesis of the disease (Sakuragawa, Sakuragaw et al. 
1977).  More recently these drugs have been used as pharmacological inducers of the 
Niemann-Pick disease phenotype in a variety of in vitro models (Roff, Goldin et al. 
1991). 
 Cellular fractionation studies following treatment with the lipidosis-inducing drugs, 
chloroquine or 4-4’-diethylaminoethoxyhexesterol, allowed for the further confirmation of  
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Figure 1.17.  The lipidosis-inducing drug AY-9944 causes the accumulation of 
intracellular inclusion bodies of lysosomal origin.  Inset is a light microscopic image of 
a tissue section from the optic nerve of a rat following repeated injections of AY-9944.  
Electron microscopic images showing (A) cytoplasmic accumulation of inclusion 
bodies in glial cells.  Increased magnification images of intracellular inclusion bodies 
are described has having (B) a lamellar structure, often referred to as a multilamellar 
body (MLB), and (C) positive staining for the lysosomal marker enzyme, acid 
phosphatase.  Reproduced with permission from the Association for Research in 
Vision and Opthamology (Sakuragawa 1976). 
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MLBs as organelles of lysosomal origin that are enriched in phospholipids, cholesterol 
and, importantly, the inducing drug (Matsuzawa and Hostetler 1980).  Such 
observations of drug and lipid accumulation in the same organelle have supported the 
hypothesis that these drugs are active within the lysosome and inhibit lysosomal lipid 
metabolism by either interacting with the lipids or the enzymes responsible for their 
metabolism.  NMR studies on the interaction of a variety of these drugs with 
phosphatidylcholine suggested that phosopholipids, with charged groups, interact with 
these drugs in a manner that depends on the relative hydrophobicity of the drug and the 
presence of a cationic side group (Seydel and Wassermann 1976).  The complex has 
been hypothesized to include hydrophobic interactions between the drug and lipid, as 
well as, charge-charge interactions between the cationic drug and the anionic portion of 
the lipid.  These findings support the hypothesis that formation of drug-lipid complexes 
inhibits the enzymatic degradation of these lipids (Lullmann, Lullmann-Rauch et al. 
1975). 
Others have hypothesized that lipidosis-inducing drugs bind the lysosomal 
hydrolases and directly inhibit their ability to hydrolyze the various lipids (Martin, Kachel 
et al. 1989).  Of interest though is the apparent lack of ability of these drugs to inhibit 
lipid metabolism in reconstituted assays using cell homogenates.  In studies that 
measured the inhibition of the lysosomal hydrolase, acid sphingomyelinase (ASMase) 
(Yoshida, Arimoto et al. 1985), it was found that the lipidosis-inducing drug, AY-9944, 
specifically inhibited the cellular activity of ASMase (Figure 1.18).  AY-9944 inhibited the 
enzymatic activity of ASMase as indicated by metabolism of sphingomyelin and the two 
marker substrates: HNP and Bis(4-MU)phosphate.  Activity measurements of a  
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Figure 1.18.  Activity of various lysosomal hydrolase enzymes in the postnuclear 
supernatant following the treatment of cells with the lipidosis-inducing drug, AY-9944.  
Compared to control, untreated cells, the cells treated with AY-9944 showed a 
significant reduction in acid sphingomyelinase activity (phosphodiesterase) as 
monitored by the hydrolysis of several substrates including carbon-14 labeled 
sphingomyelin.  Of the various hydrolase activities measured only acid 
sphingomyelinase activity was significantly reduced.  The lipidosis-inducing drug did 
not appear to non-specifically inhibit lysosomal hydrolase activity.  Reproduced with 
permission Oxford University Press (Yoshida, Arimoto et al. 1985). 
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variety of other lysosomal hydrolases however revealed no change following AY-9944 
treatment.  These results suggested that the reduced activity was enzyme specific and 
did not result from a generalized reduction in lysosomal hydrolase activity.   
Interestingly, these authors also found that addition of AY-9944 to cellular 
homogenate resulted in no direct inhibition of ASMase activity.  Inhibition of ASMase 
appeared to require exposure of living cells to the AY-9944 prior to the homogenization 
process in order to cause significant inhibition.  These studies suggested that although 
these drugs appear to specifically inhibit the activity of select lysosomal enzymes (i.e., 
ASMase), they do not directly inhibit them.  The indirect inhibition of these enzymes has 
been hypothesized to occur through drug-induced degradation of the enzymes by 
blocking their intralysosomal binding and promoting their degradation by luminal 
proteases (Hurwitz, Ferlinz et al. 1994; Kolzer, Werth et al. 2004).  Additionally, the 
similarity of the drug-induced lipidosis to Niemann-Pick disease has resulted in the 
hypothesis that these drugs actually inhibit the intracellular vesicle-mediated trafficking 
of lipids rather than their actual enzymatic metabolism (Underwood, Andemariam et al. 
1996), as has been hypothesized to be the case in Niemann-Pick disease.  Illustrations 
of the various hypothetical mechanisms of the drug-induced lipidosis are represented in 
Figure 1.19. 
Although the biochemical mechanism through which drugs cause the gross 
accumulation of lipids is poorly understood, a variety of functional screening methods 
exists to assess this cytopathology in the drug development process.  These models 
simply allow drugs to be studied for their ability to cause the phenotypic accumulation of 
lipids within the lysosomal compartment and have resulted in high throughput studies  
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Figure 1.19.  Amine-induced lysosomal lipidosis.  Illustrated are the hypothesized 
mechanisms by which amine-drugs accumulating in the lysosome (DH+) cause the 
lysosomal accumulation of lipids. At the membrane, lipids are metabolized by lipases 
to form degradation products.  Mechanism 1 is the inhibition of lysosomal hydrolase 
activity, either directly or indirectly.  Mechanism 2 is the formation of drug-lipid 
complexes that inhibit lipid metabolism.  Mechanism 3 is the inhibition of vesicle-
mediated trafficking of lipids out of the lysosome. 
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evaluating the drug properties that are critical and predictive for the drug-induced 
lipidosis.  These studies have found the primary pharmacophore to consist of a 
molecule that is both weakly basic and hydrophobic.  The diversity of pharmacological 
agents with vastly different primary mechanisms of actions that fall into this category 
suggests that the drug-induced lipidosis is not related to any distinct pharmacological 
class of drugs but rather a non-specific effect associated with the physicochemical 
properties of the drug.  The physicochemical properties used to describe the weakly 
basic component are its pKa value and the calculated net charge of the drug at pH 4.0 
(NC pH 4.0) (Tomizawa, Sugano et al. 2006).  These drugs typically have pKa values 
around 8 to 10, but using the parameter of NC pH 4.0 allows for the exclusion of drugs 
that contain a weakly basic amine but are zwitterionic.  The hydrophobicity of these 
drugs is best represented by logP, which is often predicted using quantitative structure 
property relationships (ClogP).  Using data from a series of publications and 
experimental measurements of drug-induced lipidosis, by measuring the cellular 
accumulation of the fluorescent phospholipid analog, NBD-PE, a series of compounds 
was characterized as either inducers of the lipidosis (positive) or not (negative).  A 
graph of ClogP versus NC pH 4.0 (Figure 1.20) for 63 compounds shows that 
compounds positive for the drug-induced lipidosis correlated with a ClogP > 1 and a NC 
pH 4.0 ≥ 1 (Tomizawa, Sugano et al. 2006).   
The cationic property of these drugs represented by pKa or NC pH 4.0 is thought 
to be of primary importance because this group imparts lysosomotropic properties to the 
drug and allows them to reach extremely high concentrations within the lysosome.  The 
hydrophobic region on the other hand is thought to be important because it allows the  
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Figure 1.20.  Physicochemical predictors of drug-induced lipidosis.  Sixty-three drugs 
characterized as either positive (filled circles) or negative (open circles) in their ability 
to induce a lipidosis were plotted as a function of their physicochemical properties.  
Calculations of the physicochemical descriptors of hydrophobicity (ClogP) and net 
charge at pH 4.0 (NC pH4.0) for each drug allowed a plot of ClogP versus NC pH 4.0 
for these drugs.  Drugs that were positive for the lipidosis appeared to have a weaky 
basic, ionizable amine (NC pH4.0 ≥ 1) and to be hydrophobic (ClogP > 1).  
Reproduced with permission the Japanese Society of Toxicology (Tomizawa, Sugano 
et al. 2006). 
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drug to associate with intralysosomal targets, such as proteins and/or lipids.  Because 
these compounds typically contain a hydrophilic region of the molecule (i.e., ionizable 
amine) along with a hydrophobic region, many of these molecules have surfactant 
properties that may play a role in their ability to cause the lipidosis (Schreier, Malheiros 
et al. 2000), possibly by associating with the interior lumen of the lysosomal membrane 
and altering its fluidity.  Such changes in the properties of the membrane may impact 
the fusion and fission events necessary for the normal trafficking of lysosomes and their 
cargoes, or it may impact the activity of membrane-associated proteins resulting in 
defects in lysosomal lipid metabolism and/or trafficking.  
Lysosomal ion trapping of hydrophobic amine-containing compounds that are 
commonly associated with the drug-induced lipidosis has been attributed to both the 
pharmacokinetic and pharmacodynamic properties of many of these agents.  
Specifically, the slow and significant accumulation of hydrophobic amine-containing 
psychotropic drugs in brain tissue has been associated with the anomalous therapeutic 
latency often observed with these agents (Kornhuber, Retz et al. 1995).  Postmortem 
determination of amantadine levels in brain tissue showed that 8 days of treatment were 
necessary to reach 50% tissue saturation.  This prolonged distribution phase was 
hypothesized to exist for other psychotropic drugs, such as antidepressants, and 
represents a novel hypothesis to the observed delay in therapeutic response with these 
agents.  Therefore, the long distribution phase of these drugs may impact their time to 
onset of activity.  In addition, the intralysosomal accumulation of lipids caused by the 
hydrophobic amine, U18666A, has been hypothesized to stabilize lysosomal 
membranes and prevent the lysosomal release of pro-apoptotic enzymes (Appelqvist, 
 
 
 49
Nilsson et al. 2011), as well as, suppress the production of HIV-1 in a cell culture model 
(Tang, Leao et al. 2009).  Similarly, the hydrophobic amine, amiodarone, has been 
shown to reduce the infection of Vero cells with SARS coronavirus (Stadler, Ha et al. 
2008) by some unknown mechanism possibly related to the lipidosis-inducing effect of 
this drug.  
Of therapeutic interest, it has also been found that following the induction of a 
lipidosis in lung alveolar macrophages amiodarone, as well as its metabolite 
desethylamiodarone, accumulate over 10-fold that seen in non-lipidotic macrophages 
(Reasor 1991).  These results suggest that the lipidosis itself may enhance the tissue 
accumulation of hydrophobic amine-drugs.  This suggests that one hydrophobic amine-
containing drug can influence the pharmacokinetic properties of a second by increasing 
its distribution to and accumulation in tissues.  Such an effect may signify the potential 
for a distribution-based pharmacokinetic drug-drug interaction.  Studies on single- 
versus multiple-dose pharmacokinetics have supported a similar effect whereby 
prolonged exposure to the hydrophobic amine, chlorphentermine, results in its 
increased tissue accumulation with chronic dosing (Lullmann, Rossen et al. 1973), 
suggesting the possibility that the lipidosis induced by the drug may facilitate an 
increase in its own apparent volume of distribution and half-life with chronic 
administration. 
 
1.6.5. Importance of drug hydrophobicity 
 In this review, data from a variety of studies illustrating the ability of amine-
containing compounds to alter lysosomal structure and function have been presented.  
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Collectively, the data have supported a general trend that the hydrophobicity of the drug 
is a key predictor in the potency and ability of the amine-containing drug to induce these 
different effects.  An illustration representing the general trends shows the relationship 
between the hydrophobicity of the lysosomotropic amine-containing drug and its ability 
to cause lysosomal alkalinization, cytoplasmic vacuolization and the lysososomal 
lipidosis (Figure 1.21).  The potency of a compound in causing alkalinization of 
lysosomes is directly related to the hydrophobicity of the drug.  Similarly, the lysosomal 
lipidosis is shown to be directly related to drug hydrophobicity, but unlike lysosomal 
alkalinization, drugs of sufficiently low hydrophobicity aren’t capable of causing the 
lipidosis.  In contrast, the cytoplasmic vacuolization is inversely related to drug 
hydrophobicity, with less hydrophobic compounds highly capable of causing the 
vacuolization, whereas the more hydrophobic compounds fail to elicit the effect. 
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Figure 1.21.  Empirical relationship between drug hydrophobicity and observed effect 
on lysosomes.  The hydrophobicity of lysosomotropic amine-containing drugs 
appears to be related to the activity of the drug in causing different effects on 
lysosomes.  Increased hydrophobicity is associated with lysosomal alkalinization and 
lysosomal lipidosis.  Decreased hydrophobicity is associated with cytoplasmic 
vacuolization.   
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Chapter 2 
  
Cationic amphiphilic drug treatment results in enhanced cellular 
accumulation of substrates for ion trapping in lysosomes
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2.1. Introduction 
In this chapter, the effect of cationic amphiphilic drug (CAD) treatment on the 
cellular accumulation and distribution of substrates for lysosomal ion trapping is 
evaluated.  Cellular accumulation of the fluorescent substrate for lysosomal ion 
trapping, LysoTracker Red (LTR), is evaluated in CAD treated cells.  The model CAD, 
imipramine, is found to cause an increase in the vesicular accumulation of LTR similar 
to that seen in NPC disease fibroblasts.  Total cellular accumulation of LTR is increased 
in both CAD treated and Niemann-Pick type C (NPC) disease fibroblasts.  Additional 
amine-containing compounds that are substrates for lysosomal ion trapping are 
increased in both vesicular staining and total cellular accumulation following CAD 
treatment.  Amine-containing compounds that are not substrates for lysosomal ion 
trapping do not change in cellular distribution or accumulation following CAD treatment.  
These findings are consistent with the hypothesis that CADs cause a cellular lipidosis 
similar to that seen in NPC disease fibroblasts resulting in an increase in the lysosomal 
ion trapping capacity of cells.  It is further hypothesized that the increase in lysosomal 
ion trapping capacity results from an expansion of the lysosomal compartment that is 
secondary to the lipidosis found in CAD treated and NPC disease cells. 
Weakly basic amine-containing drugs accumulate in lysososomes (i.e., 
lysosomotropic amines) through an ion trapping-based mechanism that results in 
intralysosomal drug concentrations several orders of magnitude greater than that seen 
in the rest of the cell (Duvvuri and Krise 2005).  In addition to the contribution of 
lysosomal ion trapping to the cellular uptake of these drugs, high intralysosomal drug 
concentrations can cause a number of structural and functional perturbations in the 
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lysosome.  In particular, a group of hydrophobic amine-containing drugs known as 
CADs cause the lysosomal accumulation of lipids similar to that seen in diseases 
resulting from inborn errors in lysosomal lipid metabolism, such as NPC disease (Roff, 
Goldin et al. 1991).  Interestingly, NPC disease cells have been shown to not only have 
enhanced accumulation of lipids but also enhanced cellular accumulation of substrates 
for lysosomal ion trapping (Kopitz, Gerhard et al. 1994; Kopitz, Harzer et al. 1996; 
Kaufmann and Krise 2008).  The mechanism through which amine-containing 
compounds hyperaccumulate in NPC disease cells remains unknown but may be 
directly related to the function of the mutated protein or may be secondary to the 
disease-induced lipidosis.   Nonetheless, the similarity between the NPC disease cells 
and CAD treated cells led to the hypothesis that CAD treatment would similarly increase 
the cellular accumulation of amine-containing compounds. 
The ion trapping of weakly basic amine-containing compounds in lysosomes 
depends on the pH gradient existing between the acidic lumen of the lysosome (~pH 4-
5) and the extralysosomal compartments (~pH 7.0).  Amine-containing drugs entering 
the lysosome through passive diffusion experience a large shift in their ionic distribution, 
favoring ionization.  Because of a marked decrease in the rate of passive diffusion of 
the ionized drug across membranes it becomes effectively trapped within the lysosome 
(de Duve, de Barsy et al. 1974).  The accumulation of drug in lysosomes can account 
for a significant portion of the cellular accumulation of these drugs (Cramb 1986).  
Therefore, changes in the lysosomal properties that dictate cellular drug accumulation 
by lysosomal ion trapping can significantly affect the cellular accumulation of these 
drugs.  For example, the cellular accumulation of these drugs depends on both the 
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volume and pH of the lysosomal compartment (de Duve, de Barsy et al. 1974), with 
changes in either resulting in alterations in the lyososomal ion trapping capacity of cells.  
Microscopy and cellular accumulation studies have suggested that NPC disease cells 
hyperaccumulate amine-containing compounds in an expanded aqueous lysosomal 
storage compartment (Kopitz, Harzer et al. 1996; Kaufmann and Krise 2008).   
Although NPC disease is perhaps best known as a lysosomal storage disease 
resulting in the pronounced lysosomal accumulation of cholesterol (Lange, Ye et al. 
1998) and other lipids (Walkley and Vanier 2009), it has also been shown to result in the 
lysosomal accumulation of amine-containing compounds.  Development of early 
diagnostic tests actually measured the increased cellular accumulation of the 
lysosomotropic amine, methylamine, as a diagnostic marker for the disease (Kopitz, 
Gerhard et al. 1994).  Later studies suggested that one of the proteins responsible for 
NPC disease, NPC1, functions as a molecular transporter in the movement of cargoes, 
including amine-containing compounds such as acriflavine (Davies, Chen et al. 2000).  
Additional studies have suggested that NPC1 may function in the vesicle-mediated 
trafficking of lysosomes and their amine-containing cargo (Kaufmann and Krise 2008).  
Therefore, lysosomal accumulation of amine-containing compounds in NPC disease 
cells may in fact result directly from dysfunctions in the proteins responsible for the 
disease or as hypothesized here it may be a secondary product of the expanded 
lysosomal compartment resulting from the lysosomal lipidosis. 
CADs are generally described as molecules containing a hydrophobic ring 
system and a hydrophilic side chain, which together make the molecule amphiphilic.  
The hydrophilic side chain contains a weakly basic ionizable amine that is cationic in its 
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protonated form and imparts lysosomal accumulation by ion trapping.  In addition, the 
ionizable amine and the relative hydrophobicity of the molecule have been postulated to 
facilitate intralysosomal binding to lipids and other membrane constituents (Halliwell 
1997).  CADs have been shown to cause the lysosomal accumulation of a variety of 
lipid species, including phospholipids (Lullmann, Lullmann-Rauch et al. 1973) and 
cholesterol (Yoshikawa 1991).  Within the lysosome they have been hypothesized to 
directly and indirectly inhibit lysosomal lipase activity, form digestion resistant drug-lipid 
complexes (Anderson and Borlak 2006) and inhibit NPC1-dependent vesicle-mediated 
lipid trafficking out of the lysosome (Lange, Ye et al. 2000).  Whatever the biochemical 
mechanism for the lipidosis, its similarity to that seen in NPC disease cells has resulted 
in the use of CADs to chemically induce NPC disease in cell culture models and led to 
the hypothesis that CADs will also cause an increase in the cellular accumulation of 
substrates for lysosomal ion trapping. 
 
2.2. Materials and methods 
2.2.1. Cell lines and reagents 
LysoTracker Red DND-99 (LTR), LysoTracker Green DND-26, MitoTracker Red 
FM, sulforhodamine 101, Dulbecco’s phosphate buffered saline (D-PBS) and 
Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Invitrogen 
(Carlsbad, CA).  Daunorubicin was purchased from Oakwood Products (West 
Columbia, SC).  Propranol and imipramine were purchased from Sigma-Aldrich (St. 
Louis, MO).  3H-propranolol was purchased from GE Healthcare (Waukesha, WI).  Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA).  
 
 
 68
Wildtype (WT) human fibroblasts (catalogue # CRL-2076) and purchased from ATCC 
(Manassas, VA).  NPC1-/- (catalogue # GM03123) and NPC2-/- (catalogue # GM18455) 
human fibroblasts were purchased from Coriell Cell Repository (Camden, NJ).  Cells 
were maintained in DMEM supplemented with 10% FBS and maintained at 37ºC and 
5% CO2, all experiments were carried out under these conditions unless otherwise 
stated.  Cells were routinely subcultured to maintain 60% to 80% confluency. 
 
2.2.2. Cellular amine accumulation assays 
Fibroblasts were seeded in multi-well polystyrene tissue culture plates and 
allowed to adhere overnight.  Cells were treated 10 µM imipramine or vehicle alone for 
48 hours under normal growth conditions.  In the last 2 hours, the amine-containing 
probes were added.  Concentrations of 100 nM LTR, 1 µM LysoTracker Green, 1 µM 
daunorubicin, 5 µM sulforhodamine 101, 100 nM MitoTracker Red and 100 nM 
propranolol containing 10 nM 3H-propranolol were used.   After the 2-hour exposure 
under normal growth conditions cells were washed twice with D-PBS rapidly to prevent 
loss of cell-associated probe by diffusion.  Cells were lysed in either 0.1 M NaOH or 
lysis buffer containing 50 mM tris base, 150 mM NaCl, 1% NP40 adjusted to pH 7.4.  
Lysed samples were immediately assessed for fluorescence or radioactivity.  
Fluorescence was measured using a Bio-Tek FL600 microplate fluorescence reader 
equipped with the appropriate excitation and emission filters for each fluorophore.  
Radioactivity was determined by adding the lysate sample to ScintiVerse BD Cocktail 
(Fisher) with radioactivity in DPM measured by a Beckman LS 60001C liquid 
scintillation counter.  Background signal contribution from non-specific binding of 
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compound to polystyrene surfaces or from the cells alone was subtracted from the 
sample measurements.  Cell protein content was measured using the BCA method.  
Fluorescence (RFU) or radioactivity (DPM) counts were normalized to cellular protein 
and overall cellular accumulation of the probe was expressed as a function of cellular 
protein in micrograms. 
 
2.2.3. Cellular microscopy and probe distribution 
Fluorescence microscopy of amine-containing probe distribution in fibroblasts 
treated with 10 µM imipramine or vehicle alone were carried out using the same 
treatment regimen as done in the ‘Cellular amine accumulation assays’ except cells 
were grown on glass coverslips.  Following the 48-hour imipramine treatment and 2-
hour exposure to the amine-containing fluorophores, the cells were washed twice with 
D-PBS and the cells on coverslips were immediately mounted on microscope slides for 
fluorescence imaging.  The cells were viewed using a Nikon Eclipse 80i microscope 
equipped with a 40x (1.30 NA) oil immersion objective.  Fluorescence images were 
acquired using the filter cube that best overlapped with the documented spectral 
properties of each fluorophore.  Samples for fluorescence imaging were excited with an 
EXFO X-Cite 120 PC fluorescence illumination system.  Images were acquired using an 
ORCA ER camera (Hamamatsu).  Images were analyzed using Metamorph version 7.0 
(Universal Imaging) or ImageJ (free online at rsbweb.nih.gov) software.  Background 
images of cells not exposed to fluorescent probe were acquired to correct for 
autofluorescence and images were scaled identically to allow for comparison.   
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2.3. Results and discussion 
2.3.1. Intracellular distribution and cellular accumulation of amine-
containing compounds in CAD treated and NPC disease fibroblasts 
  The initial studies sought to compare NPC disease cells to CAD treated cells in 
their capacity to accumulate an amine-containing substrate for lysosomal ion trapping.  
Therefore, the fluorescent substrate for lysosomal ion trapping, LTR, was identified as a 
model compound that could be monitored by fluorescence microscopy to qualitatively 
assess the cellular accumulation and distribution of the compound.  In addition, its 
fluorescence properties facilitate quantitative measurements of cellular accumulation of 
the probe.  The model CAD chosen for these studies was imipramine because of its 
well-documented ability to cause a cellular lipidosis similar to that seen in NPC disease 
cells (Rodriguez-Lafrasse, Rousson et al. 1990).  Cell lines used included WT 
fibroblasts and NPC disease fibroblasts that result from mutations in the late 
endosomal/lysosomal proteins Niemann-Pick C1 (NPC1) or Niemann-Pick C2 (NPC2), 
denoted NPC1-/- and NPC2-/-, respectively.  Mutations in either protein, NPC1 or 
NPC2, result in a nearly identical phenotype that is described by the lysosomal 
accumulation of cholesterol and other lipids (Chang, Reid et al. 2005) and has been 
related to a general reduction of egress of cholesterol and other cargoes out of the 
lysosome (Neufeld, Wastney et al. 1999; Kaufmann and Krise 2008; Goldman and Krise 
2010). 
 Fluorescence microscopy studies of LTR accumulation and distribution were 
carried out in WT fibroblasts, with or without imipramine treatment, and NPC1-/- 
fibroblasts (Figure 2.1).  Similar to previous studies, NPC disease fibroblasts show a  
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Figure 2.1.  Increased vesicular accumulation of LTR in CAD treated and NPC 
disease fibroblasts.  Wildtype (WT) control fibroblasts were left untreated or treated 
with 10 µM imipramine (WT + imipramine) for 24 hours under normal growth 
conditions.  WT and imipramine treated WT fibroblasts along with NPC disease 
(NPC1-/-) fibroblasts were exposed to 200 nM LTR for 2 hours prior to imaging.  
Compared to WT cells, both imipramine treated WT cells and NPC disease cells 
show an increase in the vesicular accumulation of the fluorescent substrate for 
lysosomal ion trapping, LTR.    
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significant increase in the punctate vesicular staining of LTR as compared to WT 
fibroblasts (Kaufmann and Krise 2008), suggesting an increase in the cellular 
accumulation of LTR in an expanded lysosomal compartment.  Similarly, WT fibroblasts 
exposed to the lipidosis-inducing imipramine treatment also resulted in a significant 
increase in the punctate vesicular accumulation of LTR.  These results suggest that 
CADs cause the accumulation of substrates for lysosomal ion trapping, similar to that 
observed in NPC disease cells through an expansion of the lysosomal compartment. 
To quantitatively verify the increased cellular accumulation of LTR observed by 
fluorescence microscopy, the total cellular accumulation of LTR was measured in WT 
fibroblasts with or without imipramine treatment, as well as, in NPC1-/- and NPC2-/- 
fibroblasts (Figure 2.2).  In agreement with the fluorescence microscopy results, LTR 
accumulated to a much higher degree in both NPC disease cell lines (i.e., NPC1-/- and 
NPC2-/-) as compared to WT cells.  Similarly, imipramine treatment significantly 
increased LTR accumulation in WT cells confirming the results from the microscopy 
studies.  Together these results suggest that both the NPC disease-induced lipidosis 
and the CAD-induced lipidosis result in an increase in the ability of cells to accumulate 
weakly basic amine-containing compounds as illustrated by both the microscopy and 
cellular uptake studies.  In addition, the microscopy studies suggest that the increase in 
cellular accumulation of these amine-containing compounds occurs through increased 
accumulation in vesicular compartments presumed to be lysosomes.  Since LTR and 
similar compounds accumulate in lysosomes through an ion trapping-based 
mechanism, it was further hypothesized that the lipidosis results in an increase in the  
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Figure 2.2.  CAD treatment increases the cellular accumulation of LTR, similar to 
NPC disease cells.  WT human fibroblasts were treated with 10 µM imipramine (WT 
(+)) or vehicle alone (WT (-)) for 24 hours.  In the last 2 hours of treatment, 200 nM 
LTR was added to the WT fibroblasts or NPC disease fibroblasts with mutations in 
either NPC1 (NPC1-/-) or NPC2 (NPC2-/-).  At the end of the treatment period cells 
were lysed and assessed for total cellular accumulation of LTR.  NPC disease cells 
accumulate more LTR than WT cells.  Imipramine treatment increased the cellular 
accumulation of LTR in WT fibroblasts.  Cellular accumulation of LTR was assessed 
by measuring fluorescence signal in the cell lysate and normalized to cellular protein 
content.  Cellular accumulation of LTR was normalized to the vehicle-treated WT 
cells and expressed as a percentage of control WT.  Cellular accumulation of LTR is 
represented as mean ± S.D. of at least three values for each sample (**, p < 0.01; 
***, p < 0.001 by Student’s t test).  
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lysosomal ion trapping capacity of cells through an expansion of the lysosomal 
compartment. 
 
2.3.2. Intracellular distribution and cellular accumulation of amine-
containing compounds following CAD treatment 
Although CAD treatment was found to increase the cellular accumulation of an 
amine-containing substrate for lysosomal ion trapping, this observation does not 
necessarily establish that the lysosomal ion trapping capacity of the cell is increased.  In 
addition to the lipidosis, CADs are surface-active agents that have been suggested to 
increase the cellular accumulation of drugs by enhancing the permeability of the plasma 
membrane (Tsao, Iga et al. 1982; Drori, Eytan et al. 1995).  Perhaps another 
mechanism of increased cellular accumulation of the amine-containing compounds 
would be through an increase in cellular cationic binding sites.  To further identify the 
mechanism through which the CAD treatment increases the cellular accumulation of 
amine-containing compounds a series of amine-containing compounds that can be 
classified as lysosomotropic or non-lysosomotropic were identified.  These compounds 
and their structures are illustrated in Figure 2.3.  The lysosomotropic compounds are all 
well-established substrates for lysosomal ion trapping and includes: daunorubicin 
(Gong, Duvvuri et al. 2003), LysoTracker Red (Lemieux, Percival et al. 2004), 
LysoTracker Green (Zheng, Zhang et al. 2010) and propranolol (Cramb 1986).  The 
non-lysosomotropic compounds on the other hand accumulate in cells through non-ion 
trapping mediated mechanisms.  Sulforhodamine 101 is a zwitterionic compound  
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Figure 2.3.  Model amine-containing compounds characterized as lysosomotropic or 
non-lysosomotropic.  Lysosomotropic amine-containing compounds are substrates 
for extensive cellular accumulation by ion trapping in lysosomes, whereas non-
lysosomotropic compounds are amine-containing compounds but fail to accumulate 
in cells by ion trapping in lysosomes.  Cellular accumulation of these compounds was 
measured following a lipidosis-inducing treatment with imipramine.  When possible 
fluorescence microscopy was used to assess the intracellular distribution of these 
compounds. 
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thought to accumulate in cells through fluid-phase endocytosis (Colin, Limagne et al. 
2011) and has been shown to be a substrate for the multidrug resistance-related protein 
(MRP1), but its uptake is insensitive to intracellular pH gradients and is therefore 
presumed not to be a substrate for lysosomal ion trapping (Gong, Duvvuri et al. 2003).  
MitoTracker Red is a cationic fluorophore that accumulates in, and specifically labels, 
mitochondria based on the negative membrane potential of the organelle (Poot, Zhang 
et al. 1996).  If only the lysosomotropic amines are affected by CAD treatment, then an 
increase in lysosomal ion trapping capacity would be suggested.  If the non-
lysosomotropic amines are also hyperaccumulated, then an increase in cationic binding 
sites or an increase in the membrane permeability will be suggested. 
WT fibroblasts were treated with the CAD, imipramine, at the lipidosis-inducing 
concentration of 10 µM for 48 hours and the cellular accumulation and distribution of the 
lysosomotropic and non-lysosomotropic compounds were assessed following a 2 hour 
exposure.  Fluorescence imaging revealed that imipramine causes a significant 
increase in the vesicular accumulation of the lysosomotropic amine-containing 
compounds, including LTR, LysoTracker Green and daunorubicin (Figure 2.4).  Imaging 
of sulforhodamine 101 and MitoTracker Red revealed no change in the cellular 
accumulation or distribution of these compounds following imipramine treatment (Figure 
2.5).   
Similarly, imipramine treatment resulted in an increase in the cellular 
accumulation of the lysosomotropic amines, including LTR, LysoTracker Green, 
daunorubicin and propranolol (Figure 2.6).  Cellular accumulation of sulforhodamine 101 
and MitoTracker Red were found to be unchanged (Figure 2.7).  Together these results  
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Figure 2.4.  Increased vesicular accumulation of lysosomotropic amine-containing 
compounds following imipramine treatment.  WT fibroblasts were left untreated 
(control) or treated with 10 µM imipramine for 48 hours.  100 nM LysoTracker Red, 1 
µM LysoTracker Green or 1 µM daunorubicin was added in the last 2 hours and cells 
were subsequently imaged by fluorescence microscopy.  The lipidosis-inducing 
imipramine treatment increased the vesicular accumulation of all three 
lysosomotropic compounds. 
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Figure 2.5.  Imipramine treatment does not affect the cellular distribution or 
accumulation of non-lysosomotropic amine-containing compounds.  WT fibroblasts 
were left untreated (control) or treated with 10 µM imipramine for 48 hours.  100 nM 
MitoTracker Red or 5 µM sulforhodamine 101 was added in the last 2 hours and cells 
were subsequently imaged by fluorescence microscopy.  The lipidosis-inducing 
imipramine treatment had no effect on the cellular distribution or accumulation of 
either of the non-lysosomotropic compounds. 
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Figure 2.6.  Increased cellular accumulation of lysosomotropic amine-containing 
compounds following imipramine treatment.  WT fibroblasts were left untreated 
(control) or treated with 10 µM imipramine for 48 hours.  100 nM LysoTracker Red, 1 
µM LysoTracker Green or 1 µM daunorubicin, or 100 nM propranolol containing 10 
nM 3H-propranolol was added in the last 2 hours and cells were subsequently lysed 
and assessed for total cellular fluorescence or radioactivity.  Cellular probe 
accumulation was normalized to cellular protein content and expressed as either 
RFU or DPM per microgram of protein.  The lipidosis-inducing imipramine treatment 
increased the cellular accumulation of all four lysosomotropic compounds.  Cellular 
accumulation is represented as mean ± S.D. of at least three values for each sample 
(**, p < 0.01 ; ***, p < 0.001 by Student’s t test).  
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Figure 2.7.  Imipramine treatment does not affect the cellular accumulation of non-
lysosomotropic amine-containing compounds.  WT fibroblasts were left untreated 
(control) or treated with 10 µM imipramine for 48 hours.  In the last 2 hours, 100 nM 
MitoTracker Red or 5 µM sulforhodamine 101 was added and cells were 
subsequently lysed and assessed for total cellular fluorescence and normalized to 
cellular protein content.  The lipidosis-inducing imipramine treatment did not affect 
the cellular accumulation of the non-lysosomotropic compounds.  Cellular 
accumulation is represented as mean ± S.D. of at least three values for each sample. 
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suggest that treatment with the CAD, imipramine, causes an increase in the cellular 
accumulation of substrates for lysosomal ion trapping without influencing the 
accumulation of amine-containing compounds that are not substrates for lysosomal ion 
trapping.  The failure to affect non-lysosomotropic amines suggests that the increased 
accumulation is not due to a non-specific increase in cellular membrane permeability or 
an increase in intracellular binding sites for cationic drugs.  Therefore, these results are 
in agreement with the hypothesis that CAD treatment causes an expansion of the 
lysosomal compartment resulting in an increased capacity of cells to accumulate 
substrates for ion trapping in lysosomes. 
Although the mechanism for the increased accumulation of the lysosomotropic 
amine-containing drugs could result through several possible mechanisms here it is 
hypothesized that CADs cause an expansion of the lysosomal compartment.  The 
observed increase in vesicular staining of the various lysosomotropic amines following 
imipramine treatment is consistent with this hypothesis.  The observation that both the 
CAD treated and the NPC disease cells show a similar increase in vesicular staining 
further suggests that the lysosomal volume expansion is possibly secondary to the 
lysosomal lipidosis seen under these conditions.  However, these results do not exclude 
the possibility that imipramine directly inhibits the NPC1-dependent transport of amines, 
especially since NPC1 has been hypothesized to function in the regulation of 
intracellular amine transport (Davies, Chen et al. 2000; Kaufmann and Krise 2008).       
Regardless of the mechanism through which imipramine causes the increased 
cellular accumulation of lysosomotropic amine-containing compounds, the ability of one 
drug (i.e., imipramine) to increase the cellular accumulation of a second (i.e., LTR, 
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LysoTracker Green, daunorubicin, propranolol) is hypothesized to illustrate a potential 
distribution-based drug-drug interaction pathway.  The 27% to 123% increase in the 
cellular accumulation of lysosomotropic amine-containing drugs following imipramine 
treatment suggests that, in vivo, imipramine could have a large impact on the tissue 
accumulation and distribution of these drugs.  Increased tissue accumulation would be 
expected to result in an increase in the volume of distribution of these drugs and the 
increased distribution to lysosome-rich tissue would result in increased drug levels in 
tissues such as the liver and lung.  Together this data suggests the CADs can cause an 
increase in the lysosomal ion trapping capacity of cells with increased cellular 
accumulation of weakly basic amine-containing drugs in an expanded lysosomal 
compartment that may have therapeutic implications, such as in drug-drug interactions.  
Further in vivo studies to illustrate its possible therapeutic relevance, as well as, in-
depth in vitro studies to understand the molecular mechanism for this interaction are 
needed.  
 
2.4. Conclusions 
This work sought to illustrate the ability of a lipidosis-inducing CAD treatment to 
cause an increase in the cellular accumulation of substrates for lysosomal ion trapping 
by causing an expansion of the lysosomal compartment.  The basis for this hypothesis 
was derived from the observation that cells from patients with the lysosomal lipid 
storage disease, NPC disease, hyperaccumulate amine-containing compounds in what 
appears to be an expanded lysosomal compartment (Kopitz, Harzer et al. 1996).  
Because CADs are well known for their ability to cause the lysosomal accumulation of 
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lipids, similar to that observed in NPC disease, it was hypothesized that CADs would 
similarly cause an increase in the cellular accumulation of amine-containing compounds 
that accumulate in lysosomes.  Therefore, the initial studies sought to illustrate the 
ability of both NPC disease cells and cells treated with the CAD, imipramine, to show an 
increase in the vesicular staining and cellular accumulation of the substrate for 
lysosomal ion trapping, LTR.  Imipramine was found to cause an increase in both the 
vesicular staining and cellular accumulation of LTR, similar to that observed in NPC 
disease cells.  Subsequent studies measuring the cellular accumulation and distribution 
of lysosomotropic amines and non-lysosomotropic amines were consistent with a 
generalized increase in the cellular accumulation of substrates for lysosomal ion 
trapping following CAD treatment.  Together, these results support a CAD-induced 
expansion of the lysosomal compartment that results in the enhanced capacity of cells 
to accumulate drugs through ion trapping-based accumulation in the expanded 
lysosomal compartment.   
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Chapter 3 
 
Cationic amphiphilic drugs cause a marked expansion of apparent 
lysosomal volume: Implications for a novel intracellular distribution-based 
drug-drug interaction
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3.1. Introduction 
 The purpose of this chapter is to evaluate the ability of a class of drugs, known 
as CADs, to cause an increase in the cellular accumulation of compounds that are 
substrates for ion trapping-based accumulation in lysosomes and to characterize the 
mechanism of this intracellular distribution-based drug-drug interaction.  As previously 
described in Chapter 1, lysosomes are a significant site for the cellular and tissue 
accumulation of weakly basic amine-containing drugs and by reaching concentrations 
within the lysosome several orders of magnitude greater than that seen in the 
extracellular space, these agents are capable of causing various physiological and 
morphological perturbations of the lysosomal apparatus.  As described in Chapter 2, 
CADs are well-documented as causing the lysosomal accumulation of lipids (Halliwell 
1997), similar to that seen in Niemann-Pick type C (NPC) disease (Sakuragawa, 
Sakuragaw et al. 1977; Roff, Goldin et al. 1991).  Interestingly, the studies in Chapter 2 
revealed that NPC disease cells and cells treated with the model CAD, imipramine, had 
an enhanced capacity to accumulate lysosomotropic amine compounds in perinuclear 
vesicular structures presumed to be lysosomes and suggested a relationship between 
the cellular lipidosis and the increased cellular accumulation of weakly basic amine-
containing compounds.   
Consistent with the findings in Chapter 2, in vivo studies have shown that 
following a drug-induced lipidosis, tissues hyperaccumulate amine-containing drugs 
when administered secondarily (Reasor 1991; Zheng, Zhang et al. 2010).  In these 
studies, the increased accumulation of amine-containing drugs was proposed to occur 
through increased lipid-binding sites for the drugs.  Here, the hypothesis is that CADs, 
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rather than increasing the intracellular binding sites for amine-drugs, actually increase 
the cellular accumulation of amine-containing drugs through an expansion of the 
aqueous volume of the lysosomal compartment; therefore, they increase the capacity of 
cells to accumulate drugs by lysosomal ion trapping.  Further, it is hypothesized that the 
expansion of the lysosomal compartment is secondary to the drug-induced lipidosis.  
Such an ability of CADs to alter the cellular retention of other amine-containing drugs 
illustrates a novel distribution-based drug-drug interaction pathway that occurs at the 
intracellular level.  
Previously described drug-drug interactions result from the ability of one drug to 
alter the pharmacokinetic properties of a second drug, including the absorption, 
distribution, metabolism, excretion or transport (ADMET) properties.  The ability of these 
interactions to cause clinically relevant changes in drug efficacy and/or toxicity has 
encouraged researchers to elucidate the various pathways through which drugs can 
interact within the complex biological matrix that is the human body.  Although the 
majority of this work involves drug interactions occurring through modulation of drug 
metabolizing enzymes (Ogu and Maxa 2000) or membrane drug transporters 
(Giacomini 1997), there has been an effort to describe how the propensity of amine-
containing drugs to accumulate in lysosomes can result in distribution-based drug-drug 
interactions (Daniel 2003).  Because of their tendency to accumulate in lysosomes and 
in lysosome-rich tissue (Daniel and Wojcikowski 1999) amine-containing drugs often 
have a high apparent volume of distribution (Bickel, Graber et al. 1983).  Therefore, if 
factors, such as drug co-administration, can influence the deposition of these amine-
containing drugs into lysosome-rich tissue then the distribution profile of these drugs 
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could be significantly altered.  Such deviations in the distribution profile of the drugs are 
expected to have implications in drug efficacy and/or toxicity. 
In Chapter 2 the model CAD, imipramine, was found to specifically increase the 
cellular accumulation of amine-containing compounds that are substrates for ion 
trapping-based accumulation in lysosomes.  Here it is shown that exposure to a variety 
of drug molecules, which are classified as CADs, results in an increase in the cellular 
accumulation of secondarily administered amine-containing compounds.  Further 
mechanistic studies reveal that imipramine causes an expansion of the lysosomal 
compartment of cells.  The lysosomal volume expansion is found to occur in a time- and 
temperature-dependent manner, consistent with an energy-dependent cellular 
remodeling process.  Treatments known to reverse the CAD-induced lipidosis prevent 
the apparent increase in lysosomal volume suggesting the volume expansion is 
secondary to the drug-induced lipidosis.  The results here are consistent with the 
hypothesis that CADs, through their ability to inhibit cellular lipid metabolism, cause an 
increase in the lysosomal volume of cells resulting in the increased cellular uptake of 
lysosomotropic amine compounds, thus revealing a novel mechanism for intracellular 
distribution-based pharmacokinetic drug-drug interactions.   
 
3.2. Materials and methods 
3.2.1. Cell lines and reagents   
LysoTracker Red DND-99 (LTR), LysoTracker Green DND-26 (LTG), anionic 
70,000 mol. wt. Oregon Green Dextran, Dulbecco’s phosphate buffered saline (D-PBS) 
and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Invitrogen 
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(Carlsbad, CA).  Daunorubicin was purchased from Oakwood Products (West 
Columbia, SC).  Nigericin, monensin, hydroxypropyl-β-cyclodextrin (HPCD), 
propranolol, imipramine, concanamycin A, ammonium chloride, haloperidol, risperidone, 
chlorpromazine, lidocaine, bupivacaine, amiodarone, and verapamil were purchased 
from Sigma-Aldrich (St. Louis, MO).  3H-propranolol was purchased from GE Healthcare 
(Waukesha, WI).  14C-methylamine was purchased from Moravek Biochemicals (Brea, 
CA).  Lipoprotein depleted serum (LPDS) was purchased from Millipore (Billerica, MA).  
Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA).  
CRL-2076 normal human foreskin fibroblasts (WT) were obtained from ATCC 
(Manassas, VA).  NPC1-/- (catalogue # GM03123) and NPC2-/- (catalogue # GM18455) 
human fibroblasts were purchased from Coriell Cell Repository (Camden, NJ).  MDA-
1986 squamous cell carcinoma cells were a generous gift from the laboratory of Dr. 
M.S. Cohen at the University of Kansas Medical Center.  All cells were maintained in 
DMEM supplemented with 10% FBS and maintained at 37ºC and 5% CO2, all 
experiments were carried out under these conditions unless otherwise stated.  Cells 
were routinely subcultured to maintain 60% to 80% confluency. 
 
3.2.2. Drug treatments 
Cells were seeded onto multi-well polystyrene plates and allowed to attach 
overnight.  Imipramine and the other CADs were added at a concentration of 10 µM for 
24 hours to 48 hours, unless otherwise specified.  Lysosomal alkalinizing treatments, 
including; 30 µM chloroquine, 10 mM ammonium chloride and 200 nM concanamycin A 
were applied for a total drug treatment time of up to 2 hours.  Lysosomal pH knockdown 
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experiments were conducted using a 2 hour treatment with the ionophores, 10 µM 
nigericin and 20 µM monensin.  In pH dependent binding studies ionophores were 
added in pH adjusted buffer for 30 minutes to 2 hours just prior to the addition of the 
fluorescent or radioactive amine probe.   The pH 5.0 and 6.0 buffers contained 150 mM 
sodium chloride, 20 mM Mes, 5 mM potassium chloride and 1 mM magnesium sulfate.  
The pH 7.3 buffer was similar except it contained 20 mM Hepes instead of Mes.  In the 
temperature-dependency study, cells were either maintained in 37ºC media or switched 
to 4ºC media followed by the addition of imipramine or vehicle alone.  After 4 hours at 
either 4ºC or 37ºC, cells were washed three times with 37ºC D-PBS and replaced with 
fresh 37ºC growth media without imipramine.  In lipidosis-reversing treatments growth 
media was removed and replaced with either fresh growth media, fresh growth media 
supplemented with 0.1% HPCD or growth media without FBS but supplemented with 3 
mg/ml LPDS.  After 24 hours, either imipramine or vehicle alone was added to each 
treatment group for an additional 24 hours.  In all experiments control cells were treated 
with vehicle only to control for potential vehicle effects.   
 
3.2.3. Cell imaging studies 
Cells were viewed using a Nikon Eclipse 80i epifluorescence microscope 
equipped with a 40x (1.30 NA) oil immersion objectives and a Texas Red HYQ filter 
cube for LTR imaging.  Cells were grown on glass coverslips and maintained under 
normal growth conditions for 24 hours with or without 10 µM imipramine.  In the last 2 
hours of treatment, 200 nM LTR was added to the cells.  Cells undergoing ionophore 
treatment, had 10 µM nigericin and 20 µM monesin added just prior to the addition of 
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LTR.  At the end of the 24-hour treatment, cells were washed three times with D-PBS 
rapidly and immediately mounted on glass microscopy slides for imaging.  Images were 
acquired using an ORCA ER camera (Hamamatsu).  Images were analyzed using 
Metamorph version 7.0 imaging software (Universal Imaging).  Images were acquired 
under identical microscope settings and scaled identically to allow for comparison.   
 
3.2.4. Amine accumulation assays 
Cells were exposed to the indicated fluorescent or radiolabeled amine-containing 
compounds under normal growth conditions for 30 minutes to 2 hours depending on the 
study.  LTR was added at a concentration of 200 nM unless otherwise noted, 
propranolol was added at a concentration of 100 nM containing 10 nM 3H-propranolol 
and 14C-methylamine was added at a concentration of 10 µM.  Cells were then washed 
with D-PBS rapidly to prevent loss of cell-associated compound.  Cells were lysed in 
either 0.1 M NaOH or lysis buffer (50 mM tris base, 150 mM NaCl, 1% NP40 adjusted to 
pH 7.4).  Lysed samples were immediately assessed for fluorescence in RFU or 
radioactivity in CPM.  Fluorescence was measured using a Bio-Tek FL600 microplate 
fluorescence reader equipped with 530 nm excitation and 590 nm emission filters.  
Radioactivity was measured using a Beckman LS 60001C liquid scintillation counter.  
Background signal contribution from non-specific binding of compound to polystyrene 
surfaces or from cell-associated signal was subtracted from the sample measurements.  
Cell protein content was measured using the BCA method, and RFU or CPM counts 
were normalized to cellular protein and overall cellular accumulation of each compound 
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was expressed as either RFU or CPM per microgram of protein or as a percentage of 
vehicle-treated control cells. 
 
3.2.5. Drug uptake and release studies   
Cells pretreated with 10 µM imipramine or vehicle alone for 48 hours were 
exposed to 100 nM propranolol, containing 10 nM 3H-propranolol and 90 nM unlabeled 
propranolol or 1 µM LTG for various times up to 2 hours.  At the designated timepoints, 
drug containing media was removed and cells were washed twice rapidly with D-PBS.  
Lysis buffer was added to each well and incubated at 37ºC for 5 minutes.  Cell lysate 
was transferred to ScintiVerse BD Cocktail (Fisher) for scintillation counting or a 96-well 
plate for fluorescence measurements and measured for protein content using the BCA 
method.  In addition, a dose-titration experiment was conducted in imipramine treated 
cells to establish a dose of propranolol and LTG necessary to give equivalent cellular 
accumulation in vehicle treated (control) and impramine treated cells (data not shown).  
Doses of 74 nM propranolol and 500 nM LTG were established in imipramine treated 
cells to obtain a similar level of uptake seen in vehicle treated cells dosed with 100 nM 
propranolol and 1 µM LTG,respectively. 
Following a 46-hour treatment with imipramine or vehicle alone, 100 nM 
propranolol (10% 3H-propranolol) or 1 µM LTG was added to vehicle-treated control 
cells and 74 nM propranolol (10% 3H-propranolol) or 500 nM LTG was added to 
imipramine treated cells.  Following a 2 hour incubation, the media was removed and 
cells were washed with 37ºC D-PBS.  Fresh media without propranolol or LTG was 
added to the cells.  Imipramine or vehicle alone was maintained in the media through 
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the entirety of the experiment.  For propranolol release, media was removed at each 
timepoint and transferred to scintillation fluid and fresh media was added.  After the last 
timepoint, lysis buffer (pH 7.4, 50 mM tris base, 150 mM NaCl, 1% NP40) was added 
and incubated at 37ºC for 5 minutes.  Cell lysate was transferred to scintillation fluid and 
the remaining cell associated 3H-propranolol was measured along with cell protein 
content using the BCA method.  For LTG release, media was removed and lysis buffer 
was added at each timepoint.  Release was measured over 2 hours and all remaining 
samples were washed at the 30-minute and 60-minute timepoints to maintain sink 
conditions.  Cell lysate from each timepoint was transferred to a 96-well plate for 
fluorescence readings and protein determination by the BCA method.  3H-propranolol in 
each sample was measured in DPM using a Beckman LS 60001C liquid scintillation 
counter. Fluorescence measurements in RFU were made using a Bio-Tek FL600 
microplate fluorescence reader equipped with 485 nm excitation and 530 nm emission 
filters.  Radioactivity and fluorescence counts were normalized to cellular protein 
content and plotted as cell-associated compound in DPM or RFU per microgram of 
protein as a function of time, respectively.  
 
3.2.6. Lysosomal pH measurements 
The influence of imipramine treatment on lysosomal pH was measured using a 
previously published protocol (Ndolo, Forrest et al. 2010) with slight modifications.  
Briefly, MDA-1986 cells were plated onto 8-chamber glass microscope slides and 
allowed to adhere overnight.  Following a 24 hour exposure to 10 µM imipramine or 
vehicle alone, growth media was replaced with phenol red free growth media containing 
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1 mg/ml anionic 70,000 mol. wt. Oregon Green Dextran.  Imipramine or vehicle alone 
was maintained in the media through the entirety of the experiment.  Cells were 
incubated for 2 hours under normal growth conditions followed by removal of the 
fluorescent dextran conjugate containing media.  Cells were washed twice with 37ºC 
sterile D-PBS.  Pre-warmed phenol red free growth media was added and cells were 
incubated under normal growth conditions for 6 hours to chase the dextran conjugated 
probe into lysosomes.  Cells were then washed twice with and then maintained in a pH 
7.4 buffer containing 150 mM NaCl, 20 mM Hepes, 5 mM KCl and 1 mM MgSO4.  
Fluorescence intensity was measured while exciting at wavelengths of 451 nm and 495 
nm on a microscope equipped with a Photon Technology International (Birmingham, 
NJ) Ratiomaster excitation spectrofluoromoter, a D/F/TR multiple bandpass dichroic 
mirror, a 525/10 nm emission filter and a photomultiplier tube detector.  Ratios of 
fluorescence intensity emissions at 525/10 nm (RFU495 nm/ RFU451 nm) were used to 
calculate lysosomal pH according to lysosomal pH calibration curves constructed in 
both imipramine treated and vehicle-treated control cells (data not shown).  Calibration 
curves were created by measuring the fluorescence emission ratio of the dextran 
conjugated probe localized to lysosomes in cells exposed to pH 4.0, 5.0, 5.5 and 6.0 
buffer containing 150 mM sodium chloride, 20 mM Mes, 5 mM potassium chloride and 1 
mM magnesium sulfate supplemented with 10 µM nigericin and 20 µM monensin, as 
established previously (Altan, Chen et al. 1998).  A linear fit of the calibration curves 
allowed calculation of the lysosomal pH from the resulting best-fit line equation. 
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3.2.7. Lysosomal volume calculations   
The amount of LTR accumulated in cells by ion trapping-based accumulation in 
lysosomes was determined in vehicle-treated control cells and cells pretreated with 10 
μM imipramine for 24 hours using eq. 1: 
         
where Dlys represents the amount of LTR accumulated in cells by ion trapping, Dtotal 
represents the amount of LTR that accumulates under normal growth conditions and 
Dnig/mon represents the amount of LTR that accumulates in cells following disruption of 
intracellular pH gradients with nigericin and monensin.   
In eq. 2 the fold change in ion trapping-based accumulation of LTR following 
treatment with imipramine (∆Dlys) is directly related to changes in both lysosomal 
volume (∆Vlys) and lysosomal concentrations of LTR (∆[D]lys). 
      
Eq.3 was derived by de Duve (1974) in his original work detailing the ion trapping 
theory for weak base accumulation in lysosomes.  The equation simply states that for a 
weakly basic compound, such as LTR, the concentration in lysosomes ([D]lys) relative to 
the extracellular space ([D]ext) is approximately equal to the ratio of the hydrogen ion 
concentration in the lysosome ([H+lys) compared to the extracellular space ([H
+]ext).   
                                          
Rearrangement of eq. 3 yields eq. 4.  Assuming that in the experiment the 
concentration of LTR in the extracellular space and the extracellular pH are held 
constant eq. 4 can be simplified to eq. 5.  It can therefore be stated that changes in the 
 (3) 
(1) 
(2) 
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lysosomal concentration of LTR in lysosomes is directly proportional to the 
concentration of hydrogen ions in the lysosomes.  
                                       
  
Substituting eq. 5 into eq. 2 yields eq.6, which relates changes in LTR ion 
trapping in lysosomes to changes in lysosomal pH and/or lysosomal volume. 
   
Direct measurements of lysosomal pH and ion trapping-based accumulation of 
LTR in vehicle-treated (control) and imipramine treated cells allowed for an 
approximation of the relative lysosomal volume change resulting from imipramine 
treatment. 
 
3.3. Results and Discussion 
The ability of CADs to induce a generalized lipidosis in vitro and in vivo has been 
extensively studied yet there remains little consensus regarding the therapeutic and/or 
toxicological ramifications of this drug-induced effect.  This report was focused on how 
exposure to the lipidosis-inducing CADs increases the cellular accumulation of amine-
containing substrates for ion trapping-based accumulation in lysosomes.  It is further 
hypothesized that increased accumulation of these amine-containing drugs results from 
a CAD-induced expansion of the aqueous volume of the lysosomal compartment.  If 
they are confirmed, these results would reveal a therapeutically important consequence 
 (4) 
 (5) 
 (6) 
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of CAD-induced lipidosis in the form of a distribution-based drug-drug interaction 
pathway.  
 
3.3.1. Effect of pharmacologically unrelated CADs on the cellular 
accumulation of substrates for ion trapping in lysosomes 
In Chapter 2 the model CAD, imipramine, caused an increase in the cellular 
accumulation of substrates for lysosomal ion trapping.  The increase in lysosomotropic 
amine accumulation could conceivably be caused by a specific pharmacological effect 
of imipramine, such as modulation of cellular amine transporter activity.  Alternatively, it 
could be generally attributed to the physicochemical attributes of the molecule (i.e., the 
fact that it is both cationic and amphiphilic).  To discern these two possibilities 
evaluation of the propensity of other drugs to enhance the lysosomal sequestration of 
LTR following pretreatment were carried out.  Specifically, a series of eight additional 
drugs similar to imipramine were evaluated; these additional drugs are both cationic and 
amphiphilic based on the physicochemical descriptors of logP and pKa (Ploemen, 
Kelder et al. 2004; Tomizawa, Sugano et al. 2006) but they have varying and known 
mechanism of actions.  The molecular structure of each CAD and their predicted pKa 
and logP values are illustrated in Figure 3.1.  Each compound is described as having a 
weakly basic amine with predicted pKa values ranging from 7.75 to 9.68.  In addition, 
each compound is predicted to be relatively hydrophobic (logP > 2).  Interestingly, all of 
the CADs regardless of their therapeutic application caused a significant increase in the 
cellular accumulation of LTR (Figure 3.2).  This data suggests that CADs cause the 
hyperaccumulation of amine-containing substrates for lysosomal ion trapping as a class  
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Figure 3.1.  Structures and predicted physicochemical properties of model CADs.  
The CADs used in this study are listed along with their structure and predicted pKa 
and logP values.  All CADs tested are relatively hydrophobic (log P > 2) and contain 
a weakly basic amine with a pKa near neutrality (pKa ≥ 7). The free software 
available from ChemAxon (http://www.chemicalize.org) was used to determine the 
predicted pKa and logP values for each compound. 
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Figure 3.2.  CADs increase the cellular accumulation of the model substrate for 
lysosomal ion trapping, LTR.  MDA-1986 cells were treated with a variety of CADs 
from a diversity of pharmacological classes at a concentration of 10 µM (white bars) 
or vehicle alone (black bar) for 24 hours.  In the last 2 hours of treatment, 200 nM 
LTR was added to the treatment media.  At the end of the treatment period cells were 
lysed and assessed for total cellular accumulation of LTR.  All CAD treated cells 
accumulated significantly more LTR than control cells.  Cellular accumulation of LTR 
was assessed by measuring fluorescence signal in the cell lysate and normalized to 
cellular protein content.  Cellular accumulation of LTR was normalized to control cells 
and expressed as a percentage of control.  Cellular accumulation of LTR is 
represented as mean ± S.D. of at least three values for each sample (***, p < 0.001 
by Student’s t test).  
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effect related to the physicochemical properties of the molecule rather than its specific 
pharmacological activity.  The significant difference in LTR accumulation observed with 
the different CADs may reflect the potency of these compounds in causing an 
expansion of the aqueous volume of the lysosome.  Because the hypothesis is that 
lysosomal volume expansion results from the cellular lipidosis, the response may be 
reflective of the potency of the drug in inhibiting lysosomal lipid metabolism.  Similarly, 
because CADs are amine-containing compounds they are also capable of causing 
mixed effects on the lysosome, such as alkalinization of lysosomes, and despite the 
expanded aqueous volume of the lysosome the concomitant alkalinization of the 
lysosomes would reduce the cellular accumulation of LTR.   
The ability of CADs to increase the cellular accumulation of amine-containing 
drugs illustrates a pathway through which drug co-administration can lead to 
distribution-based pharmacokinetic drug-drug interactions.  These results, at first 
glance, would appear to directly contradict earlier work that has illustrated the capacity 
of amine-containing drugs to inhibit the cellular uptake of each other by competing for 
uptake into lysosomes (Daniel and Wojcikowski 1999).  This competition was presumed 
to occur through the ability of these drugs to buffer the lysosomal pH and inhibit the 
lysosomal uptake of secondarily applied amine-containing drugs.  These discrepancies 
are believed to have originated from differences in drug dosing and duration of 
exposure leading to differential physiological effects on cells and the lysosomal system 
as illustrated by the dose-dependent effect of imipramine on the cellular accumulation of 
LTR, illustrated later in this chapter (Figure 3.18).  These earlier studies relied on short-
term, higher-dose drug treatments which are known to cause lysosomal alkalinization 
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(Ishizaki, Yokogawa et al. 2000) and therefore reduced ion trapping of amine-containing 
drugs in lysosomes without allowing the time-dependent expansion of the lysosomal 
compartment observed in this chapter, see Figure 3.14.  This current study relied on 
longer durations of drug exposure with relatively lower treatment doses, which is more 
closely associated with the induction of a cellular lipidosis (Yoshida, Arimoto et al. 1985; 
Liscum and Faust 1989; Martin, Kachel et al. 1989).  In fact, later in this chapter, 
experiments were carried out with treatments that are known to cause lysosomal 
alkalinization (Ohkuma and Poole 1978; Woo, Shinohara et al. 1992) and it was found 
that they all significantly reduced the cellular accumulation of LTR in contrast to the 
ability of the CADs to increase LTR accumulation (Figure 3.17).  Thus, the results here 
do not argue against previous observations of potential drug-drug interactions occurring 
through drug-induced lysosomal alkalinization, but offer an additional pathway through 
which amine-containing drugs that accumulate in lysosomes can influence the 
pharmacokinetic properties of each other depending on their physiological effect on 
lysosomes.  Since the therapeutic concentration of most CADs is well below the 
concentrations necessary to cause lysosomal alkalinization and because most of the 
CADs are used as chronic therapies it could be argued that the CAD-induced lipidosis is 
a more likely clinical scenario than lysosomal alkalinization.  By enhancing the cellular 
retention of a secondarily applied drug, one would expect changes in the 
pharmacokinetic profile of that drug, such as an increase in its volume of distribution, 
through enhanced tissue accumulation, as well as, increased distribution to tissues 
enriched in lysosomes, such as the liver and lung.  Without in vivo data, the potential for 
such a drug-drug interaction to be of therapeutic relevance is only speculative, but it is 
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possible that such changes in the macroscopic pharmacokinetic properties of a drug 
could result in altered therapeutic response. 
 
3.3.2. Importance of intact intracellular pH gradients on the CAD-induced 
cellular accumulation of substrates for lysosomal ion trapping 
In addition to the lipidosis caused by CADs, they are also known to cause 
changes in cellular membrane permeability (Tsao, Iga et al. 1982; Drori, Eytan et al. 
1995), either of which could enhance cellular drug accumulation by providing additional 
intracellular binding sites for drugs or increasing permeation of drugs into cells, 
respectively.  Specifically, CADs have been described as causing the cellular 
accumulation of phospholipid species, such as the anionic lysosomal phospholipid, 
lysobisphosphatidic acid (LBPA) (Yamamoto, Adachi et al. 1971).  Like other 
phospholipids, LBPA has been proposed to bind lysosomotropic amine-containing drugs 
(Kolzer, Werth et al. 2004), most likely through charge-charge and hydrophobic 
interactions (Seydel and Wassermann 1976).  Therefore, their accumulation within 
lysosomes may provide additional intralysosomal retention sites for these drugs.  
Previous studies in Chapter 2 indicated that non-lysosomotropic amines such as 
sulforhodamine 101 and MitoTracker Red did not experience enhanced accumulation in 
cells pretreated with CADs.  These results were consistent with the notion that CAD-
induced enhancement of amine uptake cannot simply be attributed to an increase in 
intracellular cationic drug binding sites or a change in cell membrane permeability, but 
rather suggested increased accumulation by ion trapping in lysosomes. 
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To confirm that the CAD-induced enhancement in amine accumulation was 
indeed reliant on intracellular pH gradients (i.e., lysosome to cytosol), the cellular 
accumulation of LTR in cells pretreated with the ionophores, nigericin and monensin 
was evaluated.  When treated with ionophores, the pH of all cellular compartments 
equals that of the pH of the cell culture medium.  Under these conditions no intracellular 
pH gradients exist and therefore no ion trapping-based accumulation can theoretically 
occur.  Both vehicle-treated control cells and cells pretreated with the CAD, imipramine, 
were treated with ionophores and evaluated for differences in LTR distribution and 
accumulation.  Interestingly, treatment of cells with ionophores negated any CAD 
induced enhancements in LTR accumulation.  Fluorescence-based imaging showed an 
increase in the vesicular accumulation of LTR in cells treated with imipramine, which 
was abolished by ionophore treatment (Figure 3.3).  Similarly, ionophore treatment 
eliminated the enhanced cellular accumulation of LTR seen in imipramine treated cells 
(Figure 3.4).  These results further suggest that the CAD-induced enhancement in LTR 
accumulation is dependent upon ion trapping and cannot simply be attributed to an 
increase in binding sites or changes in membrane permeability in CAD treated cells.   
Because intralysosomal lipid binding of amine-containing drugs is thought to 
result from both hydrophobic and ionic interactions, the ionized state of the lipid-species 
and the drug may be important in complex formation under physiological conditions.  
Since the ionization state is strongly influenced by pH, the formation of the lipid-drug 
complex may be extremely pH sensitive and might not have been observed under the 
experimental conditions in Figure 3.4.  This was due to the ionophore treatment that 
was conducted with an extracellular pH of 7.4 that is far greater than the normal  
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Figure 3.3.  Disruption of intracellular pH gradients reverses the CAD-induced 
increase in vesicular accumulation of LTR.  MDA-1986 cells were treated with 10 μM 
imipramine or vehicle alone (control) for 24 hours.  In the last 2 hours of treatment, 
ionophores (10 µM nigericin and 20 µM monensin) were added to eliminate 
intracellular pH gradients ((+) nig/mon) or the cells were left untreated ((-) nig/mon).  
In addition, 200 nM LTR was added immediately following the addition of ionophores.  
After 2 hours under normal growth conditions, cells were washed and imaged.  The 
increase in vesicular accumulation of LTR in imipramine treated cells was reversed 
by ionophore treatment indicating that intact intracellular pH gradients are important 
in the imipramine-induced increase in LTR accumulation. 
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Figure 3.4.  Disruption of the intracellular pH gradient reverses the CAD-induced 
cellular accumulation of LTR.  MDA-1986 cells were treated with 10 μM imipramine 
(white bars) or vehicle alone (black bars) for 24 hours.  In the last 2 hours of 
treatment, ionophores (10 µM nigericin and 20 µM monensin) were added to 
eliminate intracellular pH gradients ((+) nig/mon) or the cells were left untreated ((-) 
nig/mon).  In addition, 200 nM LTR was added immediately following the addition of 
ionophores.  After 2 hours under normal growth conditions, cells were lysed and LTR 
accumulation was assessed by measuring cell associated fluorescence signal.  
Without ionophores, imipramine treatment resulted in a significant increase in the 
amount of LTR accumulated in cells.  Ionophore treatment decreased LTR 
accumulation to similar levels in control and imipramine treated cells.  Cellular 
accumulation of LTR is represented in fluorescence counts (RFU) per µg of protein 
as mean ± S.D of three values for each sample (*, p < 0.05 by Student’s t test).  
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lysosomal pH of 5.0.  To examine the possibility of enhanced pH-dependent lipid 
binding following imipramine treatment, the pH-dependent cellular binding of the 
lysosomotropic amines LTR and propranolol was measured.  LTR and propranolol 
accumulation was measured in imipramine and vehicle-treated control cells following 
ionophore treatment in pH controlled solutions.  Ionophore treatment dissipates cellular 
pH gradients and equilibrates the intracellular pH with the extracellular media.  
Therefore if imipramine causes an increase in pH-sensitive intralysosomal lipid binding 
of LTR or propranolol it should be observed at the lower pH.  Imipramine treatment 
failed to affect LTR accumulation at pH 7.3, 6.0 or 5.0 (Figure 3.5).  Similarly, 
imipramine treatment failed to increase propranolol accumulation at pH 5.0 (Figure 3.6), 
which is the normal lysosomal pH of this cell line.  Together these results suggest that 
increased intralysosomal binding is in fact not the mechanism for enhanced retention of 
these drugs following imipramine treatment.   
Additionally, the hydrophilic substrate for lysosomal ion trapping, methylamine 
would not be expected to participate in the hydrophobic interactions predicted for other 
more hydrophobic amine-containing compounds, such as propranolol, and would 
perhaps serve exclusively as a measure of cellular uptake through ion trapping.  
Therefore, the ability of imipramine to affect the cellular accumulation of methylamine 
was assessed (Figure 3.7) and found to be significantly increased, further suggesting 
that increased accumulation of the amine-containing compounds occurs through an 
increase in lysosomal ion trapping capacity of cells mediated by CAD exposure. 
Together, these results argue that although the lipidosis may be important in the 
CAD-induced enhancement in accumulation of substrates for lysosomal ion trapping,  
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Figure 3.5.  CAD treatment does not increase the cellular binding of LTR in a pH-
sensitive manner.  MDA-1986 cells were treated with 10 μM imipramine (white bars) 
or vehicle alone (black bars) for 24 hours.  Cells were subsequently placed in isotonic 
solutions buffered at pH 5.0, 6.0 and 7.3 along with ionophores (10 µM nigericin and 
20 µM monensin) to allow equilibration between intracellular pH and extracellular pH.  
Following the addition of ionophore, 200 nM LTR was added.  After 30 minutes cells 
were lysed and LTR accumulation was assessed by measuring cell associated 
fluorescence signal.  Without an intact intracellular pH gradient lysosomal ion 
trapping doesn’t occur, therefore cellular accumulation is expected to represent 
cellular binding of LTR.  LTR didn’t show a pH-sensitive difference in cellular binding 
in control versus imipramine treated cells.  Cellular accumulation of LTR is 
represented in fluorescence counts (RFU) per µg of protein as mean ± S.D of three 
values for each sample.  
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Figure 3.6.  CAD treatment does not increase the cellular binding of propranolol in a 
pH-sensitive manner.  MDA-1986 cells were treated with 10 μM imipramine (white 
bar) or vehicle alone (black bar) for 24 hours.  Cells were subsequently placed in an 
isotonic solution buffered at pH 5.0 along with ionophores (10 µM nigericin and 20 
µM monensin) to allow equilibration between intracellular pH and extracellular pH.  
Following the addition of ionophore, 100 nM propranolol containing 10 nM 3H-
propranolol was added.  After 2 hours cells were lysed and 3H-propranolol 
accumulation was assessed by measuring cell associated radioactivity and 
normalized to cellular protein content.  Without an intact intracellular pH gradient 
lysosomal ion trapping doesn’t occur; therefore, cellular accumulation is expected to 
represent cellular binding of propranolol.  Propranolol didn’t show an increase in 
cellular binding at pH 5.0 in control versus imipramine treated cells.  Cellular 
accumulation of propranolol as a percentage of the vehicle-treated control was 
determined and is plotted as the mean ± S.D of three values for each sample.  
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Figure 3.7.  CAD treatment increases the cellular accumulation of the hydrophilic 
amine, methylamine.  MDA-1986 cells were treated with 10 μM imipramine (white 
bars) or vehicle alone (black bars) for 24 hours.  In the last 2 hours of treatment, 10 
µM 14C-methylamine was added.  After 2 hours cells were lysed and 14C-
methylamine accumulation was assessed by measuring cell associated radioactivity 
and normalized to cellular protein content.  Imipramine treatment caused a significant 
increase in the cellular accumulation of the hydrophilic amine, methylamine.  Cellular 
accumulation of methylamine as a percentage of control is plotted as the mean ± S.D 
of three values for each sample (**, p < .01 by Student’s t test). 
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that an increase in cellular binding of the drug to lipids, or other cellular constituents, is 
not the mechanism of increased cellular accumulation.  The dependence on intact 
intracellular pH gradients further suggests that imipramine increases the capacity of 
cells to accumulate amine-containing drugs by ion trapping in lysosomes, either through 
changes in lysosomal pH or lysosomal volume.  These results are in agreement with 
previous in vivo and in vitro findings that the CAD-induced lipidosis causes an increase 
in the tissue and cellular accumulation of a secondarily administered amine-containing 
drug (Lullmann, Rossen et al. 1973; Hein, Lullmann-Rauch et al. 1990; Honegger, 
Zuehlke et al. 1993), but in addition to the previous observation it was demonstrated 
that increased drug accumulation does not occur through increased lipid binding.  Here 
it is argued that, in contrast to increased cellular drug binding, CADs cause an 
expansion of the lysosomal compartment, and therefore increase the cellular 
accumulation of amine-containing drugs through an increase in the lysosomal ion 
trapping capacity of cells. 
 
3.3.3. CAD-induced lipidosis and enhanced lysosomal ion trapping 
A similarity in the pharmacological response of imipramine in causing both a 
cellular lipidosis and enhanced accumulation of substrates for ion trapping in lysosomes 
suggests a possible relationship between the two events.  Although the two effects 
could be independent of one another, it is likely that the hypothesized CAD-induced 
expansion of the lysosomal compartment is secondary to the lysosomal accumulation of 
lipids.  If the expanded lysosomal compartment is indeed secondary to the drug-induced 
lipidosis, then reversal of the lipidosis would also be expected to reverse the lysosomal 
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volume expansion.  To test this hypothesis, several treatments that prevent the lipidosis 
were employed, including 0.1% HPCD (Abi-Mosleh, Infante et al. 2009) and 
growth in lipoprotein depleted media (i.e., LPDS) (Thomas, Tuck-Muller et al. 1989).  
Interestingly, both treatments showed a significant reduction in the cellular accumulation 
of LTR following imipramine treatment resulting in levels similar to that seen in vehicle-
treated control cells (Figure 3.8).  In addition, growth in LPDS also reduced the cellular 
accumulation of LTR in NPC disease cells, NPC1-/- and NPC2-/- (Figure 3.9).   
Together these results support the hypothesis that the lipidosis, whether 
mediated by CAD treatment of through inborn errors in lipid metabolism, results in the 
enhanced accumulation of substrates for lysosomal ion trapping, presumably through 
an expansion of the lysosomal compartment.  The expansion of the lysosomal 
compartment may result simply from the accumulation of undigested membranous lipid 
material in lysosomes or may reflect a generalized defect in the vesicle-mediated 
trafficking of lysosome, as has been previously hypothesized in CAD treated (Kaufmann 
and Krise 2008) and NPC disease cells (Neufeld, Wastney et al. 1999).  If a blockage of 
the outflow of lysosomes and their cargoes were to occur, an increase in the resting 
volume of the lysosomal compartment may be expected.  The ability of lipid depletion to 
at least partially reverse the apparent lysosomal volume expansion in both CAD treated 
and NPC disease cells would suggest that the trafficking defect is secondary to the 
accumulation of lipids and may not be a direct result of inhibition of vesicle-mediated 
trafficking by CADs or dysfunctional NPC1 or NPC2.  Previous findings that vesicle-
mediated efflux trafficking of the lysosomal cargo, 14C-sucrose, is inhibited by the 
lysosomal accumulation of cholesterol (Neufeld, Wastney et al. 1999) would support the  
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Figure 3.8.  Inhibitors of the cellular lipidosis prevent the CAD-induced enhancement 
in lysosomal ion trapping capacity.  MDA-1986 cells were treated with either normal 
cell growth media, normal growth media supplemented with 0.1% HPCD or growth 
media without FBS, but supplemented with 3 mg/ml LPDS, as indicated in the figure.  
Following 24 hours of growth under the indicated conditions, 10 µM imipramine 
(white bars) or vehicle alone (black bars) was added for a 24-hour treatment.  In the 
last 2 hours of treatment, 200 nM LTR was added to the media.  At the end of the 
experiment, cells were lysed and cell associated fluorescence was measured and 
normalized to cellular protein content.  Despite the ability of imipramine to increase 
the cellular accumulation of LTR under normal cell growth conditions, pretreatment 
with 0.1% HPCD or growth in LPDS-containing media prevented this increase.  
Cellular accumulation of LTR as a percent of the vehicle-treated control cells is 
represented as mean ± S.D of three values for each sample (***, p < .001 by 
Student’s t test). 
 
 
 116
 
 
 
 
Figure 3.9.  Reversal of the cellular lipidosis in NPC disease cells reduces the 
lysosomal ion trapping capacity.  NPC disease fibroblasts with either loss-of-function 
mutations in NPC1 (NPC1-/-) or NPC2 (NPC2-/-) were treated for 72 hours with 
either normal cell growth media (black bars) or growth media without FBS, but 
supplemented with 3 mg/ml LPDS (white bars).  In the last 2 hours, 200 nM LTR was 
added to the media.  At the end of the experiment, cells were lysed and cell 
associated fluorescence was measured and normalized to cellular protein content.  
Growth in LPDS-containing media decreased LTR accumulation in both NPC disease 
cell lines. Cellular accumulation of LTR as a percent of the control cells in normal 
growth media for each cell line was determined and is represented as mean ± S.D of 
three values for each sample (**, p < .01; ***, p < .001 by Student’s t test). 
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hypothesis that lysosomal lipid accumulation may in fact result in an expanded 
lysosomal compartment through a blockage in the vesicle-mediated trafficking of 
lysosomes.    
 
3.3.4. Influence of CAD treatment on the cellular uptake and release of 
substrates for lysosomal ion trapping 
Having established that CADs cause an increase in cellular accumulation of 
substrates for ion trapping-based accumulation, the potential basis for this was 
examined further.  Although numerous mechanisms of increased accumulation may 
exist, an understanding of the impact of CAD treatment on the uptake and release of the 
amine-containing compounds will facilitate a more thorough understanding of the basis 
for this apparent intracellular interaction.  Lysosomtropic amines  have a  complicated 
release mechanism, including the potential for vesicle-mediated efflux (Michalik, 
Pierzchalska et al. 2003; Gong, Duvvuri et al. 2006), transporter mediated efflux 
(Willingham, Cornwell et al. 1986) and simple passive-diffusion (Dudley and Brown 
1995).  Since enhanced intralysosomal drug binding was not observed, it is reasoned 
that increases in drug uptake following CAD exposure would be indicative of an 
increase in the capacity of the cell to ion trap the drug in lysosomes, either through a 
change in the pH or volume of the lysosomal system.  Decreases in drug release 
following CAD exposure would be indicative of either inhibition of transporter-mediated 
or vesicle-mediated drug efflux.  Using the model substrates for lysosomal ion trapping, 
propranolol and LTG, it was found that imipramine treatment causes a profound 
increase in the uptake of both propranolol (Figure 3.10) and LTG (Figure 3.12), but 
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shows no inhibition of release for neither propranolol (Figure 3.11) nor LTG (Figure 
3.13).  These results indicate that CADs increase the uptake of drugs that accumulate 
by ion trapping without significantly influencing release.  Increased uptake is presumed 
to reflect an increase in the lysosomal ion trapping of the drugs and is dependent on 
both the volume and pH of the lysosomal compartment.   
 
3.3.5. Time- and temperature-dependence of enhanced cellular 
accumulation of substrates for lysosomal ion trapping following CAD 
treatment 
  Based on the theory of ion trapping, the extent of lysosomal accumulation 
depends on the physicochemical properties of the drug (i.e., pKa and alpha), as well as, 
the properties of the lysosomal system, such as pH and volume (de Duve, de Barsy et 
al. 1974).  Since the inherent physicochemical properties of the drug are not influenced 
by CAD treatment it is assumed that the properties of the lysosomes must be altered.  
Therefore, the effect of imipramine treatment on lysosomal pH was measured and it 
was found that exposure to 10 µM imipramine for 24 hours resulted in no significant 
change in lysosomal pH (pH 5.0 ± 0.9), as compared to vehicle-treated control cells (pH 
4.9 ± 0.2).   
The lack of a change in lysosomal pH following CAD treatment further supports 
the hypothesis that CADs are causing an expansion of the lysosomal compartment.  
This compartment volume expansion is suspected to result from a cellular remodeling 
process, such as through the inhibition of the vesicle-mediated efflux trafficking of  
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Figure 3.10.  Enhanced uptake of substrates for lysosomal ion trapping following 
CAD treatment.  Fibroblasts were treated with 10 µM imipramine (white circles) or 
vehicle alone (black circles) for 48 h.  In the last 2 hours 100 nM propranolol 
containing 10 nM 3H-propranolol was added to the cell media for exposure times of 
up to 120 minutes.  Cells were lysed and measured for associated 3H-propranolol 
and normalized to cellular protein content.  Cellular uptake of propranolol was rapid 
with the majority occurring in the first 5 minutes and steady state levels were 
achieved within 1 hour.  Despite the similarity in the uptake profile of propranolol in 
both imipramine treated and control cells, imipramine treated cells took up 
significantly more propranolol at each timepoint.  Cellular accumulation of 3H-
propranolol was measured in radioactivity counts (DPM) and normalized to cellular 
protein in µg and is represented as mean ± S.D of three values for each sample (**, p 
< 0.01 by Student’s t test).  
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Figure 3.11.  CAD treatment does not inhibit the release of substrates for lysosomal 
ion trapping.  Fibroblasts were treated with 10 µM imipramine (white circles) or 
vehicle alone (black circles) for 48 hours.  In the last 2 hours, 100 nM propranolol 
containing 10 nM 3H-propranolol and 74 nM propranolol containing 7.4 nM 3H-
propranolol was added to vehicle-treated and imipramine treated cells, respectively.  
Following the 2 hour treatment period the propranolol release into the media was 
measured.  Imipramine or vehicle alone was maintained in the release media.  The 
cell media was removed at timepoints up to 1 hour and replaced with fresh media to 
maintain sink conditions.  After the last timepoint, cells were lysed.  Cell lysate and 
media samples were measured for 3H-propranolol content to determine total cellular 
accumulation and the release profile.  3H-propranolol was normalized to cellular 
protein content in the cell lysate.  Imipramine treated cells showed a rapid release of 
propranolol that was similar to vehicle-treated control cells.  Cell associated 3H-
propranolol was measured in radioactivity counts (DPM) and normalized to cellular 
protein in µg and is represented as mean ± S.D of three values for each sample.  
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Figure 3.12.  Enhanced uptake of substrates for lysosomal ion trapping following 
CAD treatment.  Fibroblasts were treated with 10 µM imipramine (white circles) or 
vehicle alone (black circles) for 48 hours.  In the last 2 hours 1 µM LTG was added to 
the cell media for exposure times of up to 120 minutes.  Cells were lysed and 
measured for associated LTG and normalized to cellular protein content.  Cellular 
uptake of LTG was rapid with the majority occurring in the first 5 minutes and steady 
state levels were achieved within 30 minutes.  Despite the similarity in the uptake 
profile of LTG in both imipramine treated and control cells, imipramine treated cells 
took up significantly more LTG at each timepoint.  Cellular accumulation of LTG was 
measured by fluorescence (RFU) and normalized to cellular protein in µg and is 
represented as mean ± S.D of three values for each sample (**, p < 0.01 by 
Student’s t test).  
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Figure 3.13.  CAD treatment does not inhibit the release of substrates for lysosomal 
ion trapping.  Fibroblasts were treated with 10 µM imipramine (white circles) or 
vehicle alone (black circles) for 48 hours.  In the last 2 hours, 1 µM and 0.5 µM LTG 
was added to vehicle treated and imipramine treated cells, respectively.  Following 
the 2-hour treatment period the LTG release was measured.  Imipramine or vehicle 
alone was maintained in the release media.  The cell media was removed at 
timepoints up to 2 hours and cells were subsequently lysed.  Media was replaced at 
30 minutes and 60 minutes to maintain sink conditions.  Cell lysate from each 
timepoint was measured for LTG content.  Cellular accumulation of LTG, as indicated 
by the initial timepoint, was not significantly different in vehicle-treated and 
imipramine treated cells.  Imipramine treated cells showed a rapid release of LTG 
that was similar to vehicle-treated control cells.  Cell associated LTG was measured 
in fluorescence counts (RFU) and normalized to cellular protein in µg and is 
represented as mean ± S.D of three values for each sample.  
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lysosomes.  Such a process is not expected to occur instantaneously, but would be 
expected to be dependent on both time and temperature.  To test this possibility, cells 
were incubated with 10 µM imipramine for varying amounts of time and the impact on 
LTR accumulation was measured.  It was found that the CAD-induced enhancement in 
LTR was a progressive process with enhanced uptake minimal at early incubation times 
and maximal after approximately 10 to 15 hours of exposure (Figure 3.14).   
Moreover, it was found that incubation of cells with 10 µM imipramine for 4 hours 
failed to enhance the accumulation of LTR unless the temperature of the incubation was 
maintained at 37ºC.  Cells incubated with or without CAD at 4ºC for 4 hours showed no 
differences in LTR accumulation at 37ºC as compared to cells maintained at 37ºC 
throughout the treatment period (Figure 3.15).  These results are important since they 
are consistent with the notion that CADs impart some type of time- and temperature-
dependent restructuring of the cells that facilitates the enhancement of LTR ion 
trapping-based accumulation and draws a correlation between the CAD-induced 
lipidosis and the observed increase in apparent lysosomal volume.  These results along 
with the propranolol and LTG release studies would argue against the possibility that 
imipramine is in some way inhibiting an acute cellular efflux pathway for LTR and other 
weakly basic drugs, but rather is consistent with imipramine inducing an energy-
dependent cellular remodeling process that results in an increased lysosomal volume 
and therefore enhanced accumulation of weakly basic drugs. 
 
 
 
 
 124
 
 
Figure 3.14.  CAD-induced enhancement in cellular ion trapping capacity is time-
dependent.  MDA-1986 cells under normal growth conditions were treated with 10 
µM imipramine for durations of 0 to 24 hours.  LTR at a concentration of 200 nM was 
added for the last 2 hours of treatment and cells were subsequently lysed.  Cellular 
accumulation of LTR was determined by fluorescence measurements of the cell 
lysate.  Fluorescence signal was normalized to cell lysate protein content.  Cellular 
accumulation of the model substrate for ion trapping-based accumulation, LTR, is 
dependent on the duration of exposure to imipramine.  A progressive increase in the 
ion trapping capacity of MDA-1986 cells was observed with imipramine treatment 
times of up to 24 hours.  Cellular accumulation of LTR as a percent of the vehicle-
treated control cells is represented as mean ± S.D of three values for each sample 
(**, p < 0.01 by Student’s t test). 
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Figure 3.15.  CAD-induced enhancement in cellular ion trapping capacity is 
temperature-dependent.  MDA-1986 cells grown under normal culture conditions 
were subsequently exposed to a 4 hour treatment with 10 µM imipramine (white bars) 
or vehicle alone (black bars) at either 37ºC or 4ºC, as indicated in the figure.  Cells 
were then washed in 37ºC buffer and 37ºC growth media containing 200 nM LTR 
was added for 30 minutes.  Cell samples were lysed and measured for cell 
associated fluorescence and normalized to cellular protein content.  Cells treated with 
imipramine at 37ºC showed a significant increase in the accumulation of LTR, 
whereas, imipramine treatment at 4ºC failed to show a change in the ion trapping 
capacity of cells as measured by LTR accumulation.  Cellular accumulation of LTR as 
a percent of the vehicle-treated control cells is represented as mean ± S.D of six 
values for each sample (***, p < .001 by Student’s t test). 
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3.3.6. Calculation of the change in apparent lysosomal volume 
The cellular accumulation of weakly basic compounds, like LTR, by ion trapping 
in lysosomes is predicted to depend on two important parameters: 1) lysosomal pH and 
2) lysosomal volume.  Approximations of the impact of changes in either parameter can 
be predicted by simple steady state equations derived in the original work describing 
lysosomal ion trapping (de Duve, de Barsy et al. 1974).  These equations (see Materials 
and methods, Section 3.2.7) simply illustrate that a change in the lysosomal pH (i.e., 
hydrogen ion concentration) or lysosomal volume results in proportional changes in 
cellular uptake by lysosomal ion trapping.  In this work, the effect of imipramine on the 
cellular accumulation of LTR by lysosomal ion trapping (Figure 3.6) and lysosomal pH 
were measured.  Therefore, these experimental values can be used to calculate the 
change in lysosomal volume following imipramine treatment.  Using the data from 
Figure 3.6, the amount of LTR accumulated in cells following ionophore treatment was 
subtracted from the amount without ionophore treatment and yielded the amount of LTR 
accumulating in cells by lysosomal ion trapping (Figure 3.16).  Imipramine treatment 
caused an approximately three-fold increase in lysosomal ion trapping-based 
accumulation of LTR.  In conjunction with the measured lysosomal pH values in 
imipramine treated and vehicle-treated cells an approximately three- to four-fold 
increase in the apparent lysosomal volume following imipramine treatment was 
calculated.  Because other acidic organelles, such as the Golgi apparatus and late 
endosomes, may contribute to LTR accumulation the calculated volume change is 
denoted as a change in the apparent lysosomal volume.  These observations were  
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Figure 3.16.  Measurement of increased ion trapping capacity following CAD 
treatment.  The amount of the model substrate for lysosomal ion trapping, LTR, 
accumulated in cells by ion trapping-based accumulation was measured in MDA-
1986 cells that were treated with 10 µM imipramine (white bar) or vehicle alone 
(black bar) for 24 hours.  In the last 2 hours of treatment, 200 nM LTR was added 
and cells were either co-treated with ionophores (10 μM nigericin and 20 μM 
monensin) to eliminate intracellular pH gradients or left untreated to retain an intact 
lysosome/cytosol pH gradient.  Cells were subsequently lysed and LTR accumulation 
was assessed by measuring cell-associated fluorescence signal.  Fluorescence 
signal was normalized to cellular protein content. The amount of LTR accumulated in 
ionophore treated cells was subtracted from the amount accumulated in cells under 
normal cell growth conditions resulting in the amount of LTR accumulated in cells by 
lysosomal ion trapping, for both vehicle-treated and imipramine treated cells.  
Imipramine treatment resulted in a significant increase in the amount of LTR 
accumulated in cells by ion trapping.  Cellular accumulation of LTR by lysosomal ion 
trapping is represented in fluorescence counts per µg of protein as mean ± S.D of 
three values for each sample (*, p < 0.05 by Student’s t test).  
 
 
 128
consistent with the microscopy studies presented in Chapter 2 that suggested an 
increase in the vesicular accumulation in an expanded lysosomal compartment. 
The results here are in agreement with recent work that has shown a 
progressive, non-steady state accumulation profile for the phospholipidosis-inducing 
drug chloroquine (Zheng, Zhang et al. 2010).  Similar to the results presented here, 
these authors found that chloroquine induced the formation of an expanded acidic 
vesicular compartment that resulted in enhanced cellular accumulation of the 
phospholipidosis-inducing drug.  Their data shows a 10- to 30-fold increase in vesicular 
volume with up to a one-unit upward shift in the vesicular pH.  Although the CAD 
treatments here showed a less pronounced increase in apparent lysosomal volume and 
no significant increase in vesicular pH at the concentration of imipramine used, it is 
believed that similar effects would be observed with increasing drug concentrations.  
The differences in vesicular volume measurements may also originate from their 
microscopy-based measurements of vesicular volume and the calculation-based 
method used in this study.  Additionally, these authors found that inhibition of the 
phospholipidosis phenotype by treatment with bafilomycin A1 reversed the expansion of 
the vesicular volume in agreement with the results presented here.  Therefore, in 
addition to the previously established capability of phospholipidosis-inducing drugs to 
increase their own cellular accumulation in an expanded acidic vesicular compartment, 
it was shown here that they also increase the cellular accumulation of other drugs that 
accumulate in these acidic subcellular compartments.  
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3.3.7. Dose dependent effect of CADs on LTR accumulation suggests 
lysosomal alkalinization with increased dose 
Previous work has illustrated the possibility that amine-containing drugs, such as 
CADs, accumulating in the lysosome can cause alkalinization of the lysosome and 
inhibit lysosomal ion trapping of secondarily administered amine-containing compounds 
(Daniel 2003), such as LTR.  The current studies confirmed these findings by measuring 
LTR accumulation in cells exposed to either 30 µM chloroquine, 10 mM ammonium 
chloride or 200 nM of the vacuolar-type H+-ATPase inhibitor concanamycin A (Figure 
3.17).  All three of these well-established lysosomal alkalinizing treatments significantly 
decreased the cellular accumulation of LTR.  Therefore, LTR accumulation in cells 
treated with a range of imipramine doses between 0.01 and 50 µM was evaluated 
(Figure 3.18).  Imipramine appeared to cause a dose-dependent effect, whereby, LTR 
accumulation increased with doses up to 1 µM.  Doses above 1 µM caused a gradual 
decrease in LTR accumulation.   
These results would be in agreement with the hypothesis that CAD treatment has 
multiple dose-dependent effects on lysosomes that influence their ability to accumulate 
substrates for lysosomal ion trapping.  Perhaps at lower, non-alkalinizing doses, an 
expansion of the lysosomal volume causes increased lysosomal ion trapping, but as the 
dose increases, the CAD begins to cause lysosomal alkalinization and reduces 
lysosomal ion trapping.  Whatever the reason for the apparent dose-response, it shows 
that the more therapeutically relevant lower imipramine doses cause an increased 
capacity to accumulate substrates for lysosomal ion trapping that is reversed at 
increased supratherapeutic doses. 
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Figure 3.17.  Alkalinization of lysosomes decreases the cellular accumulation of the 
model substrate for lysosomal ion trapping, LTR.  MDA-1986 cells grown under 
normal cell culture conditions were treated for 2 hours with vehicle alone (black bar) 
or various treatments previously shown to cause lysosomal alkalinization (white 
bars), including 30 µM chloroquine, 10 mM ammonium chloride or 200 nM 
concanamycin A.  LTR at a concentration of 200 nM was added concomitant to the 
various treatments.  At the end of the 2-hour treatment cells were lysed and 
measured for cellular accumulation of LTR by measuring cell associated 
fluorescence signal.  Fluorescence counts were normalized to cellular protein 
content.  Cellular accumulation of LTR was normalized to percent vehicle-treated 
control.  All lysosomal alkalinizing treatments significantly reduced the lysosomal ion 
trapping capacity of cells as indicated by the decreased cellular accumulation of LTR.  
Cellular accumulation of LTR as a percent of the vehicle treated control cells is 
represented as mean ± S.D of at least three values for each sample (***, p < .001 by 
Student’s t test).  
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Figure 3.18.  Cellular accumulation of the model substrate for lysosomal ion trapping, 
LTR, following CAD treatment is dose-dependent.  Fibroblasts were treated for 24 
hours with a range of imipramine concentrations between 0 and 50 µM imipramine.  
In the last 2 hours, 200 nM LTR was added.  Samples were subsequently lysed and 
measured for cell-associated fluorescence.  Fluorescence signal was normalized to 
the cellular protein content of each sample.  Cellular accumulation of LTR was 
normalized to percent vehicle-treated control (i.e., 0 µM imipramine).  Imipramine, at 
doses below 1 µM caused a dose-dependent increase in the cellular accumulation of 
LTR.  At concentrations above 1 µM, this trend is reversed.  Cellular accumulation of 
LTR as a percent of the vehicle-treated control cells is represented as mean ± S.D of 
at least three values for each sample (***, p < .001 by Student’s t test).  
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3.4. Conclusions 
Collectively, this work illustrates a novel intracellular drug-drug interaction 
pathway resulting from the ability of CADs to cause an expansion of the apparent 
lysosomal volume of cells.  This lysosomal volume expansion was found to be 
secondary to the CAD-induced cellular lipidosis and to result in the increased cellular 
uptake of drugs that are substrates for ion trapping-based accumulation in lysosomes.  
A change in the cellular uptake and accumulation of these drugs reveals a novel 
distribution-based drug-drug interaction pathway with clinically relevant implications that 
necessitates further in vivo studies. 
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Chapter 4 
 
 Drug-induced lysosomal volume expansion fails to cause a generalized 
decrease in lysosomal enzyme activity
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4.1. Introduction 
In this work it is hypothesized that the drug-induced lysosomal volume expansion 
results in the apparent dilution of enzymes within the lysosomal compartment and 
results in a generalized decrease in lysosomal hydrolase activity that causes the 
lysosomal accumulation of undigested lipids (Lullmann, Lullmann-Rauch et al. 1973) 
and other lysosomal cargoes (Kaufmann and Krise 2008) that is often observed 
following CAD treatment.  Such findings would be important in understanding the 
biochemical mechanism through which CADs inhibit the normal metabolism of lipids that 
results in the toxicological phenomenon often referred to as phospholipidosis.  
Therefore, this chapter assesses lysosomal hydrolase activity in cells with an expanded 
lysosomal compartment as a possible mechanism of a general reduction in the 
metabolism of substrates for lysosomal enzymes. 
Lysosomes play an important role in the cellular metabolism of numerous 
substrates, including: lipids, carbohydrates, nucleic acids and proteins.  The digestion of 
these substrates within lysosomes occurs primarily via enzymatic hydrolysis that is 
favored by the acidic environment of the lysosome (Sun-Wada, Wada et al. 2003).  
Changes in the properties of lysosomes have been shown to effect lysosomal hydrolase 
activity, such as lysosomal alkalinization (Ohkuma, Chudzik et al. 1986).  Interestingly, 
in Chapter 3 it was found that hydrophobic amine-containing drugs, commonly referred 
to as cationic amphiphilic drugs (CADs), can alter lysosomes by causing an expansion 
of the lysosomal compartment without significantly affecting lysosomal pH.  The 
expansion of the lysosomal compartment appears to be related to the concomitant 
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lipidosis caused by these drugs and may indicate a relationship between the two 
events.   
Lysosomal enzymes are synthesized in the endoplasmic reticulum and 
transported to the Golgi apparatus where the majority of lysosomal proteins undergo 
posttranslational tagging with phosphomannosyl resulting in binding to mannose-6-
phosphate receptors (M6PR) with subsequent transport to lysosomes.  Entry into the 
acidifed endosomal/lysosomal compartments causes the receptor-enzyme complex to 
dissociate.  Within the lysosome the enzyme often enters as an inactive pro-form that 
requires further activation by other lysosomal enzymes (Kornfeld 1986).  In addition, the 
acidic pH optimum for activity of these enzymes allows them to be highly active within 
the acidified lysosome (Coffey and De Duve 1968).  Genetic defects resulting in 
defective synthesis, trafficking, processing or catalytic activity of these enzymes can 
result in one of a number of lysosomal storage diseases (Kornfeld 1986).  Similarly, 
drugs that affect any of these processes would also be predicted to affect lysosomal 
enzyme activity.  Drugs that cause lysosomal alkalinization resulting in inhibition of 
lysosomal hydrolase activity (Ohkuma, Chudzik et al. 1986) would fit this category.  A 
group of hydrophobic amine-containing drugs that are often referred to as CADs are 
well known to inhibit the normal lysosomal digestion of lipids resulting in a phenotype 
similar to that observed in many lysosomal storage diseases (Schneider, Korolenko et 
al. 1997).  Although the mechanism through which these drugs inhibit lysosomal lipid 
metabolism remains unclear it has been observed that these drugs, for the most part, 
fail to directly inhibit enzyme-mediated hydrolysis of lipids and other lysosomal enzyme 
substrates in cellular homogenate (Yoshida, Arimoto et al. 1985).  The necessity of a 
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physiologically intact cellular system for these drugs to inhibit lysosomal lipid 
metabolism suggests that these drugs inhibit lysosomal lipid metabolism through an 
indirect pathway.  The finding in Chapter 3 that CADs cause an expansion of the 
lysosomal compartment led to the hypothesis that CADs may actually inhibit lysosomal 
lipid metabolism through the dilution of lyososomal enzymes that results from an 
expanded lysosomal compartment.  It was reasoned that changes in the absolute 
concentration of the enzymes within the lysosome could result in a possible reduction in 
enzyme activity, and therefore, the accumulation of enzyme substrates within the 
lysosome.  These substrates would not only include lipids, but also carbohydrates, 
nucleic acids and proteins. 
In this chapter, the effect of the expanded lysosomal compartment, following 
CAD treatment, is investigated as a mechanism of reduced lysosomal hydrolase 
activity.  Following treatment with the CAD, imipramine, the lysosomal hydrolase activity 
as determined by the proteolytic degradation of a fluorescently labeled protein, DQ-
BSA, is measured.  Similarly, the activity of the lysosomal hydrolase, cathepsin B, is 
measured using a synthetic substrate specific for the enzyme. 
 
4.2. Materials and methods 
4.2.1. Cell lines and reagents  
DQ-BSA, Dulbecco’s phosphate buffered saline (D-PBS) and Dulbecco’s 
modified Eagle’s medium (DMEM) were purchased from Invitrogen (Carlsbad, CA).  
Daunorubicin was purchased from Oakwood Products (West Columbia, SC).  Z-Arg-
Arg-7-amido-4-methylcoumarin hydrochloride (Z-R-R-NHMec) and imipramine were 
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purchased from Sigma-Aldrich (St. Louis, MO).  Fetal bovine serum (FBS) was 
purchased from Atlanta Biologicals (Lawrenceville, GA).  MDA-1986 squamous cell 
carcinoma cells from the laboratory of Dr. M.S. Cohen at the University of Kansas 
Medical Center were maintained in DMEM supplemented with 10% FBS and maintained 
at 37ºC and 5% CO2, all experiments were carried out under these conditions unless 
otherwise stated.  Cells were routinely subcultured to maintain 60% to 80% confluency. 
 
4.2.2. DQ-BSA proteolytic activity assay 
 MDA-1986 cells were seeded onto 96-well plates at 5 x 103 cells/well in growth 
media containing DQ-BSA at concentrations up to 100 µg/ml.  Time-based 
measurements of fluorescence signal were obtained using a Bio-Tek FL600 microplate 
fluorescence reader with excitation and emission wavelengths set at 485 nm and 530 
nm, respectively.  Good signal to noise and a linear increase in fluorescence was 
observed with 100 µg/ml DQ-BSA at 48 hours.  Therefore, MDA-1986 cells were 
subsequently seeded in a 96-well plate with 100 µg/ml DQ-BSA for 48 hours without 
drug addition (control) or along with 10 µM imipramine.  The cell-associate fluorescence 
signal of each sample was measured.  The cells were subsequently lysed by the 
addition of 0.1 M NaOH and cellular protein content was determined by the BCA 
method.  Fluorescence signal was normalized to sample protein content.  Proteolytic 
activity was expressed as fluorescence per microgram of cell protein.  
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4.2.3. Cellular cathepsin B activity assay 
 MDA-1986 cells were seeded in a 96-well plate at 1 x 104 cells/well and allowed 
to adhere.  Samples were either left untreated (control) or treated with 10 µM 
imipramine for 24 hours.  The cathepsin B substrate, Z-R-R-NHMec was added to the 
cells in order to attain concentrations up to 125 µM and cells were maintained at 37°C.  
Immediately upon addition of the substrate, time-based fluorescence measurements 
were obtained using a Bio-Tek FL600 microplate fluorescence reader with excitation 
and emission wavelengths set at 360 nm and 460 nm, respectively.  Kinetic plots of 
fluorescence versus time for each substrate concentration were constructed for control 
and imipramine treated cells.  Initial rates of product formation determined by the slope 
of the early linear region of each plot was termed the “Reaction Velocity” in RFU per 
minute.  A Michaelis-Menten plot of the reaction velocity as a function of substrate 
concentration was constructed for control and imipramine-treated cells.  The data were 
fit by non-linear regression to the Michaelis-Menten equation using SigmaPlot (SPSS 
Inc., Chicago, IL) from which the constants Vmax and Km were obtained. 
 
4.3. Results and discussion  
4.3.1. Lysosomal volume expansion and cellular protein degradation 
 Exogenously supplied bovine serum albumin (BSA) has been used as a marker 
for the lysosomal hydrolase mediated proteolysis of endocytosed proteins (Ohkuma, 
Chudzik et al. 1986).  The ability of basic substances and ionophores to inhibit the 
digestion of BSA has been proposed to result from the lysosomal alkalinizing effect of 
these compounds.  Therefore the digestion of BSA may serve as a marker for the 
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lysosomal hydrolase activity of cells.  The first objective was to determine whether 
expansion of the lysosomal compartment by CAD treatment would affect the 
degradation of exogenously supplied BSA.  It was reasoned that a decrease in BSA 
degradation would be indicative of a general reduction in lysosomal hydrolase activity.  
To measure BSA degradation a highly fluorescently tagged form of the protein, known 
as DQ-BSA, was employed.  The high degree of fluorescent labeling results in a low 
level of fluorescence due to self-quenching, but upon proteolytic degradation the 
fluorophores become un-quenched and a relative increase in fluorescence is observed 
(Figure 4.1).  Cells were treated with the CAD, imipramine, at the dose and duration 
illustrated as causing an expansion of the lysosomal compartment in Chapter 3.  In 
addition, DQ-BSA was added for the 48-hour treatment.  CAD treatment resulted in no 
apparent change in the level of proteolytic degradation of DQ-BSA, as measured by the 
cell-associated fluorescence (Figure 4.2).  Contrary to the hypothesis, expansion of the 
lysosomal compartment by CADs did not result in a generalized reduction in lysosomal 
hydrolase activity as measured by the proteolytic digestion of BSA.  Although, DQ-BSA 
has been suggested as having both lysosomal and non-lysosomal degradation 
pathways (Sameni, Moin et al. 2000), and therefore, it may be conceivable that non-
lysosmal-mediated degradation may be compensatory in the CAD treated cells, or non-
lysosomal degradation may be the primary route of digestion.  Therefore, specific 
measurement of lysosomal hydrolase activity in living cells may provide a clearer picture 
of the impact of lysosomal volume expansion on lysosomal hydrolase activity. 
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Figure 4.1.  DQ-BSA proteolytic activity assay.  Fluorescently labeled bovine serum 
albumin (DQ-BSA) is highly self-quenched yielding low fluorescence.  Upon 
proteolytic degradation of DQ-BSA to fluorophore-labeled peptides the reduced self-
quenching results in increased fluorescence.  Generation of fluorescence signal 
provides a quantitative measurement of proteolytic activity. 
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Figure 4.2.  Effect of CAD-induced lysosomal volume expansion on proteolytic 
activity.  MDA-1986 cells were left untreated (control) or treated with 10 µM 
imipramine for 48 hours in the presence of 100 µg/ml DQ-BSA.  Proteolytic activity 
was determined by measuring cell-associated fluorescence.  The CAD, imipramine, 
caused no significant change in proteolytic activity. Cell-associated fluorescence was 
normalized to cellular protein content and proteolytic activity is represented as mean 
± S.D. of at least three values for each sample. 
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4.3.2. Lysosomal volume expansion and cathepsin B activity 
 A water-soluble substrate for cathepsin B has been previously used to measure 
lysosomal enzyme activity in living cells (Ulbricht, Spiess et al. 1995).  The non-
fluorescent enzyme substrate, Z-R-R-NHMec is hydrolyzed by cathepsin B to form the 
fluorescent product, 7-amino-4-methylcoumarin, which allows measurement of enzyme 
activity using a simple fluorescence plate reader-based assay (Figure 4.3).  The 
specificity of this substrate for cathepsin B allows for the measurement of lysosomal 
hydrolase activity in live cells, presumably without contribution from extralysosomal 
sources of hydrolysis.  Judging by the structure of the probe, it would not be expected to 
be membrane permeable based on the two arginine residues that would be positively 
charged at physiological pH, but it and similar cathepsin B substrates have been shown 
to be rapidly hydrolyzed (Ulbricht, Spiess et al. 1995) and localized to intracellular 
vesicular compartments that are presumed to be lysosomes (Premzl, Turk et al. 2006), 
suggesting that it rapidly accesses the lysosomal compartment.  The cellular activity of 
cathepsin B was measured by applying the non-fluorescent substrate Z-R-R-NHMec to 
cells and measuring the formation of the fluorescent hydrolysis product.  Following a 24-
hour treatment with vehicle alone or the lysosomal volume expanding CAD, imipramine, 
concentrations of the Z-R-R-NHMec between 5 µM and 125 µM were added to cells and 
fluorescence signal was measured as a function of time.  By measuring the initial rate of 
product formation by a linear fit of the early timepoints, the reaction velocities were 
determined in RFU/min and plotted for vehicle treated (control) and imipramine treated 
cells (Figure 4.4).  As seen by the plot, the lysosomal volume expanding CAD treatment 
didn’t appear to significantly affect the reaction velocities at any of the substrate  
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Figure 4.3.  Cathepsin B activity assay.  The non-fluorescent substrate Z-R-R-
NHMec is hydrolyzed by the lysosomal hydrolase cathepsin B to form a fluorescent 
product, 7-amino-4-methylcoumarin.  Generation of the fluorescent product allows 
enzyme activity measurements in biological systems by measuring the change in 
sample fluorescence as a function of time. 
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Figure 4.4.  Effect of CAD-induced lysosomal volume expansion on cellular 
cathepsin B activity.  MDA-1986 cells were left untreated (control) or treated with 10 
µM imipramine for 24 hours.  Z-R-R-NHMec was added at concentrations between 5 
µM and 125 µM.  Formation of the Z-R-R-NHMec hydrolysis product, 7-amino-4-
methylcoumarin, was measured by time-based fluorescence reading and the initial 
rates were determined and defined as reaction velocities in RFU/min.  A plot of 
reaction velocities versus substrate concentration is presented.  Cathepsin B activity 
is represented as mean ± S.D. of at least three values for each sample.  Data were fit 
with a non-linear regression to the Michaelis-Menten equation using SigmaPlot, 
control curve (R2 = 0.9354) and imipramine curve (R2 = 0.9391).  Km and Vmax were 
determined from the triplicate measurements and expressed as a mean ± S.D.      
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concentrations tested.  The triplicate measurements were fitted to the Michaelis-Menten 
equation to obtain Km and Vmax.  The Vmax for control and imipramine treated cells 
were 640.5 ± 13.0 RFU/min and 639.0 ± 5.3 RFU/min, respectively.  The Km for control 
and imipramine treated cells were determined to be 28.85 ± 1.22 µM and 26.87 ± 1.35 
µM, respectively.  Therefore, no appreciable changes in the kinetic paramters of 
cathepsin B were observed following imipramine treatment.  These results further 
illustrate that the lysosomal volume expansion caused by CAD treatment doesn’t result 
in a general reduction in the lysosomal hydrolase activity of cells.     
 
4.4. Conclusions 
This work sought to describe the effect of lysosomal volume expansion on 
lysosomal hydrolase activity as a potential mechanism of indirect inhibition of lysosomal 
lipid metabolism following CAD treatment.  The hypothesis that lysosomal volume 
expansion could result in reduced enzymatic activity was not supported by the results.  
Because CADs cause both a lysosomal volume expansion and an increase in the 
lysosomal accumulation of undigested lipids, it was hypothesized that the lysosomal 
volume expansion may result in a generalized reduction in lysosomal hydrolase activity 
that decreases the metabolism of lipids and other lysosomal enzyme substrates.  This 
hypothesis was based on previous observations that CADs fail to directly inhibit 
lysosomal lipid hydrolase activity, but rather require an intact cellular system in order to 
mediate their activity.  Although, this indirect inhibition could result through a variety of 
mechanism, the observation of a drug-induced expansion of lysosomes warranted 
further investigation as a possible mechanism.  By treating with the lysosomal volume 
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expanding CAD, imipramine, it was found that cells showed no change in either 
proteolytic digestion of the fluorescently labeled protein, DQ-BSA, or lysosome-specific 
hydrolase activity as measured using the cathepsin B substrate, Z-R-R-NHMec.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152
4.5. References 
Coffey, J. W. and C. De Duve (1968). "Digestive activity of lysosomes. I. The digestion 
of proteins by extracts of rat liver lysosomes." The Journal of biological chemistry 
243(12): 3255-3263. 
Kaufmann, A. M. and J. P. Krise (2008). "Niemann-Pick C1 functions in regulating 
lysosomal amine content." The Journal of biological chemistry 283(36): 24584-
24593. 
Kornfeld, S. (1986). "Trafficking of lysosomal enzymes in normal and disease states." 
The Journal of clinical investigation 77(1): 1-6. 
Lullmann, H., R. Lullmann-Rauch, et al. (1973). "Drug-induced phospholipidosis." 
German medicine 3(3-4): 128-135. 
Ohkuma, S., J. Chudzik, et al. (1986). "The effects of basic substances and acidic 
ionophores on the digestion of exogenous and endogenous proteins in mouse 
peritoneal macrophages." The Journal of cell biology 102(3): 959-966. 
Premzl, A., V. Turk, et al. (2006). "Intracellular proteolytic activity of cathepsin B is 
associated with capillary-like tube formation by endothelial cells in vitro." Journal 
of cellular biochemistry 97(6): 1230-1240. 
Sameni, M., K. Moin, et al. (2000). "Imaging proteolysis by living human breast cancer 
cells." Neoplasia 2(6): 496-504. 
Schneider, P., T. A. Korolenko, et al. (1997). "A review of drug-induced lysosomal 
disorders of the liver in man and laboratory animals." Microscopy research and 
technique 36(4): 253-275. 
 
 
 153
Sun-Wada, G. H., Y. Wada, et al. (2003). "Lysosome and lysosome-related organelles 
responsible for specialized functions in higher organisms, with special emphasis 
on vacuolar-type proton ATPase." Cell structure and function 28(5): 455-463. 
Ulbricht, B., E. Spiess, et al. (1995). "Quantification of intracellular cathepsin activities in 
human lung tumor cell lines by flow cytometry." Biological chemistry Hoppe-
Seyler 376(7): 407-414. 
Yoshida, Y., K. Arimoto, et al. (1985). "Reduction of acid sphingomyelinase activity in 
human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs." J 
Biochem 98(6): 1669-1679. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 154
Chapter 5 
 
Lysosomal volume expansion and alkalinization caused by amine-containing 
drugs
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5.1. Introduction  
In this chapter, the effect of hydrophobic (logP > 2.5) and hydrophilic (logP < 2.5) 
amine-containing compounds on the structural and functional properties of lysosomes 
related to the lysosomal ion trapping capacity of cells is evaluated.  The lysosomal ion 
trapping-based accumulation of amine-containing drugs is well established as causing a 
number of dose-dependent functional and structural perturbations in lysosomes, 
including: alkalinization of the normally acidic lysosome (Ohkuma and Poole 1978), 
osmotic swelling of lysosomes (Ohkuma and Poole 1981; Morissette, Lodge et al. 2008) 
and the lysosomal accumulation of undigested lipids (Halliwell 1997).  In chapters 2 and 
3, exposure to hydrophobic amine-containing drugs, known as CADs, were found to 
cause an apparent expansion of the lysosomal compartment that results in the 
increased cellular accumulation of substrates for ion trapping in lysosomes.  
Interestingly, previous studies have also illustrated the ability of amine-containing drugs 
to cause an apparent expansion of the aqueous volume of lysosomes resulting in a 
cytoplasmic vacuolization (Morissette, Moreau et al. 2004).  In this chapter it is 
hypothesized that the cytoplasmic vacuolization caused by some amine-containing 
drugs is distinct from the CAD-induced lysosomal lipidosis and that the cytoplasmic 
vacuolization is accompanied by a concomitant alkalinization of lysosomes that results 
in a failure to cause the increase in lysosomal ion trapping capacity observed with the 
lysosomal lipidosis following CAD treatment.   
Weakly basic amine-drugs accumulate in lysosomes through an ion trapping-type 
mechanism that is driven by the pH gradient existing between the acidic lysosome and 
the extralysosomal environment (de Duve, de Barsy et al. 1974).  Therefore, the amount 
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of drug accumulated in cells by ion trapping in lysosomes is dependent on the pH 
gradient existing between the lysosome and the extralysosomal space, as well as, the 
volume of the lysosomal compartment.  A change in either the lysosomal volume or pH 
is presumed to result in significant deviations in the lysosomal ion trapping capacity of 
cells.  The alkalinization of lysosomes by exposure to high concentrations of amine-
drugs would be expected to decrease the lysosomal ion trapping capacity of cells, 
whereas the expansion of the lysosomal compartment in cytoplasmic vacuolization and 
lysosomal lipidosis would be expected to increase the lysosomal ion trapping capacity.  
Therefore, the interplay between lysosomal alkalinization and expansion of the 
lysosomal compartment caused by these drugs is important in predicting the effect they 
will have on the lysosomal ion trapping capacity of cells.  Such an ability of one 
compound to alter the cellular disposition of another has been predicted here (see 
chapter 3), as well as by others (Daniel and Wojcikowski 1999), to represent the 
potential for distribution-based drug-drug interactions.   
The proposed mechanisms whereby amine-containing drugs cause lysosomal 
alkalinization, cytoplasmic vacuolization and lysosomal lipid accumulation would 
suggest that these effects occur through distinct molecular mechanisms.  Empirical 
evidence suggests that hydrophobicity (i.e., logP) is a key predictor of the ability and 
potency of these compounds in causing these effects on the lysosome.  Hydrophobicity 
has been found to be directly related to potency in causing alkalinization in isolated 
lysosomes (Ishizaki, Yokogawa et al. 2000).  Similarly, the lysosomal lipidosis has been 
strongly correlated with amine-containing drugs of significant hydrophobicity (logP > 2.5) 
(Lullmann-Rauch 1979) and cytoplasmic vacuolization is primarily observed with the 
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less hydrophobic amine-containing compounds (Ohkuma and Poole 1981).  Such 
observations suggest a potential dichotomy amongst amine-containing compounds 
where the hydrophobicity of the drug is a key predictor of its effect on lysosomes.  
Therefore, the ability of amine-containing drugs, based on their relative hydrophobicity, 
to affect key lysosomal properties, such as pH and volume, suggests that 
hydrophobicity may also be an important predictor in the ability of these compounds to 
affect the lysosomal ion trapping capacity of cells. 
Here, the model hydrophilic amine, ammonium chloride, and the model 
hydrophobic amine, imipramine, are evaluated for their ability to cause cytoplasmic 
vacuolization, lysosomal lipid accumulation and lysosomal alkalinization.  It is shown 
that these compounds differ in their potency and capability in altering the functional and 
structural properties of lysosomes.  Although, ammonium chloride causes an apparent 
expansion of the aqueous volume of lysosomes (i.e., cytoplasmic vacuolization) it fails 
to cause an increase in the lysosomal ion trapping capacity of cells.  The failure to 
cause an increase in lysosomal ion trapping is attributed to the concomitant 
alkalinization of lysosomes that occurs at the high doses necessary to cause the 
cytoplasmic vacuolization. These results support the hypothesis that hydrophobic and 
hydrophilic amine-containing compounds differ in their potency and ability in altering the 
properties of lysosomes. 
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5.2. Materials and methods 
5.2.1. Cell lines and reagents 
NBD-PE, LysoTracker Red DND-99 (LTR), Dulbecco’s phosphate buffered saline 
(D-PBS) and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from 
Invitrogen (Carlsbad, CA).  Propranol, procainamide, Nile red, mannitol, methylamine, 
imipramine, ammonium chloride, neutral red, morpholine, imdazole, isopropylamine, 
diisopropylamine, U18666A, amiodarone, and verapamil were purchased from Sigma-
Aldrich (St. Louis, MO).  Fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Lawrenceville, GA).  CRL-2076 human foreskin fibroblasts and HeLa 
cervical adenocarcinoma cells purchased from ATCC (Manassas, VA) were maintained 
in DMEM supplemented with 10% FBS and maintained at 37ºC and 5% CO2, all 
experiments were carried out under these conditions unless otherwise stated.  Cells 
were routinely subcultured to maintain 60% to 80% confluency. 
 
5.2.2. Neutral red uptake inhibition assay 
 Fibroblasts seeded at 1 x 104 cells/well in 96-well plates were allowed to adhere 
overnight under normal growth conditions.  Media was replaced with fresh media 
containing titrated drug concentrations in triplicate.  Cells were incubated for 1 hour 
under normal growth conditions followed by the addition of 10 µM neutral red for an 
additional 1 hour.  Upon removal of media each well was washed once with 4°C D-PBS 
and replaced with a destain solution containing 50% ddH20, 49% ethanol and 1% glacial 
acetic acid.  Fluorescence was measured using a Bio-Tek FL600 microplate 
fluorescence reader with excitation and emission wavelengths set at 530 nm and 645 
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nm, respectively.  Background signal from neutral red treated wells without cells was 
subtracted from each reading and untreated control cells were used to normalize 
fluorescence readings to calculate “Neutral Red Uptake Inhibition (% of control)” that 
was plotted as a function of drug concentration on a log scale.  The resulting data were 
fitted using a 3- or 4-parameter Hill equation in SigmaPlot (SPSS Inc., Chicago, IL) and 
the concentration of drug necessary to cause a 50% inhibition of neutral red uptake (i.e., 
IC50) was calculated.  A Pearson’s correlation of the log of the IC50 versus logP was 
conducted using Wessa statistics software (free online at www.wessa.net). 
 
5.2.3. WST-1 cell viability assay 
 Cell viability in imipramine treated HeLa cells was measured using the WST-1 
cell viability assay according to the manufacturer’s protocol (Roche Molecular 
Biochemicals, Mannheim, Germany).  The WST-1 assay measures mitochondrial 
dehydrogenase activity through the formation of a reduction product with an absorbance 
at 450 nm.  Briefly, HeLa cells were seeded in a 96-well plate at a density of 5 x 103 
cells/well and allowed to adhere overnight under normal growth conditions.  Media was 
removed and replaced with media containing imipramine at concentrations up to 200 
µM for 24 hours.  WST-1 reagent was added to each sample and maintained under 
normal growth conditions for 3 hours.  A microplate absorbance reader was used to 
measure sample absorbance at 450 nm.   Untreated control cells served as the 100% 
viability reference from which ‘Dehydrogenase Activity’ was determined and plotted 
against imipramine concentration on a log scale.  The data was fit to a 4-parameter Hill 
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equation using SigmaPlot (SPSS Inc., Chicago, IL) that was used to calculate the 
concentration necessary to cause 50% inhibition of dehydrogenase activity (IC50).   
 
5.2.4. NBD-PE accumulation 
 HeLa cells were seeded onto a 24-well plate at 2.5 x104 cells/well in growth 
media containing 50 µM NBD-PE with or without concomitant drug treatment following a 
previously established protocol (Fujimura, Dekura et al. 2007) with slight modifications.  
Cells were maintained under normal growth conditions for 96 hours.  Cells were washed 
twice with warm D-PBS and lysed with 0.1 M NaOH.  Lysate fluorescence was 
measured using a Bio-Tek FL600 microplate fluorescence reader with excitation and 
emission wavelengths set at 485 nm and 530 nm, respectively.  Cell lysate was 
measured for protein content using the BCA method and fluorescence signal was 
normalized to protein content.  NBD-PE accumulation was expressed as the mean and 
standard deviation from triplicate measurements. 
 
5.2.5. Cell microscopy studies 
 Fibroblasts grown on chambered glass microscope slides were exposed to 70 
µM neutral red for 6 hours followed by a brief washing in 37°C D-PBS and a 2 hour 
chase in fresh 37°C media with or without 200 nM concanamycin A.  Cells were 
subsequently washed once with 37°C D-PBS and sealed with a coverslip for imaging.  
Nile red staining required the addition of 2 µg/ml Nile red for 30 minutes under normal 
growth conditions and cells were washed twice with room temperature D-PBS prior to 
 
 
 161
imaging.  Vacuolization studies utilized drug treatment times between 2 hours and 24 
hours and cells were either imaged alive or after fixing with 4% paraformaldehyde. 
The cells were viewed using a Nikon Eclipse 80i or Eclipse TE2000-U 
microscope equipped with either a 40x (1.30 NA) or 60x (1.40) oil immersion objective 
for fluorescence or DIC miscroscopy.  Fluorescence images were acquired using the 
filter cube that best overlapped with the documented spectral properties of each 
fluorophore.  Samples for fluorescence imaging were excited with an EXFO X-Cite 120 
PC fluorescence illumination system.  Images were acquired using an ORCA ER 
camera (Hamamatsu).  Images were analyzed using Metamorph version 7.0 (Universal 
Imaging) and/or ImageJ (free online at rsbweb.nih.gov) software.  Background images 
of cells not exposed to fluorescent probe were acquired to correct for autofluorescence 
and images were scaled identically to allow for comparison.   
 
5.3. Results and discussion 
5.3.1. Effect of hydrophilic amine-containing drug treatment on the 
lysosomal ion trapping capacity of cells 
In chapter 3 the hydrophobic amine, imipramine was shown to increase the 
lysosomal ion trapping capacity of cells by causing an increase in the volume of the 
lysosomal compartment.  Although, increased imipramine concentrations resulted in 
increased lysosomal ion trapping capacity up to a point, at higher concentrations a 
paradoxical decrease in the lysosomal ion trapping capacity of cells was observed 
(Figure 3.18).  This effect was presumed to reflect the concomitant dose-dependent 
alkalinization of lysosomes caused by imipramine.  Interestingly, ammonium chloride 
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and other hydrophilic amine-containing compounds have been well documented as 
causing an osmotically driven expansion of the lysosomal compartment (Ohkuma and 
Poole 1981; Morissette, Lodge et al. 2008).  To investigate whether ammonium chloride 
causes an increase in the lysosomal ion trapping capacity of cells, similar to impramine, 
cells were treated with a range of ammonium chloride concentrations for 24 hours and 
in the last 2 hours LTR was added and cellular accumulation of the probe was 
measured and normalized to untreated control (Figure 5.1).  Unlike imipramine, 
ammonium chloride failed to cause any appreciable increase in the lysosomal ion 
trapping capacity of cells at any dose tested.  Rather, ammonium chloride showed only 
a dose-dependent decrease in lysosomal ion trapping presumed to represent the well-
established alkalinizing effect of the this amine on lysosomes (Ohkuma and Poole 
1978).  The inability of ammonium chloride to cause an increase in the lysosomal ion 
trapping capacity of cells, despite the well documented ability to cause an expansion of 
the lysosomal compartment, in the form of cytoplasmic vacuolization, suggests that the 
expanded compartment is not capable of participating in lysosomal ion trapping 
because the compartment doesn’t have an intact pH gradient.   
5.3.2. Lysosomal volume expansion through lysosomal lipid accumulation 
and cytoplasmic vacuolization 
 The expansion of the lysosomal compartment in cells treated with hydrophilic and 
hydrophobic amine-containing compounds presumably occurs through distinct 
molecular mechanisms.  Although a thorough understanding of either mechanism is 
lacking, the expanded compartment that results is hypothesized to be distinctly different 
even though recent work has attempted to describe them as occurring through the  
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Figure 5.1.  Dose-dependent decrease in lysosomal ion trapping capacity following 
hydrophilic amine-containing drug treatment.  HeLa cells were treated for 24 hours 
with a range of ammonium chloride concentrations between 0 and 500 mM.  In the 
last 2 hours, 200 nM LTR was added.  Samples were subsequently lysed and 
measured for cell associate fluorescence.  Cellular accumulation of LTR was 
normalized to percent vehicle-treated control.  Ammonium chloride caused a dose-
dependent decrease in the cellular accumulation of LTR.  Cellular accumulation of 
LTR as a percent of the vehicle treated control cells is represented as mean ± S.D of 
six values for each sample (*, p < .05; ***, p < .001 by Student’s t test).  
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same osmotically driven mechanism (Morissette, Ammoury et al. 2009).  Cytoplasmic 
vacuolization induced by hydrophilic amines is believed to occur through an osmotic 
expansion of the lysosomal compartment driven by high lysosomal amine 
concentrations (Ohkuma and Poole 1981), whereas lysosomal lipidosis induced by 
hydrophobic amines is believed to occur through the inhibition of lysosomal lipid 
metabolism (Halliwell 1997).  Cytoplasmic vacuolization is visual by light microscopy, 
reversible by treatment with membrane-impermeable osmotic agents and is mostly 
devoid of lipids in the vacuole lumen (Morissette, Lodge et al. 2008).  On the other 
hand, the lysosomal lipidosis caused by hydrophobic amine-containing compounds 
results in an expanded lysosomal compartment that is not readily visible by light 
microscopy, but can be visualized by electron microscopy or fluorescent labeling of the 
lipid-laden vesicles (Brown, Sullivan et al. 1992; Fujimura, Dekura et al. 2007).  These 
compartments are described as containing vesicular and lamellar structures 
representing the accumulation of undigested lipids.  Therefore, the mechanism of 
lysosomal volume expansion and the character of the expanded compartment in drug 
treated cells are believed to be distinctly different for imipramine and ammonium 
chloride. 
Using a light microscope, equipped with a high resolution differential interference 
contrasting (DIC) objective, cytoplasmic vacuolization following treatment with the 
model vacuolizing amine, 2.5 mM procainamide, was readily visible (Figure 5.2).  The 
extremely large vacuolar structures that appear to consume the entire cytoplasm of the 
cell are typical.  Treatment with the membrane-impermeable osmotically active sugar, 
mannitol, at concentrations between 200 mM and 800 mM dose-dependently inhibited  
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Figure 5.2.  Cytoplasmic vacuolization following hydrophilic amine-containing drug 
exposure.  Fibroblasts treated with (+), or without (-), 2.5 mM procainamide for 24 
hours were imaged by DIC microscopy.  (A) Cells treated with procainamide 
contained large perinuclear vacuolar structures that filled the cytoplasm.  (B) 
Expansion of the highlighted insets from (A) clearly illustrates the distinct vacuolar 
structures that are indicative of the drug-induced cytoplasmic vacuolization. 
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the appearance of cytoplasmic vacuoles (Figure 5.3).  Cellular staining with the lipid-
dye, Nile red, failed to significantly label the interior of the procainamide-induced 
vacuoles (Figure 5.4).  Treatment with the lipidosis-inducing hydrophobic amine, 100 
µM propranolol, resulted in no marked cytoplasmic vacuolization and the only vesicular 
structures present were labeled with Nile red.  Therefore, in accordance with previous 
findings, the drug-induced cytoplasmic vacuoles are reversible by treatment with 
membrane-impermeable osmotically active agents and fail to show a significant level of 
lipid-staining within their lumen (Morissette, Lodge et al. 2008).  The lack of a 
cytoplasmic vacuolization that is negative for Nile red staining in the lipidosis-inducing 
propranolol treatment supports the hypothesis that the lysosomal lipidosis is in fact 
distinct from the osmotically driven cytoplasmic vacuolization. 
 Because cytoplasmic vacuolization is a dose-dependent effect (Ohkuma and 
Poole 1981), a possible dose-dependent formation of cytoplasmic vacuoles following 
treatment with ammonium chloride (Figure 5.5) and imipramine (Figure 5.6) was 
evaluated.  Treatment with titrated concentrations of ammonium chloride revealed a 
dose-dependent formation of large cytoplasmic vacuoles.  Vacuolization appeared to 
begin at concentrations of 10 to 20 mM, but were not completely evident until a 
concentration of 50 mM was reached.  In contrast, imipramine failed to cause a 
pronounced cytoplasmic vacuolization at any of the tested doses and actually 
significantly affected cell attachment and apparent viability at 200 µM.  A cell viability 
assay measuring mitochondrial dehydrogenase activity using the tetrazolium salt WST-
1 confirmed that imipramine had an IC50 of 72 ± 3 µM (Figure 5.7).  Therefore, the 
hydrophobic amine, imipramine, failed to cause the cytoplasmic vacuolization induced  
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Figure 5.3.  Membrane-impermeable osmotic agents reverse the drug-induced 
cytoplasmic vacuolization.  Fibroblasts were treated for 2 hours with (+) or without (-) 
procainamide in the presence of mannitol at concentrations between 0 mM and 800 
mM.  Cells were subsequently fixed in 4% PFA and imaged by DIC microscopy.  The 
membrane-impermeable osmotically active sugar, mannitol, inhibited the 
procainamide-induced cytoplasmic vacuolization in a dose-dependent manner. 
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Figure 5.4.  Cytoplasmic vacuoles are mostly devoid of lipids.  Fibroblasts were left 
untreated (control) or treated with 2.5 mM procainamide or 100 µM propranolol for 24 
hours.  Cells were stained with 2 µg/ml Nile red for 30 minutes and imaged by DIC 
and fluorescence microscopy.  Fluorescence in the green channel is indicative of a 
neutral lipid rich environment, whereas signal in the red channel indicates association 
of the dye with polar lipids.  Procainamide treated cells are marked by the 
accumulation of large cytoplasmic vacuoles that are mostly devoid of the lipid stain.  
The lipidosis-inducing hydrophobic amine-drug, propanolol, failed to cause the 
formation of cytoplasmic vacuoles that negatively stain with the lipid dye. 
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Figure 5.5.  Ammonium chloride induces a dose-dependent cytoplasmic 
vacuolization.  HeLa cells treated for 2 hours with ammonium chloride concentrations 
between 0 mM and 50 mM were imaged by DIC microscopy.  Cytoplasmic 
vacuolization appeared to begin around 10 mM, but was pronounced at the 50 mM 
dose.  
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Figure 5.6.  Imipramine fails to induce a cytoplasmic vacuolization at any dose 
tested.  HeLa cells treated for 2 hours with imipramine concentrations between 0 µM 
and 200 µM were imaged by DIC microscopy.  Cytoplasmic vacuolization was not 
observed at any of the tested doses.  At the 200 µM dose, cells became detached 
from the glass surface.  
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Figure 5.7.  Imipramine causes a dose-dependent decrease in cell viability.  HeLa 
cells in a 96-well plate were treated with concentrations of impramine between 0.1 
µM and 1000 µM for 24 hours.  Cell viability was measured using the water-soluble 
tetrazolium salt (WST-1) to measure mitochondrial dehydrogenase activity.  Percent 
dehydrogenase activity normalized to untreated cells is plotted as a function of the 
imipramine treatment concentration (log scale).  The data was fit with a 4-parameter 
Hill equation using SigmaPlot from which the concentration of imipramine resulting in 
50% inhibition of dehydrogenase activity (IC50) was calculated.  Dehydrogenase 
activity as a percent of the vehicle treated control cells is represented as mean ± S.D 
of four values for each data point.  
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by ammonium chloride, even at the highest dose tested and further supports the 
hypothesis that the lysosomal volume expansion described as cytoplasmic vacuolization 
is distinct from the lysosomal lipidosis. 
The failure of imipramine to cause cytoplasmic vacuolization may indicate that it 
doesn’t stimulate the NPC1-dependent fusion of late endosomes and lysosomes as has 
been suggested with hydrophilic amine-containing compounds (Kaufmann and Krise 
2008), like ammonium chloride.  In fact, it was found that hydrophobic amines, like 
imipramine, actually inhibit the NPC1-dependent fusion of late endosomes and 
lysosomes necessary to form the amine-induced vacuoles and may actually inhibit the 
formation of these enlarged vacuoles.  Similarly, if amines do in fact cause cytoplasmic 
vacuolization through an osmotically driven process then the concentration of the amine 
in the lysosome would be crucial in increasing the osomotic pressure within the 
lysosome (Ohkuma and Poole 1981).  Therefore, imipramine may simply fail to reach 
the intralysosomal concentrations necessary to cause cytoplasmic vacuolization before 
it becomes cytotoxic.  Regardless of the mechanism, the hydrophobic amine failed to 
cause the cytoplasmic vacuolization caused by high millimolar concentrations of the 
hydrophilic amine, suggesting that hydrophobic amines don’t cause lysosomal volume 
expansion through the same mechanism as hydrophilic amines. 
The lysosomal accumulation of lipids which is typical of the drug-induced lipidosis 
can be assessed by measuring the cellular accumulation of the fluorescently-labeled 
phosopholipid analog, NBD-PE (Tomizawa, Sugano et al. 2006).  Accumulation of the 
lipid-analog was measured in cells grown for 96 hours in the presence of 50 µM NBD-
PE that were treated with vehicle alone (control), 10 µM imipramine or 10 mM 
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ammonium chloride (Figure 5.8).  Although both treatments significantly increased 
cellular accumulation of NBD-PE, imipramine treatment resulted in a far greater (i.e., 
285%) increase as compared to ammonium chloride (i.e., 42%).  The mild lipidosis 
caused by ammonium chloride may result from the alkalinization of lysosomes at the 
high treatment concentration used.  Lysosomal alkalinization has been shown to 
decrease lysosomal protease activity (Ohkuma, Chudzik et al. 1986) and may similarly 
decrease lysosomal lipase activity, since these enzymes have pH dependent activities 
with an acidic optimum (Sando and Rosenbaum 1985).  The inability of the hydrophilic 
amine to cause the severe lysosomal lipidosis seen with imipramine isn’t surprising 
based on numerous structure activity relationships that have shown hydrophobicity to 
be a key predictor for the drug-induced lysosomal lipidosis (Tomizawa, Sugano et al. 
2006; Natalie, Margino et al. 2009).  The failure of these studies to see a lipidosis with 
hydrophilic amines may have been related to the lower drug doses they restricted their 
studies to as compared to the high dose used here.  Together the importance of 
hydrophobicity in causing the lipidosis suggests that the hydrophobic portion of the 
molecule plays a key role in its ability to cause lysosomal volume expansion through 
inhibition of lipid metabolism.  Whether this is through facilitating interactions of the drug 
with intralysosomal targets, such as phospholipids, the lumenal membrane or specific 
proteins would require further mechanism-based studies. 
The distinction between the lysosomal volume expansion by lysosomal lipid 
accumulation and cytoplasmic vacuolization supports the hypothesis that these 
cytopathologies occur through distinct molecular mechanisms and may be related to the 
relative hydrophobicity of the amine-containing compound.  Therefore, the failure of  
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Figure 5.8.  Amine-containing drug treatment results in increased cellular 
accumulation of the phospholipid analog, NBD-PE.  HeLa cells were left untreated 
(control) or treated with 10 mM ammonium chloride or 10 µM imipramine in growth 
media containing 50 µM of the fluorescent phospholipid analog, NBD-PE.  After 96 
hours cells were lysed and cell associated NBD-PE was measured by fluorescence 
and normalized to cellular protein content.  Although imipramine caused the greatest 
increase in NBD-PE accumulation, both drug treatments resulted in a statistically 
significant increase in probe accumulation. Cellular accumulation of NBD-PE in RFU 
per µg of protein is represented as mean ± S.D of at least three values for each 
sample (*, p < .05; ***, p < .001 by Student’s t test).  
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ammonium chloride to cause the increased lysosomal ion trapping capacity of cells may 
reflect its inability, or decreased potency, in causing a significant expansion of the 
lysosomal compartment through an increase in the lysosomal accumulation of lipids.  
The importance of a lysosomal expansion via the lipidosis may reflect a lysosomal 
volume expansion that can occur at doses inferior to those necessary to cause 
alkalinization of lysosomes, while cytoplasmic vacuolization may only occur at doses far 
above those necessary to cause a marked alkalinization of lysosomes. 
 
5.3.3. Lysosomal alkalinization following treatment with hydrophobic and 
hydrophilic amine-containing compounds 
  In addition to expansion of the lysosomal compartment the other effect of amine-
containing drugs on lysosomes that can significantly affect the lysosomal ion trapping 
capacity of cells is alkalinization of lysosomes.  Therefore, the combination of the 
lysosomal volume expanding and lysosomal alkalinizing effects of these drugs is 
presumed to dictate their impact on the lysosomal ion trapping capacity of cells.  If 
ammonium chloride and other hydrophilic amine-containing compounds cause 
lysosomal alkalinization at doses well below those necessary to cause expansion of the 
lysosomal compartment, then, an increase in the lysosomal ion trapping capacity would 
not be expected to occur.  Similarly, the increased potency of hydrophobic amine-
containing compounds to cause the lysosomal volume expansion at concentrations 
below those necessary to cause lysosomal alkalinization may explain why the increase 
in lysosomal ion trapping capacity seen at lower concentrations of imipramine is 
reversed with increasing concentrations (see Figure 3.18).  
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Alkalinization of lysosomes resulting from exposure to amine-containing 
compounds was assessed using an indirect assay that relies on short-term exposure to 
amine-containing drugs along with the fluorescent substrate for lysosomal ion trapping, 
neutral red.  This assay relies on the simple assumption that the cellular uptake of the 
lysosomotropic amine dye, neutral red, is directly dependent on the presence of an 
intact lysosomal pH gradient.  Therefore, alkalinization of lysosomes will result in a 
decrease in the cellular uptake of neutral red.  The short-term drug treatments were 
used to prevent the possible confounding effects of drug-induced expansion of the 
lysosomal compartment, which has been shown to be minimal with short exposure 
times, as illustrated in Chapter 3.  The cellular uptake of neutral red results in 
pronounced vesicular staining and cellular accumulation that is prevented by co-
treatment with the V-ATPase inhibitor concanamycin A (Figure 5.9).  These results 
confirm the importance of lysosomal pH in neutral red uptake into cells as well as the 
uptake into vesicular structures that are presumed to be lysosomes.  The assay was 
designed for a 96-well plate format in which cells are incubated with different drugs at a 
range of concentrations for one hour followed by the addition of neutral red with a one-
hour incubation under normal growth conditions.  After washing and lysing the cells, the 
cell-associated neutral red in each sample is quantified by fluorescence and the 
percentage inhibition in cellular uptake is plotted against the drug concentration (Figure 
5.10).  The dibasic amine-containing drug chloroquine is well known for its ability to 
cause lysosomal alkalinization in the low micromolar range (Poole and Ohkuma 1981) 
and shows a sigmoidal dose-response in the inhibition of neutral red uptake.  The 
resulting data were fitted using the 4-paramter Hill equation and the concentration  
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Figure 5.9.  Neutral red accumulates in cells by ion trapping in lysosomes.  
Fibroblasts were treated with neutral red followed by treatment with (+) or without (-) 
the V-ATPase inhibitor concanamycin A (Con A).  (A) Fluorescence micrographs 
show a punctate vesicular staining that is inhibited by treatment with Con A.  (B) Total 
cellular accumulation of the fluorescent molecule was also inhibited by Con A 
treatment.  Together this data supports neutral red accumulation in lysosomes by ion 
trapping that accounts for about 97% of the total cellular accumulation of the 
fluorophore. Cellular uptake of neutral red in RFU per µg of protein is represented as 
mean ± S.D of three values for each sample (***, p < .001 by Student’s t test).  
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Figure 5.10.  Dose-dependent inhibition of cellular uptake of neutral red by the 
lysosomotropic amine-containing drug, chloroquine.  Fibroblasts were treated with 
titrated concentrations of chloroquine in triplicate for a total of 2 hours.  After the first 
hour, 10 µM neutral red was added and allowed 1 hour for uptake.  Cells were 
subsequently washed and cell-associated fluorescence was measured.  Percent 
inhibition of neutral red uptake was plotted against chloroquine dose (log scale).  The 
data were fitted with a 4-parameter Hill equation.  The resulting equation was used to 
calculate the concentration of chloroquine necessary to inhibit total neutral red 
uptake by 50% (IC50).  The IC50 value represents the potency of the drug in inhibiting 
neutral red uptake presumably through alkalinization of lysosomes.  Inhibition of 
cellular uptake of neutral red as a percent of the vehicle-treated control cells is 
represented as mean ± S.D of three values for each sample.  
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necessary to cause 50% inhibition of neutral red uptake was calculated (i.e., IC50) using 
the resulting equation. The IC50 value for chloroquine was found to be 2.6 ± 0.3 µM in 
agreement with the high potency lysosomal alkalinizing effect of this drug.   
Next, several amine-containing compounds that are either confirmed or 
suspected substrates for lysosomal ion trapping with pKa values near neutrality were 
chosen to be representative of amine-containing drugs that can be further characterized 
as hydrophobic (logP > 2.5) or hydrophilic (logP < 2.5) (Figure 5.11).  Similar to 
chloroquine, these drugs were measured for their dose-dependent inhibition of neutral 
red uptake and the resulting data were fitted to the Hill equation from which IC50 values 
were calculated.  The IC50 values represent an indirect measurement of lysosomal 
alkalinization, with decreased IC50 values indicating increased potency in causing 
lysosomal alkalinization and vice versa.  The compounds are listed in Table 5.1 along 
with their respective pKa, logP and IC50 values.  A plot of the log10 transformed IC50 
versus the logP of each compound is presented (Figure 5.12).  A Pearson product-
moment correlation was calculated and a significant correlation between the potency of 
the compound in causing lysosomal alkalinization (i.e., log IC50) and its hydrophobicity 
(i.e., logP) was observed (r = -0.82, n = 10, p < 0.01).   
These results confirm that hydrophobic amine-containing drugs are far more 
potent at causing lysosomal alkalinization with IC50 values in the low micromolar range, 
as compared to the high micromlar to low millimolar range seen with the hydrophilic 
compounds.  Although the hydrophobic compounds are much more potent at causing 
lysosomal alkalinization, they also appear to cause expansion of the lysosomal 
compartment in the low micromolar range that allows for the increased lysosomal ion  
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Figure 5.11.  Lysosomotropic amine-containing drugs are divided into two groups 
based on their relative hydrophobicity.  Hydrophobicity is predicted by logP values 
determined using the logP plug-in from the MARVIN software freely available at 
www.chemaxon.com.  Compounds with logP < 2.5 are considered hydrophilic and 
compounds with logP > 2.5 are termed hydrophobic. 
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Table 5.1.  Lysosomotropic amine-containing compounds assessed for causing 
lysosomal alkalinization using the neutral red uptake inhibition assay.  Each 
compound is listed along with its predicted logP and pKa values determined using 
plug-ins from the MARVIN software freely available at www.chemaxon.com.  The 
IC50 is the concentration of compound needed to inhibit the cellular uptake of neutral 
red by 50%.  Dose-dependent inhibition curves were generated experimentally and 
fitted with the Hill equation in SigmaPlot.  The absolute IC50 was calculated using the 
resulting equation and represented as the mean ± S.D of three values for each 
compound.  
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Figure 5.12.  Amine-drug hydrophobicity correlates with potency in causing 
alkalinization of lysosomes.  A plot of the IC50 values (log scale) and logP values from 
Table 2.1 illustrates the relationship between hydrophobicity (logP) and potency in 
causing lysosomal alkalinization (IC50). A Pearson’s correlation of the log of the IC50 
versus logP was conducted using Wessa statistics software (r = -0.82, n = 10, p < 
0.01), freely available online at www.wessa.net.   
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trapping capacity observed with these compounds.  However the hydrophilic amine-
containing compounds cause lysosomal alkalinization at concentrations well below the 
middle to high millimolar concentrations necessary to cause cytoplasmic vacuolization 
and suggests that despite the ability of these compounds to cause an expansion of the 
lysosomal compartment they are much more potent at causing alkalinization of 
lysosomes and therefore fail to cause the increase in lysosomal ion trapping capacity of 
cells seen with the hydrophobic amines. 
In contrast to the increased lysosomal ion trapping capacity observed following 
treatment with imipramine, ammonium chloride failed to cause a significant increase in 
the lysosomal ion trapping of cells as measured by the cellular accumulation of LTR.  In 
chapter 3, the increase in lysosomal ion trapping capacity observed with imipramine 
was found to result from an expansion of the lysosomal compartment that was related to 
the lysosomal lipidosis caused by imipramine.  Despite the ability of ammonium chloride 
to cause an expansion of the lysosomal compartment (i.e., cytoplasmic vacuolization), it 
was found to cause lysosomal alkalinization at doses far inferior to those needed to 
cause cytoplasmic vacuolization.  Therefore, the failure of ammonium chloride to cause 
an increase in the lysosomal ion trapping capacity of cells appears to be due to a 
concomitant alkalinization of lysosomes. 
 
5.4. Conclusions 
In this chapter the effect of hydrophobic (logP > 2.5) and hydrophilic (logP < 2.5) 
amine-containing compounds on the structural and functional properties of lysosomes 
related to the lysosomal ion trapping capacity of cells is evaluated.  Measurement of the 
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lysosomal ion trapping capacity of cells in the form of LTR accumulation following 
treatment with the model hydrophilic amine, ammonium chloride, failed to show an 
increase in the lysosomal ion trapping capacity of cells, but rather simply a dose-
dependent inhibition.  Lysosomal volume expansion in the form of cytoplasmic 
vacuolization was evaluated by DIC microscopy and appears to be distinct from the 
lysosomal lipidosis as determined by the absence of vacuole staining with the lipid 
marker, Nile red.  The model hydrophilic amine, ammonium chloride, was found to 
cause cytoplasmic vacuolization, but requires an extremely high dose (i.e., 50 mM).  In 
contrast, the model hydrophobic amine, imipramine, failed to induce the cytoplasmic 
vacuolization at doses up to 200 µM.  Imipramine was found to be dose-limited by the 
compounds relative cytotoxicity (IC50 = 72 µM).  The lysosomal lipidosis evaluated by 
the cellular accumulation of the fluorescent phospholipid analog, NBD-PE, revealed that 
high-dose ammonium chloride causes an increase in lysosomal lipid accumulation but 
fails to cause the intense accumulation that is seen following low micromolar doses of 
imipramine.  Using a series of 9 lysosomotropic amine-containing compounds it is found 
that, in agreement with a previous report in isolated lysosomes (Ishizaki, Yokogawa et 
al. 2000), the hydrophobic compounds are significantly more potent inducers of 
lysosomal alkalinization as compared to the hydrophilic compounds.  Together these 
results support the hypothesis that hydrophobic and hydrophilic amine-containing 
compounds distinctly differ in their ability to alter the functional and structural properties 
of lysosomes.  Hydrophobic amine-containing compounds are potent at causing 
lysosomal alkalinization and lysosomal lipidosis, but fail to cause cytoplasmic 
vacuolization.  Hydrophilic amine-containing compounds are weak inducers of 
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lysosomal alkalinization and lysosomal lipid accumulation, but capable of causing 
cytoplasmic vacuolization at high doses.  Despite the ability of hydrophilic amine-
containing compounds to cause an apparent expansion of the aqueous volume of 
lysosomes (i.e., cytoplasmic vacuolization) their failure to cause an increase in the 
lysosomal ion trapping capacity of cells is presumed to result from the concomitant 
alkalinization of lysosomes that negates any potential increase in lysosomal ion 
trapping. 
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Chapter 6 
 
Summary, conclusions and future directions 
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6.1. Summary and conclusions 
 With advanced techniques to determine the subcellular distribution of drugs it is 
becoming evident that drugs often fail to show a homogenous distribution within the cell, 
but rather tend to accumulate within specific subcellular compartments (Baik and 
Rosania 2011).  The tendency to accumulate to a high degree within these 
compartments has been demonstrated to affect the pharmacokinetic and 
pharmacodynamic properties of the drug, but have also been observed to result in 
perturbations in the normal structural and functional properties of the organelle 
(Kaufmann and Krise 2007).  This ability to affect the physiological function of the 
organelle has raised concerns about possible toxicological ramifications, but has also 
resulted in hypothesized therapeutic applications.  Therefore, it is important to gain an 
understanding of the mechanisms through which these drugs affect the properties of the 
organelle, as well as the potential therapeutic implications of these effects. 
The subcellular disposition of weakly basic amine-containing drugs in lysosomes 
has been well documented as affecting the functional and structural properties of the 
organelle (Lullmann-Rauch 1979; Ohkuma and Poole 1981; Poole and Ohkuma 1981).  
In fact, the ability of amine-containing drugs that accumulate in lysosomes to cause a 
dose-dependent alkalinization of the lysosome has been demonstrated to result in 
numerous biological effects of potential pharmacological and toxicological relevance 
(Baxt 1987; Christensen, Myers et al. 2002; Savarino, Boelaert et al. 2003; Talloczy, 
Martinez et al. 2008; Matsui, Ito et al. 2010; Ashfaq, Javed et al. 2011), including 
intracellular distribution-based drug-drug interactions (Daniel 2003).  Amine-containing 
drugs are also known to cause the lysosomal accumulation of lipids, resulting in the 
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drug-induced syndrome known as phospholipidosis (Lullmann-Rauch 1979).  The 
phenotypic similarity between the drug-induced lipidosis and the lysosomal lipid storage 
disease, Niemann-Pick type C (NPC) disease, has resulted in the wide-spread use of 
these drugs in inducible models of the disease (Rodriguez-Lafrasse, Rousson et al. 
1990).  Interestingly, cells isolated from patients suffering from NPC disease have been 
characterized as having an expanded aqueous volume of the lysosomal compartment 
(Kopitz, Harzer et al. 1996).  Therefore, a similar effect was predicted to occur following 
the disease-like lipidosis caused by many of these amine-containing drugs.   
An expansion of the aqueous volume of the lysosomal compartment would be 
expected to impact the cellular accumulation of drugs by ion trapping in lysosomes (de 
Duve, de Barsy et al. 1974) and would illustrate a novel mechanism through which 
drugs can interact at the subcellular level.  Therefore, the influence of the drug-induced 
lysosomal accumulation of lipids on the cellular accumulation of weakly basic-amine 
containing drugs and the mechanisms involved were the focus of this thesis.  In this 
work, the drug-induced expansion of the lysosomal compartment was evaluated for its 
impact on the lysosomal ion trapping capacity of cells and lysosomal enzyme activity. 
Hydrophobic amine-containing drugs that are well established as causing the 
lysosomal accumulation of lipids (Roff, Goldin et al. 1991) were found to cause an 
increase in the lysosomal ion trapping capacity of cells similar to that seen in cells 
isolated from patients suffering from NPC disease.  Using the model hydrophobic 
amine, imipramine, the increased lysosomal ion trapping was found to occur through a 
time- and temperature-dependent process consistent with an energy-dependent 
remodeling of the cell resulting in an expansion of the aqueous volume of the lysosomal 
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compartment.  Reversal of the cellular lipidosis caused a reduction in the apparent 
volume of the lysosomal compartment and suggested that the drug-induced expansion 
of the lysosomal compartment is secondary to the cellular accumulation of lipids, rather 
than a direct effect of the drug.  These finding argue that hydrophobic amine-containing 
drugs do not cause an expansion of the lysosomal compartment by directly inhibiting 
the trafficking of lysosomes as has been previously hypothesized (Goldman, Funk et al. 
2009).  Rather these findings would support the hypothesis that these drugs cause the 
lysosomal accumulation of lipids and that the change in the lipid content of lysosomes 
causes the observed inhibition in the vesicle-mediated efflux trafficking of lysosomes 
and therefore results in an expanded lysosomal compartment. 
 The possibility that lysosomal volume expansion, following hydrophobic amine-
treatment, could result in a decrease in the cellular activity of lysosomal enzymes was 
also evaluated.  An expansion of the lysosomal compartment was hypothesized to 
possibly decrease lysosomal enzyme activity by decreasing their apparent 
concentration within the lysosome.  Although changes in lysosomal pH have been 
shown to impact lysosomal hydrolase activity (Ohkuma, Chudzik et al. 1986), the impact 
of lysosomal volume expansion was previously unknown and, if found, was 
hypothesized to potentially contribute to the drug-induced accumulation of undigested 
lipids in lysosomes.  Measurements of lysosomal enzyme activity, using both 
exogenously supplied protein and a specific substrate of cathepsin B, revealed no 
change in enzymatic activity.  Therefore, in contrast to lysosomal pH changes, 
lysosomal volume expansion does not appear to have a significant effect on lysosomal 
enzyme activity.  The lack of an effect on lysosomal enzyme activity may reflect an 
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increase in enzyme expression concomitant with the expansion in the lysosomal 
volume. 
 In addition to the expansion of the lysosomal compartment that was observed 
here, hydrophilic amine-containing drugs that are not typically associated with the 
lysosomal accumulation of lipids (Tomizawa, Sugano et al. 2006), have also been 
illustrated as causing expanded vacuolar compartments that are of lysosomal origin and 
often referred to simply as cytoplasmic vacuoles (Morissette, Lodge et al. 2008).  This 
expanded compartment was determined to be distinct from the expanded compartment 
resulting from the lipidosis-inducing, hydrophobic amine-drug treatment and was not 
found to increase the capacity of cells to accumulate secondarily applied amines by ion 
trapping.  The model hydrophilic amine, ammonium chloride, caused the formation of 
cytoplasmic vacuoles, but failed to increase the lysosomal ion trapping capacity of cells.  
This failure to increase the lysosomal ion trapping of cells despite the vacuolization was 
attributed to a concomitant alkalinization of the lysosomal compartment.  Therefore, the 
hydrophobicity of the amine-containing drug may be an important parameter in 
predicting the ability of a drug to increase the lysosomal ion trapping capacity of cells 
through an expansion of the lysosomal compartment.  
 
6.2. Future directions 
 Future studies that focus on the mechanistic basis and the potential therapeutic 
implications of the lysosomal volume expansion are necessary.  Although the in vitro 
findings revealed the potential for a profound effect of lysosomal volume expansion on 
the cellular accumulation of amine-containing drugs, in vivo experiments are necessary 
 
 
 194
to verify the physiological relevance of these findings.  An in vivo study in rats has 
shown that treatment with the hydrophobic amine-containing drug, chlorphentermine, 
increases the cellular accumulation of a secondarily administered hydrophobic amine-
containing drug, amiodarone (Reasor 1991).  Although the authors attributed the 
increased accumulation of amiodarone to an increase in the binding to the 
concomitantly accumulating phospholipids, it may be that the observed increase in drug 
accumulation actually occurred through an expansion of the lysosomal compartment, as 
hypothesized in this work.  Further in vivo studies measuring the effect of the drug-
induced lipidosis on the cellular accumulation of an amine-containing drug that is a 
substrate for ion trapping in lysosomes, but is not predicted to bind phospholipids, such 
as methylamine, would help elucidate whether the increased drug accumulation in vivo 
occurs through phosopholipid binding or an expansion of the aqueous volume of the 
lysosome.  Additionally, in vivo pharmacokinetic studies on the impact of lysosomal 
volume expansion would be necessary to illustrate how the pharmacokinetic parameters 
of the drug are altered.  Intuitively, an increase in the tissue accumulation of drug would 
result in an increased volume of distribution that would affect the necessary loading 
dose to achieve target plasma concentrations and would be expected to increase the 
half-life, if clearance remains unaffected.  Such changes in the pharmacokinetic 
properties of a drug may or may not have therapeutic relevance especially since most 
lysosomotropic amine-containing drugs already have a large volume of distribution 
(Yokogawa, Ishizaki et al. 2002).   
 Future in vitro studies are necessary to understand the nature of the expanded 
lysosomal compartment and the biochemical mechanism through which it is formed.  
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Initially, an understanding of the source of the expanded compartment is needed.  
Presumably, an expansion of the lysosomal compartment represents a defect in the 
homeostatic regulation of the trafficking of lysosomes and their contents, either through 
an increase in their formation or a decrease in their clearance.  Because material moves 
in and out of lysosomes through multiple pathways, it would be important to identify the 
disrupted pathway that results in the lysosomal volume expansion.  Previous studies 
have illustrated that amine-containing drugs can cause that appearance of expanded 
vacuolar compartments that contain autophagic and lysosomal markers (Morissette, 
Ammoury et al. 2009), and therefore, may signify an increase in lysosomal volume 
mediated by an increase in the formation of acidic autophagolysosomal vacuoles, or a 
decrease in their clearance.  Similarly, lysosomal volume expansion could originate 
from an increase in the biogenesis of lysosomes, or perhaps an increase in endocytic 
uptake or a decrease in exocytic efflux of lysosomes and their cargoes, which has also 
been previously hypothesized (Neufeld, Wastney et al. 1999; Kaufmann and Krise 
2008).   
 In summary, the lysosomal volume expansion described in this thesis is 
characterized as a pathway through which amine-containing drugs can modify the 
properties of the lysosomal system.  The expanded lysosomal compartment is shown to 
be a site for enhanced cellular accumulation of secondarily administered amine-
containing drugs and reveals a novel mechanism of intracellular distribution-based drug-
drug interactions.  
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Appendix 
 
Exposure of cells to hydrogen peroxide can increase the intracellular 
accumulation of drugs 
 
 
Reprinted with permission from R. S. Funk and J. P. Krise.  Exposure of cells to 
hydrogen peroxide can increase the intracellular accumulation of drugs.  Molecular 
Pharmaceutics 4, (2007), 154-159.  Copyright 2007 American Chemical Society. 
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